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Opioids are the first choice in the treatment of severe acute and chronic pain. Apart from 
their intended effect (analgesia), opioids come with a variety of side effects with respiratory 
depression as potentially life-threatening. Opioid-Induced Respiratory Depression (OIRD) 
is often moderate to mild from which the patient recovers spontaneously or is rescued 
by other means such as stimulation of the patient to take a deep breath or chin lift. In 
severe cases of OIRD, breathing becomes initially irregular, followed by cyclic breathing 
(breathing shows an on/off pattern alike Cheyne-Stokes breathing) and apnea. Rescue 
is by resuscitation, intubation and assisted ventilation and reversal of opioid effect by 
naloxone. The incidence of respiratory depression from opioid treatment, acute or chronic, 
is poorly documented. A recent systematic review of the literature on post-operative OIRD 
estimates an average incidence of 0.5% with a range of 0.2-2%.1 This suggests that only 
1 in 200 patients develops a respiratory event from opioids that requires an intervention. 
There are indications that this number is an underestimation with an incidence of OIRD 
many times higher than 1:200. For example, following patient controlled analgesia with 
morphine hypoventilation (defined by a respiratory rate < 8 breaths.min-1) occurs in one 
in three patients.2 No valid data are available on the occurrence of OIRD in chronic pain 
patients.1 Accidental deaths from OIRD in this patient population are often attributed 
to the progression of underlying disease (for example cancer), old age or co-existing 
diseases. Although a recent systematic review of case reports on OIRD in chronic pain 
patients does not provide quantitative data on the occurrence of OIRD, it does provide 
important information on its development:3 (i) Since the year 2000, methadone, fentanyl 
and oxycodone are predominantly involved in OIRD while before 2000 morphine was the 
most prevalent cause of OIRD, (ii) the incidence of OIRD increased sharply in non-cancer 
chronic pain patients over the last 10 years and (iii) co-medication affecting the opioid’s 
pharmacokinetics and dynamics is an important cause for opioid toxicity. Observation 
#2 is probably related to an increased awareness to treat severe chronic pain and also 
due to the aggressive promotion of opioids by the pharmaceutical industry. Observation 
#3 is important in chronic pain patients but also important in perioperative and acute 
settings when opioids are combined with additional drugs that depress ventilation (such 
as midazolam, propofol, muscle relaxants). 
1.2 MECHANISMS OF ACTION
The drive to breathe is generated in multiple respiratory centers in the brainstem.1 
Respiratory neurons receive inputs from various sites in the CNS (cortex, limbic 
system, hypothalamus, spinal cord), a set of receptors located in the brainstem (central 
chemoreceptors), and in the carotid bodies (peripheral chemoreceptors). These 
chemosensors send information, changes in pH, PCO2 and PO2 of the CSF and arterial 
blood, to the brainstem respiratory centers, which appropriately adjust breathing rate 
and pulmonary tidal volume. For example, acidosis, hypercapnia and hypoxia will cause 
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hyperventilation, while hypocapnia and alkalosis will reduce minute ventilation. Opioid 
effects on μ-opioid receptors (MOR), expressed on respiratory neurons, are the main cause 
for the reduction of the drive to breathe. When an opioid is administered to a patient and 
the injection rate is sufficiently slow (over minutes) or the passage of the opioid across 
the blood-brain barrier is slow, depression of the respiratory neurons in the brainstem 
coincides with the accumulation of arterial CO2. The stimulatory effect of the increased 
CO2 at the peripheral and central chemoreceptors will offset the decrease in tidal volume 
and reduced respiratory rate. OIRD is then observed as an increase in arterial (and end-
tidal PCO2) with little effect on ventilation. When the opioid is infused rapidly and 
passage across the blood-brain barrier is fast, the depression of the respiratory neurons 
in the brainstem will dominate as there is insufficient time for CO2 to accumulate in the 
body. This then will cause severe OIRD with hypoventilation and initially near normal 
PCO2 values. See also Chapters 2 and 3 of this thesis.
Although the incidence of opioid-induced respiratory depression is low, fatalities do 
regularly occur. For example, Lötsch et al.4 describe a young female (BMI 19 kg/m2) 
who had peripheral orthopaedic surgery under general anesthesia (sevoflurane 2-3% 
with 200 μg fentanyl). In the recovery room the patient received four doses of morphine 
over 2 hours, reaching a total of 35 mg or 0.7 mg.kg-1. Forty minutes after the last dose 
she developed OIRD followed by a fatal cardiac arrest. At that time estimated brain 
concentrations were about 150 nM, which is above the toxic range for morphine. This case 
understates the need for a close understanding of the pharmacokinetics and dynamics 
of any opioid that is used in any patient. The physicians involved in this case did not 
take into account the very slow passage of morphine across the blood-brain barrier which 
caused a peak in central effect hours following peak plasma concentration. And while the 
onset of analgesic occurred relatively rapidly following the last dose, the fatal respiratory 
depression occurred 40 min later. This report demonstrates further the need to view OIRD 
in light of the opioid’s wanted effect, analgesia. There are few studies that address the 
composite effects of opioids. One way to compare the different effects of one opioid is 
to construct a safety or utility function. These functions, originally used in economics 
and first applied in pharmacology by Sheiner and Melmon in 1978,5 are constructed 
by estimating the difference in probability of analgesia and respiratory depression as 
derived from experimental pharmacokinetic/pharmacodynamic modelling studies. 
While application of these functions is currently difficult to envision in a clinical setting, 
they are useful in the development of novel opioids aimed at maximizing analgesia while 
simultaneously minimizing OIRD, for example when making a choice for a drug dose to 
test in a phase III trial from data obtained in phase II studies. For further elaboration see 




Development of an opioid that is without any respiratory depression or other dangerous 
side effects (the holy grail of opioid pharmacology) seems not possible. At least no such 
drugs have been developed so far. Fortunately, the pharmaceutical industry still does 
attempt to develop opioids with restricted respiratory depressant properties. Various 
companies are focussing on single chemical molecules that activate multiple receptor 
system including the MOR and a secondary system that possibly counteracts the side 
effects of the activated MOR. Again the properties of such opioids should always be viewed 
in terms of their wanted effects. For example, the opioid buprenorphine is known to have 
a ceiling in its respiratory depressant effects. Such a phenomenon is only advantageous 
when respiratory ceiling does not coincide with ceiling in analgesia. Indeed ceiling in 
analgesia seems to occur at higher (supra clinical) doses than respiratory ceiling.6 This is 
further adressed in Chapter 5 of this thesis.
Opioid effect is extremely variable with effects that may vary a factor 20-40 between 
patients. The cause of variety is multiple and has pharmacokinetic and pharmacodynamic 
origins. Known causes of variability include genetics (for example due to polymorphic 
enzymes involved in drug metabolism),3 sex (women are more sensitive to opioids than 
men),7 underlying disease (in children repetitive hypoxic events from obstructive sleep 
apnea are associated with increased opioid sensitivity; in Alzheimer’s disease opioid 
sensitivity seems reduced due to the loss of descending inhibition), age (the elderly have 
an increased opioid sensitivity),8,9 co-medication and smoking (smoke contains polycyclic 
aromatic hydrocarbons that interact with metabolizing enzymes in an often unpredictable 
fashion).4 Other factors are less well known and poorly studied, such as for example the 
nutritional state of the patient and the circadian rhythm, factors that play an important role 
in the pharmacodynamics of other drugs such as inhalational anesthetics and opioids.10 
See also Chapter 6 of this thesis.
1.4 AIM OF THIS THESIS
The aim of this thesis is to investigate the influence of strong opioids on the control of 
breathing, taking into account their analgesic properties. 
In Chapter 2 the respiratory pharmacokinetics and dynamics of opioids are discussed. 
Furthermore, an overview is given of agents that are able to reverse OIRD. Apart from 
agents that antagonize the MOR, other agents are discussed that stimulate breathing 
via other receptor systems and theoretically restore breathing without compromising 
analgesia.
In Chapter 3 the respiratory depressant effects of the potent opioid remifentanil are 
modelled using a mathematical model that incorporates the depressant effect of 
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remifentanil on respiratory neurons in the brainstem and the stimulatory effects of carbon 
dioxide on the chemoreceptors. This model enables us to predict the behaviour of the 
ventilatory control system under various remifentanil administration paradigms. 
In Chapter 4 a safety function or utility function is described for the strong opioid fentanyl. 
As discussed above, the function describes the opioid’s behaviour in light of its benefit 
(analgesia) and harm (respiratory depression). 
In Chapter 5 the respiratory behaviour of an experimental opioid (MR30365/07) is 
studied and compared to placebo and fentanyl. By performing dose-response studies for 
respiratory depression and analgesia it is shown that this opioid behaves differently from 
fentanyl. Possible mechanisms are discussed. 
In Chapter 6 the influence of the circadian rhythm on pharmacodynamic effect of fentanyl 
is studied. In a first approach, fentanyl’s analgesic effects are studied at 4 time points: 
02 AM, 08 AM, 2PM and 8PM. 
All experiments were performed in healthy young volunteers in the Anesthesia & Pain 
Research Unit of the Department of Anesthesiology of the Leiden University Medical 
Centre (LUMC). 
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Opioids induce respiratory depression.1 Morphine, however, remains the gold standard 
for the treatment of postoperative pain and opioids such as the fentanyl derivatives are 
widely used as part of anesthetic procedures. Although the overall risk of postoperative 
respiratory depression is relatively low with an estimated total incidence of respiratory 
events in the range of 0.5 to 2%,1 it is nevertheless wise to remember that the first 24 hours 
after surgery represent a high risk period for a respiratory event as a result of opioid use,2 
that fatal outcomes to respiratory depression may occur3 and that this risk is exacerbated 
in some patient groups.1-4 Similarly, opioid-induced respiratory depression in chronic 
opioid treatment remains rarely reported and is most probably grossly underreported.4 
Effective rescue treatment, usually with naloxone, is available to reverse opioid-induced 
respiratory events, particularly in an emergency setting. However, naloxone antagonizes 
both opioid-induced respiratory depression and analgesia. Consequently, pain 
management during crisis recovery of hypoventilation/apnea will be compromised. There 
are clear advantages, therefore, in the design and availability of drugs that antagonize the 
respiratory depressant effects of opioids without decreasing their analgesic actions. 
Opioid-induced analgesia and respiratory depression arise from stimulation of μ-opioid 
receptors (MORs). MORs are expressed on neurons involved in the control of breathing, 
primarily located in the brainstem. Opioid-induced breathing alterations are complex, but 
may be characterized by an increase in arterial carbon dioxide concentration (hypercapnia) 
and reduction in tidal and minute volume. Respiration becomes slow, irregular (with 
hypercapnia and hypoxia,5 and eventually fatal apnea may occur. The respiratory 
centers responsible for these complex events are many and varied.6 The main drive for 
respiration is located in the brainstem, particularly in the respiratory rhythm generating 
areas such as the pre-Bötzinger complex (although this area has not been identified in 
humans), which is active during inspiration and is opioid-sensitive,7 in association with 
the retro-trapezoid and parafacial respiratory groups (which are active in expiration and 
are insensitive to opioids), together with input from other brain areas and tonic drive from 
multiple chemoreceptor areas in the lower brainstem.6  Opioid-receptors responsible for 
respiratory depression are abundant at a number of anatomical loci within the respiratory 
centers, particularly at the pre-Bötzinger complex.6,7 
The current review will address opioid receptor-mediated respiratory depression, its 
reversal by naloxone and, in particular, some possibilities into mechanisms and drug 
prospects that may inhibit opioid-induced respiratory depressant effects, without 
reducing analgesia. 
2.2 THE ROLE OF OPIOID RECEPTORS IN RESPIRATORY DEPRESSION
Opioids exert their pharmacological effects through interactions with multiple opioid 
receptors, initially classified as μ-, κ- and δ-opioid receptors,8 to which the non-classical 
nociceptin receptor (nociceptin/orphanin FQ peptide receptor) may be added.9 Opioid 
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receptors are members of a large seven trans-membrane superfamily of G-protein coupled 
receptors (GPCRs). Opioid ligand attachment to the receptor results in binding of the 
Gi/o protein and formation of a Gαi-guanosine tri-phosphate (GTP) complex, which is 
primarily responsible for perhaps the best known opioid intracellular pathway, inhibition 
of adenylyl cyclase and reduction of intracellular cyclic adenosine mono-phosphate 
(cAMP) levels, resulting in changes in membrane currents and inhibition of transmitter 
release. Various other intracellular signaling pathways may also be activated by opioid 
binding (such as the MAPK/ERK (microtubule-associated protein kinase/extracellular 
signal-regulated kinase) and Akt (Protein Kinase B)), which may result in activation or 
inhibition of many cellular proteins and signaling mechanisms that lead to different 
biological outcomes.10,11 
Pharmacodynamic responses to opioid stimulation depend on the nature of the receptor 
and the affinity and efficacy of the opioid for that receptor. The common properties of 
morphine, for example, are attributable to binding and activation of the MOR12 and 
result in morphine-induced actions such as analgesia, respiratory depression, sedation, 
euphoria, constipation, vomiting and nausea. MORs are located in the central nervous 
system in centers associated with pain13 and stimulation induces strong analgesia. With 
regard to respiration, MORs are found in abundance in respiratory control centers in the 
pons and brainstem (see above and 6,7).
Using the more recent techniques of gene knockout studies, a link between MOR-
induced analgesia and respiratory depression has been demonstrated clearly; in MOR 
knockout mice the administration of morphine or other MOR agonists, failed to induce 
both antinociception and respiratory depression.14,15 Hence all known MOR agonists, 
such as morphine, fentanyl, hydromorphone etc., induce potentially both analgesia and 
respiratory depression. To investigate whether opioid analgesic drugs without respiratory 
depressant effects may be developed, there has been interest over many years in opioid 
agonist ligands specific for κ- and δ-opioid receptors.16,17 However, the development of 
analgesic agents acting at these opioid receptors has been limited by the association of 
such ligands with serious adverse events other than respiratory depression. For example 
ligands at the κ-opioid receptor may cause psychotomimetic and dysphoric effects,18,19 
ligands at the δ-opioid receptor may cause convulsions.25 Further development of 
therapeutically useful drugs acting at these opioid receptors still may be possible, for 
example (dimeric) peptides to act as multiple opioid ligands (e.g., δ-κ ligands).21,22 
Although MOR-induced analgesia invariably has the potential to also induce respiratory 
depression, there has been much speculation whether different opioids, dose regimens, 
routes of administration and other measures may separate these μ-opioid properties. 
Although naloxone is a competitive antagonist at the MOR and its administration may 
normally reverse both respiratory depression and analgesia, in clinical practice, the 
judicial use of naloxone titration may be used to selectively reverse respiratory effects, 
rather than analgesic effects, since respiratory depression may occur at a higher degree of 
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receptor occupancy than necessary for some degree of analgesia.1,23 
The possibility that MOR subtypes may exist and hence that subtype selective opioid 
ligands could allow separation of respiratory depression and analgesia, was supported 
by studies in which separation of these morphine-induced actions in rats was achieved 
with the use of the antagonist naloxonazine.24 In these studies, two receptor subtypes, 
μ1- and μ2-opioid receptors, were described; the μ1-opioid receptor was held responsible 
for the analgesic effects and the μ2-opioid receptor for respiratory depressant effects.19 
Naloxonazine showed selective antagonism of μ1-opioid receptor sites.24  Some separation 
of μ-opioid-induced analgesic and respiratory depressant effects has also been shown 
with the metabolite of morphine, morphine-6-glucuronide (M6G), which like its parent 
molecule morphine is a potent MOR agonist.25 In experimental human and clinical studies 
M6G induces less respiratory depression than morphine at equianalgesic doses.26-28 This 
selectivity of action has been attributed to selective effects on MOR subtypes, since some 
receptor binding studies have shown M6G to have a lower affinity for the μ2-opioid 
receptor compared to the μ1-opioid receptor.29, 25 An affinity profile for M6G of μ1 > μ2, 
therefore, may be expected to demonstrate a profile of analgesia with less respiratory 
effect than morphine. A note of caution is necessary, however, μ1- and μ2-opioid receptor 
subtypes have not been formally recognized;30 sufficiently selective ligands to define 
the μ1- and μ2 receptor subtypes, correlation with identified MOR splice variants and 
adequate experiments in humans are lacking so far. 
Apart from opioid receptor selectivity, the pharmacokinetics (PK) and pharmacodynamics 
(PD) of different opioids will also play a significant role in determining the actions of an 
opioid in vivo. Indeed, PK-PD human studies and modeling is proving of great value in 
further understanding and subsequently choosing of opioids for clinical use.1,28,31-32 
2.2.1 FULL OPIOID AGONISTS
Many of the common opioids in therapeutic use for pain management, such as morphine 
and its derivatives, and fentanyl and its congeners, are full agonists at the MOR. Acting 
at the MOR, all opioid agonists may induce respiratory depression over some part of 
their dose-response range, particularly at high doses. In vitro and in vivo studies show 
that full agonists at the MOR display relatively fast association and dissociation to and 
from the receptor.33-34 For rapidly acting drugs like fentanyl, the in vivo rate constants 
for receptor association and dissociation are fast relative to their PK in brain and plasma, 
indicating that in vivo binding to, and dissociation from, the MOR occurs essentially 
instantaneously.34 When considering the time courses of opioid-induced biological 
effects, including respiratory effects, association/dissociation from the receptor is not the 
rate determining factor and neither are the rates of drug removal from the plasma, since 
these opioids undergo rapid metabolism. The most important factor for opioid agonists in 
determining the link between plasma concentration and respiratory depressant outcome, 
as demonstrated by mechanism-based PK-PD modeling in humans, is the rate of transfer 
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of a drug from the plasma to an effect (i.e. a receptor containing) compartment.28,31,34 
A schematic diagram of the relationship between biophase kinetics, receptor kinetics 
and outcome is shown in Fig 1. For opioid agonists with a fast rate of transfer, such as 
remifentanil, alfentanil and fentanyl, the half-life for the transfer of drug from plasma to 
receptor site (t½ke0) is short. For example, t½ke0 estimates from opioid-induced changes in 
electroencephalographic activity range from 0.8 to 1.3 min for remifentanil, 0.6 to 1.3 min 
for alfentanil and 4.7 to 6.6 min for the fentanyl.34 As a result of the fast rate of transfer, 
biological effects will commence rapidly, whilst they may be more delayed for opioid 
agonists like morphine with slower rates of drug transfer to the effect compartment (e.g., 
t½ke0 estimates from morphine-induced miosis: 2.8– 3.9 h).31 A consequence of the rapid 
transfer and immediate association of potent opioids (like fentanyl) to the MOR is that 
infusion of a high intravenous dose may lead to a rapid onset of dangerous levels of 
respiratory depression and apnea before arterial carbon dioxide concentration may rise 
sufficiently to stimulate breathing.35 Such rapid respiratory effects may be less evident if 
the t½ke0 of the agonist is slower. Hence for the induction of rapid respiratory depression 
at equianalgesic doses, a hierarchy of opioid agonists may be deduced from fastest to 
slowest: alfentanil > fentanyl > morphine > M6G.28,31,34 For opioid agonists of markedly 
less lipophilicity, such as morphine and M6G,20 transfer to the effect site compartment is 
very slow (M6G t½ke0 ranges from 1.4 to 6.4 h), hence biological effects such as respiratory 
depression are considerably slower in onset.28,36 For compounds like M6G, slow transfer 
rates to different effect compartments may result in marked differences in the t½ke0 
estimates for the induction and time courses of various M6G-induced biological effects. 
With the complex hydrophilic nature of M6G,32 these variations in t½ke0 may be related to 
a number of factors, including transfer between brain compartments.37 
Figure 1. Schematic diagram of the pharmacokinetics of an opioid analgesic in the body (system) and central nervous 
system (CNS) compartments. After disposition part of the drug reaches the brain compartment after passage across 
the blood-brain barrier (with half-life t½ke0). Next the drug will distribute to the receptor site and attach to the 
receptor with association (on) and dissociation (off) kinetics. 
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 2.2.2 OPIOID PARTIAL/MIXED AGONISTS: BUPRENORPHINE
One approach to the development of opioid analgesic drugs with lower risk factors for 
respiratory depression has been the development of partial agonists at the MOR, such as 
buprenorphine.38 Partial agonists typically display a less than maximum or ceiling effect 
in their dose-response relationships, as has been described for buprenorphine-induced 
respiratory effects.35,39 At a very high dose (80% of its LD50), buprenorphine has minimal 
respiratory responses compared to fentanyl or morphine.40 A reduced maximum respiratory 
depressant effect has obvious advantages for the safety profile of buprenorphine. Unlike 
respiratory events, buprenorphine-induced analgesia, at least over clinical dose ranges, 
does not typically show a ceiling effect in postoperative pain.41 In detailed animal studies, 
buprenorphine has been shown to achieve maximum antinociceptive effects in some, 
although not all, animal models42 and, when antinociceptive ceiling effects are observed, 
these may be reached only at high doses, higher than those required for the maximal 
respiratory effects and outside of the ‘clinical dose range’.35,38,43 A recent review of the 
clinical use of buprenorphine by a consensus group of experts, reiterated that, consistent 
with receptor theory, buprenorphine behaves as a full μ-opioid receptor agonist for 
analgesia, with no ceiling effect, whilst there is a ceiling effect for respiratory depression 
with buprenorphine, clearly reducing the likelihood of potentially fatal adverse events.45
When considering onset and offset of buprenorphine effect, it is necessary, in addition 
to the biophase distribution kinetics (t½ke0, that was the sole determinant parameter for 
biological on/offset effects of fentanyl) to add the rate of the association and dissociation 
of buprenorphine to and from the MOR.34 A characteristic feature of buprenorphine is 
its slow receptor binding kinetics; buprenorphine displays slow association kinetics and 
even slower dissociation kinetics.33,46 For comparison in respiratory studies, the t½ke0 for 
fentanyl and buprenorphine were 16.4 and 75.3 min respectively, and whilst dissociation of 
fentanyl from the receptor was essentially immediate, the half time of receptor dissociation 
for buprenorphine was 68 min.35 PK-PD models need to reflect these differences and, for 
buprenorphine, only the combined expressions for biophase equilibrium and receptor 
kinetics describe accurately buprenorphine’s effects on respiratory function [34]. 
Buprenorphine has high affinity at δ- and κ-receptors, but efficacy at these receptors is 
highly variable. Although dependent upon the system tested, buprenorphine is described 
usually as a partial agonist at the MOR, an antagonist at the δ-receptor and a low efficacy 
agonist or antagonist at the κ-receptor.47 Interaction with these other receptor types may 
reflect buprenorphine’s actions on some pain systems, such as neuropathic systems,48-49 
but are unlikely to have a major influence on respiratory function.
2.2.3 OPIOID PARTIAL/MIXED AGONISTS: TRAMADOL
Tramadol is a racemic opioid widely used for relief of acute and chronic pain50 and is 
considered to have a low potential for respiratory depression.51,52 At opioid receptors, 
tramadol is an opioid agonist, selective for MORs, but with a low affinity for these 
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receptor sites, approximately 6000 times less than morphine.53,54 The major metabolite 
of tramadol, O-desmethyltramadol (ODT) is a more potent agonist at the MOR, with an 
affinity approximately 200 times greater than that of the parent drug.51 Both parent and 
metabolite may participate in the overall actions of tramadol. With tramadol, however, 
the low incidence of respiratory effects compared to analgesic effects, is due to additional 
non-opioid mediated actions that contribute to the analgesia. Tramadol is a monoamine 
re-uptake inhibitor. Both (+)- and (-)-tramadol inhibit the synaptic reuptake of 5-HT and 
noradrenaline. This leads to an increased stimulation of monoamine spinal descending 
inhibitory pathways and possibly of brainstem and thalamic analgesia-inducing sites.55 
The analgesic effects of tramadol, therefore, are thought to result from the sum of opioid 
receptor and monoamine reuptake activities55 as evidenced by studies in animals with 
pharmacological antagonists, which show that naloxone, yohimbine (an α2-receptor 
antagonist) and ritanserin (a 5-HT2 receptor antagonist) may all partially block the 
antinociceptive effects of tramadol.53,56,57 Still, patients receiving tramadol may experience 
respiratory depression, particularly after a considerable time lag from dosing, since 
elimination of its more potent metabolite ODT is slow (elimination half-life 5.6 h). However, 
since this MOR agonist displays a slow transfer from plasma to the effect compartment 
(and back),58 carbon dioxide accumulation will restrict exaggerated respiratory effects. In 
contrast to pure opioid agonists, therefore, drugs like tramadol with mixed actions may 
provide effective and safer analgesic regimens for the management of postoperative pain 
in modern clinical practice.59 
2.3 INVOLVMENT OF MICROGLIA IN OPIOID-INDUCED RESPIRATORY DEPRESSION: 
ROLE OF TOLL-LIKE RECEPTOR 4 (TLR4)
There may be possibilities for using non-neuronal opioid effects for the development 
of novel therapeutic analgesics with reduced risk of respiratory depression. One such 
possibility comes from expanding knowledge on the role of immune cells in opioid-related 
mechanisms. Glial cells and inflammatory mechanisms, along with neuronal responses, 
are important mechanisms in some types of pain58 and opioid interaction with glial cells 
through interactions with non-opioid receptors, for example the toll-like receptor 4 (TLR4) 
protein, may offer further targets for the novel therapeutic development of analgesics.1 
Opioids may interact with microglia via activation of MORs,59 but recent studies on opioid-
induced glial activation through non-opioid receptor mechanisms have revealed new 
insights into opioid-induced centrally mediated effects such as analgesia and respiratory 
depression.
Recognition of the role of microglia (and astrocytes) in pain mechanisms originated in the 
1990s and glial activation has become accepted as an important mechanism contributing to 
neuropathic and chronic pain.63 In various animal models following nociceptive peripheral 
tissue or nerve injury microglia are activated by a variety of factors. The activated state 
is characterized by glial release of a diverse range of proinflammatory mediators, such 
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as cytokines, chemokines and prostaglandins that produce a battery of effects, not least 
the enhancement of neuronal excitability and pain. Several activation signals have been 
described between neurons and glia, including fractalkine acting through glial CX3CR1 
sites [64] and ATP acting through P2X-type receptors.65 A further mechanism of glial 
activation is via stimulation of toll-like receptors and this receptor type may have particular 
relevance to opioid mechanisms. Morphine stimulates proinflammatory mediator release 
from glia and elevated proinflammatory mediators and the TLR4 receptor appear to play 
a key role in this process.66,68 TLR4s are distributed on microglia, but not on neurons69 
and glial TLR4s are activated by opioids to release proinflammatory mediators.68 The 
importance of TLR4 in opioid-induced activation of glial cells and subsequent release of 
neuroexcitatory mediators has been demonstrated, for example, by knockout mice lacking 
TLR4, which show markedly less proinflammatory cytokine release after a peripheral 
nerve lesion and less neuropathic pain-like behaviour.70 Other toll-like receptors, TLR2 
and TLR3, may also play related roles.71,72 An opioid-induced effect that may arise from 
opioid stimulation of these TLR4 and subsequent release of proinflammatory mediators 
is hyperalgesia.67,68 Hyperalgesia, an effect directly counter to the analgesic actions of 
opioids, is a well recognized feature of opioids in animals and humans and may be an issue 
in patient analgesic care [see reviews73-75]. Opioid-induced stimulation of TLR4, however, 
is not dependent on classical opioid receptors. This may be illustrated by the lack of 
stereoselectivity requirements in opioids for stimulation of TLR4, hence the (+)-morphine 
isomer has been shown to induce glial activation and hyperalgesia,76 as has the opioid 
receptor inactive morphine metabolite morphine-3-glucuronide (M3G).77  
If glial cells and TRL4 receptors are implicated in playing a part in the overall analgesic 
actions of opioids, are they also involved in other opioid-induced effects such as 
respiratory depression? Although this has been little researched, there is some evidence in 
favor of this concept. Glial cells have been implicated in respiratory mechanisms and, in 
brain slices, selective blockade of the glial Krebs cycle has been shown to inhibit rhythmic 
respiratory burst activity.78 More specifically, glial cells have been shown recently to 
contribute to the purinergic excitation of the respiratory rhythm generating pre-Bötzinger 
complex.79 Studies on glial and astrocyte function are more complex to carry out in vivo, 
but again recently, their role modulating central CO2 chemosensitivity and ventilation 
has been described.80 Similarly, the result of glial activation, namely proinflammatory 
mediator release, may also influence respiratory function. Interleukin 6, for example, has 
been implicated in respiratory diseases and may be considered as a biomarker for the 
risk assessment of asthma or chronic obstructive lung disease81 and may alter respiratory 
mechanics.82 It is possible, therefore, that opioids may interact via TRL4 with glial cells in 
the respiratory centers to influence respiratory control. Further evidence of this has been 
obtained with the use of minocycline to block morphine-induced TLR4 stimulation and 
glial activation and this will be considered below.
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2.4 NALOXONE-REVERSAL OF OPIOID-INDUCED RESPIRATORY DEPRESSION
Since the consequences of opioid-induced respiratory depression may be serious, even 
fatal, it is a clear clinical priority that rapid and effective reversal of respiratory depression 
is available. As discussed previously, opioid-induced respiratory depression is largely 
mediated through MORs, hence antagonists at this receptor site are key agents for its 
reversal. Two opioid antagonists are available clinically as rescue medications, but the one 
approved for this therapeutic indication and by far the most commonly used is naloxone. 
In the clinic, many studies have shown that naloxone may be used effectively for the 
rapid treatment of opioid-related events, although the extent and duration of naloxone-
induced reversal of opioid-induced respiratory effects is highly variable.83-85 When 
considering effective reversal regimens for naloxone, the PK and PD characteristics of the 
opioid analgesic (i.e., rate of metabolism, receptor kinetics and efficacy at the MOR) and 
of the antagonist itself must be taken into account. We have reviewed these agonist and 
antagonist PK-PD interactions extensively elsewhere1 and here present a brief summary. 
Naloxone is a competitive antagonist at the MOR with fast receptor association and 
dissociation kinetics.86 Naloxone is also lipophilic and therefore has rapid access to the 
brain (t½ke0 is short, 6.5 min). Consequently, transfer and equilibrium of naloxone from 
the plasma to brainstem MORs is rapid.87 As for full MOR agonists, for naloxone receptor 
kinetics is not the rate-limiting factor governing its ability to reverse opioid agonist 
actions. For full agonists such as fentanyl, single bolus administrations of naloxone are 
expected to completely reverse opioid-induced respiratory depression but this effect is 
critically dependent on the dose and mode of administration of naloxone and its PK. 
The elimination half-life of naloxone is about 33 min87; hence, with any opioid agonist 
that has a longer elimination half-life than naloxone (e.g., morphine, M6G, methadone), 
care must be taken since renarcotization may occur with time, particularly after a bolus 
administration of naloxone. Care must also be taken if rapidly metabolized opioid agonists 
are administered by continuous infusion, rather than by bolus injection, since following 
a bolus administration of naloxone, reversal of any respiratory depression will initially 
be rapid and complete, but respiratory depressant effects may reassert themselves as the 
agonist infusion continues and naloxone plasma levels decline.88 Even rapidly metabolized 
agonists, such as fentanyl, will show renarcotization if they are administered in high doses 
or by multiple injections (as occurs during anesthesia), as fentanyl plasma levels will 
remain high, whilst naloxone levels decline after a single bolus administration. However, 
a continuous infusion of naloxone may be used successfully to reverse even high doses 
of fentanyl.89  The viability of the use of naloxone for opioid reversal reaches some limits 
with opioid agonists exhibiting ultra-short duration of action (e.g. remifentanil, t½ke0= 1 
min, plasma elimination t½ = 3min),33 where simply stopping the infusion is more effective 
than attempting to achieve naloxone-induced reversal of effects. 
More complex interactions, however, exist between long lasting partial agonists, 
like buprenorphine, and naloxone. Respiratory effects observed with rising doses of 
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buprenorphine exhibit an apparent maximum or ceiling effect.35 Naloxone showed a 
complex and bell-shaped dose-response curve for reversal of buprenorphine-induced 
respiratory effects:85 bolus doses of naloxone that successfully reverse opioid agonist 
depressant effects (up to 0.8 mg) failed to reverse the respiratory depressant effects of 
buprenorphine, higher doses (2 - 4 mg) showed reversal of the effects, but even higher doses 
(5 - 7 mg) showed a decline in reversal activity.85 As discussed previously, the biological 
actions of buprenorphine is governed not only by plasma half-life and drug transfer to 
the effects compartment(s), but also by slow receptor kinetics. The slow association and 
dissociation of buprenorphine with the MOR is at the basis of the difficulties observed 
for the reversal of buprenorphine-induced respiratory depression by naloxone.36,90 A PK-
PD model of the reversal of buprenorphine-induced respiratory depression by naloxone 
predicts that continuous infusions of naloxone are required for reversal of buprenorphine’s 
respiratory effects (doses of 4 - 8 mg.h-1).85,87 This was experimentally verified.85 The cause 
of the bell-shaped naloxone dose-response curve, however, remains unknown, although 
it may involve buprenorphine effects at receptor sites other than the μ-opioid receptors.38
PK-PD modeling, therefore, may be used to design adequate naloxone regimens for reversal 
of opioid-induced respiratory depressant effects of opioid agonists. As shown in Fig. 2, 
PK-PD modeling demonstrates that an opioid with slower dissociation kinetics is more 
difficult to reverse with naloxone and consequently reversal develops more slowly and 
may require continuous infusion of the antagonist while the duration and magnitude of 
the reversal is dependent on the naloxone dose. The estimated order of difficulty (in terms 
of speed of reversal, Fig. 2), therefore, for naloxone to reverse a series of opioid agonists 
Figure 2. Effect of slowing of receptor dissociation kinetics on the rate of reversal of opioid-induced respiratory 
depression by a single dose of naloxone. Simulation data adapted from ref [32]. With slower the dissociation, the 
rate of reversal slows. At t = 0 an opioid dose is given; at t = 55 min a naloxone dose is given. 
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taking into account the range of μ-opioid receptor kinetics is (from most difficult to least 
difficult): buprenorphine > M6G > morphine > fentanyl.32 For full MOR agonists with 
rapid receptor kinetics, the PK of the opioid agonist and naloxone are evenly important in 
determining the administration regimen of naloxone required.88 
2.5 ALTERNATIVE STRATEGIES TO REVERSE OPIOID-INDUCED RESPIRATORY 
DEPRESSION
Naloxone is a MOR competitive antagonist with high affinity and low efficacy at the 
receptor site and shifts MOR agonist dose-response curves to the right in a parallel 
manner.91 In receptor model terms, naloxone fulfills the concept of a classical competitive 
antagonist that is able to displace the agonist at a single conformational active site of 
the receptor and then, with its low efficacy, is unable to produce the conformational 
changes that are required to induce intracellular responses leading to biological effects. 
Naloxone will antagonize the whole range of opioid effects: opioid-induced analgesia, 
respiratory depression, sedation, gastrointestinal effects, etc. Naloxone, therefore, may 
reverse respiratory depression very effectively, particularly in an emergency situation, but 
will also reverse opioid-induced analgesia presenting real clinical difficulties. To try to 
design MOR antagonists to selectively reverse some opioid-induced biological actions, 
but not others, e.g. to antagonize respiratory depression, but not analgesia, is theoretically 
and practically difficult with competitive antagonists, and resides in trying to introduce 
different PK and PD characteristics, or selectivity for MOR subtypes, if they exist. PK-PD 
modeling shows that it may be possible to titrate naloxone to reverse respiratory depressant 
effects and not compromise analgesia in some situations where respiratory depression 
may occur at higher receptor occupancy than some degree of analgesia.1 However, it is 
difficult to see a ‘naloxone-based’ approach to this problem being able to achieve complete 
reversal of opioid-induced respiratory depression whilst leaving opioid-induced analgesia 
unaffected. 
It may also be valid to mention at this point, that more recent experimental studies on 
ligand interactions with receptor conformations have shown that the ‘one size fits all’ type 
of activation (as described above for naloxone) is not adequate to describe the observations 
in all systems. There appears to be diversity in receptor activation states, whereby 
ligands of varied efficacies produce different receptor conformational changes, thereby 
stabilizing conformationally distinct active states of the receptor, and not a single active 
conformational state. Ligands of different efficacies, therefore, may effect stimulation of 
different active conformational states of the same receptor leading to activation of separate 
intracellular signaling pathways and varied biological outcomes, i.e., functional selectivity 
[see review 92]. On this model, allosteric antagonist ligands (‘biased’ antagonism) may be 
able to selectively antagonize certain conformational active states of the receptor resulting 
in selective reversal of some biological effects. An example of the effect of allosteric 
receptor sites is given for AMPA receptors later in this review. These concepts have been 
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discussed for opioid receptors.93,94 As members of the GPCR superfamily, opioid receptor 
activation by different opioid ligands may stimulate different Gα subunits.90 At least 
one hypothetical possibility arising from ligand specificity for Gα activation may be the 
separation of analgesic effects from respiratory depression and other unwanted side effects 
of opioids.93 However, for opioid receptors at present there remains uncertainty whether 
different opioid-induced effects may result from effects at different receptor types rather 
than different active site conformations of one receptor, or if indeed selective stimulation of 
Gα subunits does occur (i.e., that analgesia and respiratory depression may be induced by 
different Gα subtypes). Nevertheless, the design of selective allosteric opioid ligands with 
varied efficacies for the μ-opioid receptor with functional selectivity remains an interesting 
concept for improvements over naloxone.
Alternative approaches, separate to any based directly on interactions with μ-opioid 
receptors, may be required for the design of selective compounds that will reverse opioid-
induced respiratory depression, without compromising opioid-induced analgesia, for use 
outside of emergency settings. We will consider two such potential approaches involving 
inhibitors of glial activation and antagonists of other transmitter systems present in 
respiratory centers.
2.5.1 INHIBITION OF GLIAL ACTIVATION
The toll-like receptor family, particularly TLR4, have been demonstrated to be involved 
in opioid-induced glial activation.66-68 However, the TLR4 requirements for opioid ligand 
binding are very different from those for classical opioid-receptors and we have previously 
made reference in this review to the lack of stereoselectivity requirements in opioid agonists 
for stimulation of TLR4. Hence the (+)-morphine isomer has been shown to induce glial 
activation and hyperalgesia,76 as has the opioid receptor inactive morphine metabolite 
M3G.77 This lack of stereospecific requirements by TLR4 is also shown by antagonists and 
both (+)- and (-)-naloxone have been demonstrated to block TLR4 mediated signalling 
and cytokine production in HEK-293 cells in vitro.94 In vivo, both isomers of naloxone 
also suppress neuropathic pain following sciatic nerve chronic constriction injury in rats.95 
The lack of stereoselective requirements in antagonists on TLR4, therefore, may enable 
development of opioid antagonist isomers that are inactive at neuronal μ-opioid receptor-
mediated analgesic effects, but may reverse glial TLR4-mediated respiratory depressant 
effects and hence separate these opioid-induced events. 
Antagonists at the TLR4 site, however, do not have to be based structurally on classical 
opioid antagonists as a diverse range of molecules may block opioid-induced TLR4-
mediated events. Minocycline is a semi-synthetic, second generation tetracycline 
antibiotic, first introduced in 1972, that has long been known to possess anti-inflammatory 
and neuroprotective effects unrelated to its antibacterial activity [see review96]. Although 
there is considerable experience with minocycline clinically, it is associated with a range 
of adverse side-effects, some of which, such as vestibular symptoms, may be serious.97 
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Minocycline exerts anti-inflammatory actions by modulating microglia and the subsequent 
release of cytokines, chemokines and other inflammatory mediators.91 Recently, PET scan 
imaging has been used to demonstrate activation of rat brain microglia by zymosan and its 
inhibition by minocycline.98 Minocycline, as an inhibitor of microglial activation, has been 
investigated in animal models of opioid-induced respiratory depression and analgesia.99 
Minocycline suppressed various measures of morphine-induced respiratory depression, 
such as tidal volume and minute ventilation, inspiratory and expiratory force, although, 
at the doses used, it did not block changes in respiratory rate. In contrast, the same doses 
of minocycline enhanced the antinociceptive effects of morphine. These contrasting effects 
of minocycline on respiration and antinonciception may both be due to inhibition of the 
release of proinflammatory agents from glia that, as discussed previously, may induce 
centrally mediated respiratory depression and hyperalgesia. In these studies, the lack of 
observed effects of minocycline on respiratory rate, compared for example with minute 
volume, is discussed in relation to the different dorsal and pontine central respiratory 
sites from which tidal volume and respiratory rate originate (e.g., ventrolateral division 
of the nucleus tractus solitarius and pre-Bötzinger complex respectively) and possible 
glial heterogeneity and/or site specific effects of opioid mediated glial events.99 Various 
further recent studies continue to explore minocycline-induced microglial inhibition of 
proinflammatory mediators and their varied effects, for example, reversal of hyperalgesia 
through minocycline-induced inhibition of cytokines from microglia and a subsequent 
reduction in potassium chloride co-transporter 2 in the spinal cord.100 
A brief further illustration of the potential for the separation of opioid-induced effects 
by inhibition of glial activation may be made with the drug AV411 (ibudilast), although 
with the differentiation of analgesia and opioid withdrawal rather than with respiratory 
depression. AV411 is a relatively non-selective phosphodiesterase (PDE) inhibitor and has 
been marketed in some countries for bronchial asthma and post-stroke dizziness.101-103 
However, AV411 is also a microglial inhibitor with anti-inflammatory effects. Its 
widespread effect on PDEs and on bronchial smooth muscle do not make the drug a target 
for exploring opioid-induced respiratory depression, but AV411 has successfully been 
shown, through actions on microglia, to significantly reduce opioid withdrawal whilst 
enhancing analgesia.101-103 Hence, both minocycline and AV411 have been demonstrated 
to inhibit glial activation and release of proinflammatory mediators resulting in enhanced 
analgesia, but with reduced other opioid-mediated events, respiratory depression 
and opioid withdrawal, respectively. Together with the non-stereoselective isomers of 
naloxone, these materials illustrate a potential direction for the development of selective 
glial inhibitors, perhaps particularly TRL4, to be targeted towards the effective separation 
of opioid-induced analgesic from respiratory depression.
2.5.2 STIMULATION OF NEUROTRANSMITTER SYSTEMS IN THE PRE-BÖTZINGER COMPLEX
Respiration is under the control of central neural networks and one of the most important 
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is located in the pre-Bötzinger complex. The pre-Bötzinger complex plays a major role 
in the modulation and generation of respiratory drive, particularly respiratory rhythms 
underlying the active inspiratory phase of breathing.6,7 MORs are located in this area and 
opioid-depressant effects, especially life-threatening apnea, may originate from within the 
complex. Many other neurotransmitter systems and receptors related to their transmitters 
are also located in this neural network, some being co-expressed with MORs. Several 
important questions now arise. If neurotransmitters in the pre-Bötzinger complex operate 
to stimulate respiratory function, would stimulation of these systems induce ventilatory 
stimulation even in the ongoing presence of opioid-induced respiratory depression? 
Would activation of stimulatory respiratory systems functionally reverse opioid-induced 
respiratory depressant effects, but without reduction of opioid-induced analgesia for 
which the mechanistic centers are located elsewhere in the brain? If so, would selective 
ligands for the respective relevant neurotransmitter receptors form the basis of new 
therapeutic agents to enhance the safety margins of opioid analgesics? Several possible 
receptor targets arise from the identification of respiratory stimulatory systems in the pre-
Bötzinger complex that suggest ventilatory drive may be increased in the presence of opioid 
respiratory depression. Three ventilatory stimulatory systems, 5-hydroxytryptamine 
(5HT), α-amino-3-hydroxy-5-methyl-D-aspatate (AMPA) and phosphodiesterase-4 (PDE4) 
will be reviewed briefly [see also review1]. (Table 1).
 
2.5.3 5-HYDROXYTRIPTAMINE (5-HT)
5HT receptor types and subtypes are expressed both centrally and peripherally and are 
involved in mediating many diverse clinical states including mood, memory and learning, 
aggression, sleep and pain, but are also present in the pre-Bötzinger complex and related 
neural networks. In this region, 5HT is a respiratory stimulatory neurotransmitter and a 
number of 5HT receptors subtypes have been identified with high density. 5HT receptors 
are members of the GPCR superfamily (except 5HT3 receptors, which are cation channels). 
5HT enhances activity in respiratory neurons in this network through an action on 5HT1A, 
5HT4 and 5HT7 receptors:104
a)  One of the earliest 5HT1A agonists to point toward a potential stimulation of respiration 
without affecting antinociception was the tetralin derivative, 8-OH-DPAT. In studies in 
Target for interference with opioid-induced respiratory depression
Opioid-receptors (on respiratory neurons in the brainstem)
Toll-like receptor 4 (TOLL on glia cells in the spinal and possibly supraspinal sites)
5 hydroxytryptamine receptors in respiratory centers in the brainstem
AMPA receptors in respiratory centers in the brainstem 
Phosphodiesterase-4 in respiratory neurons
Table 1
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rats, for example, 8-OH-DPAT was demonstrated to reverse opioid-induced depression 
of ventilation without antagonizing antinociception.105,106 In the most recent studies, 
8-OH-DPAT was demonstrated to recover breathing following fentanyl-induced 
respiratory depression in the rat in vivo.107 The partial agonist buspirone has also been 
investigated, which unlike 8-OH-DPAT, was available for studies in man and was shown 
in clinical cases to improve rhythmical respiration where damage to the brainstem 
caused apneustic breathing.108,109 However, buspirone failed to counteract opioid-
induced respiratory depression induced in healthy volunteers.110 Buspirone is probably 
a poor tool to explore the capacity of 5-HT1A ligands to induce respiratory stimulation 
since it is a partial agonist and full agonists at this receptor site may be required to effect 
strong ventilatory improvements.111  The most recent 5-HT1A full agonist to be studied in 
rats for reversal of opioid-induced respiratory depression is repinotan, which has been 
shown to be effective in stimulating ventilation without impairing antinociception.112 It 
is worth noting, however, that repinotan-induced stimulation of spontaneous breathing 
after morphine-induced respiratory depression displayed a ‘bell-shaped’ dose-response 
curve, hence reversal of the opioid-induced respiratory effects by repinotan was dose 
dependent and declined at higher doses. Bell-shaped dose response relationships 
are known for other 5-HT1A-induced responses, e.g. neuroprotection, and have been 
suggested to arise from dose dependent effects eliciting opposing stress responses.113 
Hence, studies with repinotan support the earlier findings with 8-OH-DPAT that full 
agonists at 5HT1A receptors may induce stimulation of respiration without reducing 
opioid-induced analgesia. Recent important mechanistic studies on 5HT1A-induced 
respiratory stimulation have demonstrated that 5HT1A receptors located on inhibitory 
glycinergic interneurons of the pre-Bötzinger respiratory networks appear to be critical 
for this function. Stimulation of these receptors leads to modulation of glycine receptors, 
network reorganization and disinhibition that restores breathing rhythms after opioid-
induced depression.114,115 Although each of the examples of 5-HT1A ligands cited above 
has limitations, selective 5-HT1A agonists may provide interesting leads for potential 
therapeutic agents to stimulate spontaneous breathing even in the presence of opioid-
induced depression of respiratory function. 
b) 5HT4(a) and μ-opioid receptors are co-localized on respiratory neurons in the pre-
Bötzinger complex, but display opposing actions resulting in 5HT4(a)-mediated increase 
in cAMP and increased inspiratory drive, compared to μ-opioid receptor-induced 
decrease in cAMP and decreased inspiratory drive.116,117 Hence, in animal studies, the 
5HT4(a) receptor agonist BIMU8 was shown to overcome fentanyl-induced respiratory 
depression and apnoea, without affecting antinonciception116 and zacopride was 
demonstrated to reverse etorphine-induced respiratory depression.118 In the former of 
these studies, the respiratory stimulating effect was believed to be specific to 5HT4(a) 
receptors because the effect of BIMU8 was antagonized by the 5HT4(a) receptor antagonist 
GR113808.104,116 However, the 5HT4(a) receptor agonist RS67333 has more recently 
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been shown to fail to recover breathing in opioid-induced respiratory depression107 
and, in human healthy volunteers, another 5HT4(a) receptor agonist, mosapride, 
also demonstrated no effect on respiratory depression induced by morphine.119 The 
negative results with mosapride and RS67333 may be attributable to low potency or PK 
considerations with insufficient effect-site concentrations being achieved, as suggested 
by PK-PD modeling for maosapride.119 or from different pharmacological profiles of 
the many 5HT4 splice variants,120 but an explanation remains a conjecture a present. 
c) Although some selective antagonists, SB-269970-A and SB-656104-A, for the 5HT7 
receptor have been reported,121 selective receptor agonists are not available for this 
receptor. A number of 5HT ligands will stimulate 5HT7 nonselectively, including 
8-OH-DPAT,122 which has raised questions as to whether the respiratory stimulatory 
actions and reversal of opioid-induced respiratory depressant effects of 8-OH-DPAT 
are mediated by 5-HT1A or 5HT7 receptors.104,118 There is a need for better selective 
ligands at 5HT7 receptors to become available before a role for these receptors within 
the respiratory networks can be defined.
2.5.4 AMPAKINES
Another respiratory stimulatory mechanism within the pre-Bötzinger complex is 
glutaminergic transmission through AMPA receptors. AMPA receptor modulators do not 
interact with the receptor site directly as agonists (or antagonists), but bind to an allosteric 
site within the glutamate receptor complex. Allosteric binding on the AMPA receptor 
modulates the kinetics of deactivation (channel closing and transmitter dissociation) and 
desensitization123 and AMPA modulators increase the duration of glutamate-induced 
AMPA receptor-gated inward currents.124 Within the pre-Bötzinger complex, activation of 
AMPA receptors is important for rhythmogenesis and induction of increased respiratory 
frequency through an increase in glutamate-mediated excitatory inspiratory drive.125 
Several distinct classes of AMPA receptor ligands have been described, with much interest 
centered upon the benzamides, a group collectively called ampakines. Several examples 
of ampakines that interact in different ways with the allosteric binding site have been 
studied in respiratory systems, e.g., CX516, CX546, CX614, CX717,1 but, for the current 
review, the focus will be on CX717 as this ampakine has been the most studied, including 
with early investigations in humans. Treatment of rats with CX717 markedly protected the 
animals from fentanyl-induced respiratory depression, mechanistically described as due 
to accentuation of the AMPA-receptor mediated glutaminergic excitation that counteracts 
the μ-opioid receptor-mediated suppression of the pre-Bötzinger complex neuronal 
excitability.126,127 Pretreatment with CX717 did not significantly alter fentanyl-induced 
antinociception.126,127 One importance of these finding with CX717 is that this material is 
available for use in humans (CX717 has been tested for safety and efficacy in the treatment 
of human ADHD [see references in126-128]). A proof of concept study has been carried 
out in healthy human volunteers to test the hypothesis that opioid-induced ventilatory 
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depression may be selectively reduced by prior administration of CX717.128 In this study, 
a single oral dose of CX717 (1500 mg) successfully reduced all measures of respiratory 
depression induced by a subsequent intravenous infusion of alfentanil administered 
to reach a target plasma concentration of 100 ng.ml-1. At this plasma concentration, 
alfentanil was shown to induce analgesia in the subjects when tested with two models of 
experimental pain, effects that were not apparently compromised by prior administration 
of CX717, but could be revered by naloxone.128 Hence, ampakines like CX717 may offer 
a therapeutic potential for the suppression of opioid-induced postoperative respiratory 
depression, and hence an increase in safety, without negating their analgesic effects. 
2.5.5 PHOSPHODIESTERASE-4-INHIBITORS
The methylxanthines caffeine and theophylline have been used to counter apneas and 
stabilize breathing in preterm infants, although both drugs are associated with adverse 
events.129 Methylxanthines block adenosine receptors and, although this has been 
suggested for the action of methylxanthines in neonates, adenosine receptor antagonists 
do not inhibit inspiratory neurons130 and alternative mechanisms for the methylxanthines 
have been sought. At concentrations of methylxanthines that have demonstrated 
respiratory effects in vitro, these agents also inhibit phosphodiesterase-4 (PDE4), 
which results in elevated cAMP and stimulation of phosphokinase A.131 As described 
previously, 5HT4(a) receptor agonist also enhance cAMP levels and stimulate inspiratory 
drive and this may be a mechanism of action for methylxanthines. More recent studies 
have supported this hypothesis and methylxanthines have been shown to reverse opioid-
induced depression of the respiratory rhythm in the pre-Bötzinger slices in the newborn 
independently of adenosine receptors and apparently associated with PDE4 inhibition.132 
In further support of this, the specific PDE4 antagonist rolipram, alone and combined 
with theophylline, was able to reactivate respiratory rhythm after severe depression with 
the μ-agonist DAMGO alone.132 Whilst all these agents are limited currently by adverse 
effects, particularly rolipram, new specifically targeted PDE4 inhibitors (particularly of 
PDE4 subtypes) may allow improved treatment for breathing control in the premature 
and newborn infants. 
2.6 CONCLUSIONS
Opioid-induced respiratory depression remains a potentially life-threatening side effect 
of opioid treatment of severe acute and chronic pain. Whilst data on the incidence of 
opioid-related morbidity remain difficult to unearth from the literature, estimates on 
respiratory events in the perioperative setting range from 0.5 to 2%. Data on respiratory 
events in chronic pain patients on potent opioid therapy are even scarcer. We assume that 
this is partly because of the unwillingness to report fatal complications and partly because 
respiratory-depression related death in chronic cancer-pain patients is an accepted 
fact in the course of the disease or is assumed to be due to the ‘natural’ progression of 
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the underlying disease. Irrespective, we consider fatal (or near-fatal) opioid-induced 
respiratory depression an avoidable complication. Strong opioids should be titrated to 
effect, or even better, to the multiple effects, analgesia and respiratory depression. While 
insufficient analgesia requires further dosing the occurrence of breathing irregularities or 
cyclic breathing is an immediate sign to stop further dosing. Evidently, knowledge on 
the pharmacokinetics and (mechanism-based) pharmacodynamics of the MOR agonist in 
relation to patient specifics (e.g., disease-state, age, fluid status, cardiac, liver and renal 
function) is at the basis of sensible titration. Separation of opioid-induced respiratory 
depression and analgesia seems improbable taken the fact that the MOR is the molecular 
target of both effects and the absence (so far) of proof in humans for distinct opioid-receptor 
subtypes involved in analgesia versus respiratory depression or selective stimulation of 
Gα subunits. Development of opioids with effect-selectivity will rely on these distinctions. 
Current practice of reversal of opioid-induced respiratory depression is based on 
antagonism of the MOR with naloxone, a non-selective antagonist that will antagonize 
not only respiratory depression but the whole range of opioid effects including opioid-
induced analgesia. Because of this loss of analgesia, the rapid onset/offset of naloxone 
(and consequently high chance of renarcotization) and naloxone’s relative difficulty 
with reversal of opioids with slow receptor dissociation alternative strategies are being 
developed. These alternative modes are aimed at reversal and prevention of opioid-
induced respiratory depression without compromising analgesia. Agents that are being 
studied include 5HT agonists, ampakines, phosphodiesterase inhibitors and drugs that 
stabilize activated glia cells in the pons and spinal cord. Especially the latter group of 
therapeutics is of interest as animal data indicate that reduction in opioid side effects 
coincides with improved analgesic efficacy.
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Opioids affect breathing by activation of μ-opioid receptors expressed on respiratory 
neurons in the brainstem.1,2 As a consequence ventilation is depressed and arterial 
carbon dioxide increases. Since carbon dioxide activates chemoreceptors in the neck and 
brainstem (peripheral and central chemoreceptors), part of the opioid-induced respiratory 
depression is concealed by carbon dioxide-induced respiratory stimulation (the so-called 
carbon dioxide chemoreflex).3 Especially, when the opioid slowly passes into the brain, 
the subsequent slow increase in carbon dioxide will offset major respiratory depression. 
On the other hand, when the opioid rapidly passes the blood-brain barrier or the opioid 
is overdosed, depression of the respiratory neurons is faster and more noticeable than the 
respiratory stimulation from the carbon dioxide increase.3 Then the opioid’s effect is most 
dangerous. In general, opioids are considered safe with about 0.5% of patients receiving 
opioids for treatment of acute pain requiring immediate treatment for sometimes life-
threatening respiratory depression.1 However, in specific patient groups this number is 
certainly much greater (e.g., patients with sleep-related apnea, obesity, muscle weakness, 
pulmonary disease). Furthermore, even in patients considered not at risk opioid-induced 
mortality still occurs.4,5 
The number of studies on the effect of potent opioid analgesics on breathing is still limited. 
Even sparser are studies that quantify intravenous opioid effect on breathing using 
meaningfully parameterized pharmacodynamic models. The latter models are important 
as they allow, apart from the reliable description of opioid effect, the comparison among 
opioids (e.g. on potency), the study of drug-drug interaction, and prediction of specific 
breathing-related idiosyncrasies, such as the occurrence and duration of apnea. Current 
available models may be divided into two groups: 1. Steady-state models, where the 
end-tidal carbon dioxide concentration (PCO2) is kept constant (by breath-to-breath 
manipulation of the inspired carbon dioxide concentration) and just the drug’s effect on 
ventilation is measured (these models are also called open-loop models as the feedback 
loop between ventilation and arterial PCO2 is broken –the loop is now open);6-10 and 2. 
Non-steady-state models, in which the effect of the drug on arterial (or end-tidal) carbon 
dioxide and ventilation are both measured (these models are also called closed-loop 
models as the feedback loop between ventilation and arterial carbon dioxide remains 
active).11-13 In contrast to steady-state models, non-steady-state models need to take 
into account the depressant effect that the opioid has on respiratory neurons in the brain 
causing the reduction of breathing and consequently the increase in arterial PCO2, but 
also and equally important, these models need to take into account the stimulatory effect 
of carbon dioxide on breathing. Only when both components are properly incorporated 
in the model reliable estimates of the drug’s respiratory potency are obtained and a 
prediction of its respiratory behavior can be made.3  
We previously performed steady-state experiments and applied steady-state models 
to describe opioid-induced respiratory effects and their interaction with anesthetics 
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(sevoflurane, propofol).9,10 While it allowed for the accurate description of the synergistic 
opioid-anesthetic interaction on breathing, this was unable to predict ‘real-life’ non-steady-
state conditions such as occur when drug concentrations rapidly change. In the current 
study we performed non-steady-state experiments by applying increases in remifentanil 
concentration of different rates of rise. Experiments were performed in healthy volunteers 
in the awake condition and at the background of a low-dose propofol infusion. Next, 
we developed a non-steady-state pharmacokinetic-pharmacodynamic model of opioid-
induced respiratory depression. 
The control of breathing is a complex system using both feedback and feed forward 
control tools to maintain cellular homeostasis.14 Hence, it is important to make choices 
when considering the site of action of opioid effect within the control system. We 
constructed a relatively simple model with drug concentration and end-tidal PCO2 as 
input and measured inspired ventilation as output. Basic characteristics of the model 
are (i) it assumes that drug and carbon dioxide have opposing effects on breathing;3 (ii) 
it is based upon the linear and well described relationship between carbon dioxide and 
ventilation, V = G (PCO2 – B), where V is inspired minute ventilation, G is the gain of the 
ventilatory control system and B the extrapolated end-tidal PCO2 at which apnea occurs 
(apneic threshold);14-16 (iii) the opioid effect is on B, while anesthetic effect is on G (Fig. 
1).10 In our study, the model’s behavior is tested to assess whether it accurately predicts 
apnea at finite opioid drug concentrations and whether all important model parameters 
are estimable (using a sensitivity analysis).
·
Figure 1. A. Effect of remifentanil on the central gain of the respiratory controller as measured by Nieuwenhuijs et 
al.6 in steady-state experiments. At remifentanil concentrations > 0 the gain remains constant at 1.6 ± 0.1 L.min-1.
Torr-1. B. Effect of remifentanil on the apneic threshold (B) of the respiratory controller as measured by Nieuwenhuijs 
et al.5 B increases linearly with increasing remifentanil concentrations according to the function B(CREM) = 39*(1 + 
CREM/6.14). C. Probability density function for end-tidal carbon dioxide concentration with σA






3.2 MATERIALS AND METHODS
3.2.1 SUBJECTS
Ten healthy male volunteers (age 18-30 years; body mass index < 28 kg.m-2) were recruited 
to participate in the study after approval of the protocol by the local Human Ethics 
Committee (Commissie Medische Ethiek, LUMC, Leiden, The Netherlands). Written 
and oral informed consent was obtained prior to inclusion in the study. All subjects were 
instructed not to eat or drink for at least 6 h before the study.
After arrival in the laboratory, an arterial line for blood sampling was placed in the 
left or right radial artery. In the contralateral arm an intravenous line was inserted for 
drug infusion. Each subject participated in three remifentanil infusions separated by 120 
min washout-intervals. The first two were without a background infusion of propofol; 
the last with a propofol infusion aimed at a target bispectral index value of 80 (average 
target plasma concentration = 1 μg.ml-1). We randomly assigned one of the two initial 
experimental runs (i.e., without propofol infusion) to be performed without blood 
sampling. In the other two runs 3-6 arterial blood samples were obtained for remifentanil 
measurements at arbitrary time points.
Remifentanil was administered using a target controlled infusion system. For remifentanil 
we used a custom-built infusion pump that was programmed with a pharmacokinetic data 
set (Remifusor, University of Glasgow, Glasgow, UK).17 We applied different remifentanil 
infusion schemes among the ten subjects as is described in table 1. We aimed at obtaining 
different rates of increases of the remifentanil plasma concentration (ranging from slow to 
fast). This was obtained by applying step increases in remifentanil plasma concentration 
(in 7 of 10 subjects we used steps of 1 ng.ml-1) with varying step durations (0.5, 1, 1.5, 2, 3, 
4 or 6 min) and with varying numbers of steps (2, 4, 5 or 6). In two subjects we performed 
a single 1-min step with step sizes of 6 and 9 ng.ml-1. In the appropriate runs, one to 
three blood samples were randomly obtained during remifentanil infusion (but always 
just prior to a change in target remifentanil concentration); following infusion two to three 
blood samples were obtained, again at random times. Each volunteer was subjected to 
three identical target remifentanil infusion schemes. In case of irregular breathing with 
periods of apnea (no breathing for periods > 10 s) and/or significant oxygen desaturations 
(SpO2< 90%) the subject was initially stimulated to take a deep breath. If this had no effect 
the subject was artificially ventilated by bag via the mask and pneumotachograph for 
20-30 s. The investigators could terminate or adapt the infusion at any time during the 
experiment when they felt that this was required to alleviate apnea and/or hypoxemia.
3.2.2 MEASUREMENTS
A face mask was applied over mouth and nose. Inspired and expired gas flows 
were measured with a pneumotachograph connected to a pressure transducer and 
electronically integrated to yield a volume signal (Hans Rudolph, Myandotta, MI). 
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During the studies the subjects inhaled 100% oxygen. The oxygen and carbon dioxide 
concentrations of the in- and expired gases and the arterial hemoglobin-oxygen saturation 
were measured with a Datex Multicap gas monitor (Datex-Engstrom, Helsinki, Finland). 
The electroencephalogram was recorded using an A-2000 monitor with software version 
3.3 (Aspect Medical Systems, Norwood, MA). The monitor computed the bispectral 
index (BIS) over 2-s epochs. We averaged the BIS-values over 1-min. End-tidal PCO2 and 
inspired minute ventilation were stored on disc for further analysis. We further report the 
measured SpO2 and BIS during the remifentanil infusions.
Samples for the determination of blood remifentanil concentrations were collected into 
tubes containing sodium heparin and immediately transferred to tubes containing 50% 
citric acid (to inactivate esterases) before freezing at –20°C. The assay method is based on 
tandem mass spectrometry detection.10
3.2.3 DATA ANALYSIS
A population pharmacokinetic-pharmacodynamic analysis was performed on the data. The 
analysis was performed in two steps. In step 1 a population remifentanil pharmacokinetic 
analysis was performed. Next using the individual Bayesian pharmacokinetic estimates a 
population pharmacodynamic analysis was performed.
Remifentanil pharmacokinetics. The description of remifentanil pharmacokinetics was 
aimed at obtaining individualized drug input functions to the pharmacological model. 
The actual infusion rates from the log file of the target controlled infusion device were 
used. The distributions of the structural parameters were fixed to the values of the three-
compartmental model reported by Minto et al.17 (i.e., the typical values and interindividual 
variabilities), and individualized by adjusting for age and lean body mass. A population 
analysis was performed which allowed for Bayesian individualization of the structural 
parameters (albeit within the constrained distribution).18 A remifentanil effect-site 
was postulated where the concentration lags with respect to the central compartment 
concentration as quantified by the equilibration half-life parameter t½ke0.
Carbon dioxide pharmacokinetics (figure 2). The relationship between carbon dioxide 
content (C) and its partial pressure (P) was assumed to be linear, so that P = λ0 · C, where 
λ0 = 0.863 Torr.(ml CO2 in 100 ml blood)-1.19 The following mass balance equations were 








= Q̇ · (PA − PV)+ λ2 · V̇CO2
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Figure 2. Schematic representation of the pharmacokinetic-pharmacodynamic model. The model has three distinct 
parts. I. The remifentanil pharmacokinetic part, consisting of the distribution of remifentanil though the body, 
including the effect-site (i.e., the respiratory controller in the brainstem) (via a rate constant, ke0). Part II is the 
respiratory controller in the brainstem. Remifentanil’s effect on the ventilatory control system results in a reduction 
of ventilation (via a delay, τ). Part III is the part that describes carbon dioxide kinetics. Carbon dioxide production 
determines together with ventilation the arterial carbon dioxide concentration. Since remifentanil causes the 
reduction of ventilation and carbon dioxide production is minimally affected, the ability of the system to clear 
carbon dioxide has diminished and arterial carbon dioxide concentrations will rise. This will have a stimulatory 
effect on the respiratory controller (part II).  The main effect of adding propofol on top of remifentanil is shown as 
an effect on the gain factor G. 
CL = clearance; CREM = remifentanil concentration in plasma; C50 = concentration remifentanil causing 50% 
respiratory depression; G = gain of the ventilatory control system or slope of the hypercapnic ventilatory response; 
PE = end-tidal carbon dioxide partial pressure; PE_0 = baseline (predrug) end-tidal carbon partial pressure; Q = 
cardiac output; ke0 = blood-effect site rate constant; τ = time constant of the ventilatory control system; V= inspired 
minute ventilation; V0 = baseline (predrug) inspired minute ventilation; VCO2= carbon dioxide production; VALV 
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where VAL is alveolar volume, PA arterial carbon dioxide pressure (which is assumed to 
equal alveolar pressure), V inspired minute ventilation, Q cardiac output, PV venous carbon 
dioxide pressure, VTS apparent tissue volume, and VCO2 is carbon dioxide production. 
Since ventilation enters the model of carbon dioxide kinetics directly (see eqn. 2) no 
correction was made for dead space ventilation. Furthermore, λ1 = k · PBW.λ0-1 .100-1 ≈ 10 
and λ2 = 100 · λ0,, where k is the volume conversion factor from standard temperature and 
pressure, dry to body temperature and air saturated with water and PBW the barometric 
pressure minus the pressure of air saturated with water. In the data analysis we fixed VAL 
to 3L.19 VCO2was estimated from the baseline end-tidal carbon dioxide concentration and 
V. These baseline values, Q and VTS were parameters to be estimated. 
Pharmacodynamic analysis: Modeling the effect of remifentanil on the ventilatory 
control system (Fig. 2). The effect of end-tidal PCO2 (PE) on ventilation under hyperoxic 
conditions can be modeled as follows:14-16
       
       
where G is the central gain, B the apneic threshold and τ a time constant. Nieuwenhuijs et 
al.10 characterized the remifentanil-propofol interaction on the ventilatory control system 
using a response modeling approach. For the present study we re-analyzed those earlier 
data to characterize the effect of remifentanil on B and G (see Figs. 1A and B). From these 
analyses we estimated that at remifentanil concentration (CREM) > 0, G remained constant 
while B increased linearly (the concentration remifentanil that doubles B is 6.14 ± 0.77 
ng.ml-1). Hence we assumed that in the current study remifentanil changed B but not G. 
In the steady-state we have:
      
with 
            
where B0 is the apneic threshold when CREM = 0 and C100 the concentration remifentanil 
that causes a doubling of B. Rewriting equation 3 and defining baseline or resting end-
tidal carbon dioxide concentration (i.e., end-tidal PCO2 before the remifentanil infusion) 
as  PE_0 we get:
  
                 
·
eqn. (2)
V̇ (Crem) = G · (P − B(Crem)) eqn. (3)















Baseline ventilation        and concentration remifentanil causing 50% 
respiratory depression,    . We then rewrite equation 6 into
.                         
Note that C50 causes 50% depression of ventilation when G.[P – PE_0] = 0, which may 
occur when PE = PE_0 (e.g., after an acute remifentanil infusion when carbon dioxide did 
not rise as yet) or when G = 0 (as may occur when combining remifentanil with high 
propofol concentrations). This equation allows for the possibility of apnea at finite drug 
concentrations which is appealing from a clinical point of view. Finally, in eqn. (2) τ was 
fixed to 2.5 min.15 
Modeling the end-tidal carbon dioxide pressure. End-tidal PCO2 is (under ‘normal’ 
circumstances) an accurate indicator of alveolar PCO2. However, close to apnea, the 
breathing pattern is such that end-tidal PCO2 as measured by the gas monitor is likely to 
be inaccurate and possibly measured too low. So, if we write for the residual error:
         
where PE is the measured value and PE the predicted value. The variance of ε should be 
smaller (σA2) when PE >  PE and larger when (σB2) when PE < PE. Therefore the probability 
density of ε was written as:
     
which is a continuously differentiable function and integrates to 1. Since the distribution 
of ε is asymmetric and the mean of ε ≠ 0, PE displayed in the figures is the mode. An 
example of the asymmetric probability density function with σA2 = 0.0225 and σB2 = 0.25 
is given in figure 1C. 
Furthermore, measured end-tidal carbon dioxide concentrations were determined to be 
missing values if they were lower than 37.5 Torr or when the corresponding measured 
ventilation was below 1 L.min-1, because in those cases it can be expected that end-tidal 
PCO2 is inaccurate.






+G · (PE − PE_0) eqn. (6)
PE = P̂E + ε eqn. (7)
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Modeling minute ventilation. Minute ventilation (V) was assumed to be normally 
distributed with variance σv2. However, during apnea manual ventilation (by mask) 
was applied. In that case the measured ventilation values were determined to be missing 
values but used for the uptake and distribution model of carbon dioxide. 
Statistical Analysis. The models as described above were implemented in NONMEM 
VII (ICON Development Solutions, Ellicott City, MD).18 The differential equations were 
solved with NONMEM’s routine ADVAN6; the probability density functions (eqn. 8) 
were used with NONMEM’S LIKELIHOOD option. NONMEM VII’s Markov Chain 
Monte Carlo Bayesian analysis method was used for parameter estimation. This method 
yields probability distributions of the model parameters from which means, standard 
errors and 95% confidence intervals can be obtained. Uninformative priors were used 
for the interindividual variability terms for the pharmacodynamic analysis (in the 
pharmacokinetic analysis these were fixed); no priors were required for the structural 
parameters because of the highly informative data. An interoccasion variability term 
was incorporated for both parameters, V0, and PE_0 (as their product is related to carbon 
dioxide production). Interindividual variability terms with a large standard error (larger 
than the estimate) were removed from the model. The burn-in samples were tested for 
convergence (all parameters and objective functions over 20 iterations, each 50 iterations 
apart; P < 0.05); 1000 iterations were used to obtain parameter distributions. Significance 
of factors representing a deviance of pharmacokinetic parameters from those obtained by 
Minto et al.,17 and significance of factors representing a decrease in the pharmacodynamic 
model parameters G and C50 were tested by checking whether their 95% confidence 
intervals excluded 1.
3.2.4 SENSITIVITY ANALYSIS
A sensitivity analysis of a proposed model will indicate whether the parameter values of 
the model can be estimated with finite precision from the measured data.20 Parameters 
may not be estimable for various reasons: because of the model structure, dependence 
on other parameters, or the specific input function chosen. We performed a sensitivity 
analysis of simulated data in which CREM increases to 5 ng.ml-1 in 5 steps using three 
distinct input functions: A. step size = 1 ng.L-1, duration of step = 1 min; B. step size = 1 
ng.ml-1, duration of step = 5 min; C. step size = 1 ng.ml-1, duration of step = 0.1 min. The 
analysis was performed by fixing one parameter (i.e. not allowing it to be estimated) at a 
time to a series of values (from 50% to 150%) of the ‘best’ value of the parameter. Next, the 
other parameters were estimated and the -2log likelihood (–2LL) values were determined. 
This so-called likelihood profile method will show whether any of the parameters are or 
are not estimable. If not, the curve of -2LL versus the fixed parameter values (the ‘cost’ 





To get an indication of the effect of slowing the rate of rise of remifentanil on the nadir in 
ventilation or duration of apnea, we performed thirty simulations on remifentanil effect 
in the absence and presence of propofol. We simulated linear increases in remifentanil 
concentration at the effect site with rates of rise of 5 to 0.17 ng.ml-1.min-1. The infusion was 
terminated when the effect-site concentration had reached 5 ng.ml-1. 
3.3 RESULTS
All subjects completed the study without unintended effects. An example of one 
experimental run is given in Fig. 3; it is the data from one subject (id003) on the effect 
of a staircase increase in remifentanil concentration during a constant propofol infusion 
(run #3). The top panel shows the target increase in remifentanil plasma concentration 
to 4 ng.ml-1. Note that the infusion was aborted early (due to the occurrence of apnea, 
panel C). Panel B shows the measured BIS values, panel C inspired minute ventilation 
per breath. BIS values were on average 80 indicating moderate sedation, in agreement 
with the observation that the subject was unresponsive to verbal command. Breathing 
reduced rapidly upon exposure to remifentanil and apnea occurred after 3 min. Apnea 
was followed by irregular and cyclic breathing which continued for 15 to 20 min, well after 
the remifentanil infusion was stopped. Note in panel D that during irregular breathing 
with low tidal volumes or apnea an accurate measurement of end-tidal carbon dioxide 
was not possible .
The infusion schemes applied in the studies are given in table 1. The estimated plasma 
concentration rates of rise varied from 0.17 to 9.0 ng.ml-1.min-1. BIS values were 93.2 ± 4.6 
(mean ± SD) in remifentanil runs and 82.2 ± 4.8 (P < 0.05) in runs where remifentanil was 
given on top of propofol. The lowest values for SpO2 were 93.8 ± 7.2% in the remifentanil 
runs and 87.5 ± 8.4 % in the remifentanil-propofol runs (P < 0.05). Saturation values < 90% 
occurred on average 30 ± 41 s in the remifentanil runs and 110 ± 86 s in the remifentanil-
propofol runs (P = 0.05). Apnea did not occur in remifentanil runs but in 8 remifentanil-
propofol runs (averaged duration = 4.4 min, range 1 to 7 min). In runs of subjects 007 and 
009 (remifentanil rates of rise 0.17 and 0.22 ng.ml-1.min-1) the duration of apnea was at its 
lowest range, 1 and 2 min respectively. 
3.3.1 PHARMACOKINETIC ANALYSIS
To get an indication of the goodness of the pharmacokinetic data fits, we plotted the 
measured concentrations versus the individual and population predicted remifentanil 
concentrations (Fig. 4A and B). The plots indicate that the pharmacokinetic model 
adequately described the data. Two examples of pharmacokinetic data fits given in figure 
4 are in agreement with this statement. The pharmacokinetic parameter estimates were 
not significantly different from those of Minto et al.17 except for parameter V2 (volume of 
compartment 2) which was a factor of 0.522 ± 0.125 (95% confidence interval 0.323-0.808) 
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Figure 3. Example of the effect of remifentanil staircase infusion against the background of a constant propofol 
infusion. A. Target plasma remifentanil concentration (TCP). B. Bispectral index (BIS). C. Measured inspired 
ventilation. Note that ventilation quickly reaches apneic values after the initiation of the remifentanil infusion. Next 
breathing remains irregular with a reduced breathing frequency and periods of cyclic breathing. To get an indication 
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 001  2.0  2  2  4  4.0  1.0
 002  1.0  2  1.5  3  4.0  0.75
 003  1.0  5  1  5  5.0  1.0 
 004  1.0  4  4  16  4.0  0.25
005  6.0  1  1  1  6.0  6.0
 006  1.0  6  0.5  3.0  6.0  2.0
 007  1.0  4  2  8  4.0  0.50
 008  1.0  4  6  24  4.0  0.17 
 009  1.0  4  3  12  4.0  0.33
 010  9.0  1  1  1  9.0  9.0
Table 2. Pharmacodynamic parameter estimates
 Estimate  SE  95% c.i. ω2  SE  95% c.i.
 V (L/min)  7.2  1.2  5.0-9.9  0.20  0.14  0.07-0.54
 P0 (Torr)  42.3  6.3  30.0-56.3  1.4  0.9  0.5-3.9
 IOV  0.24  0.13  0.11-0.53
 VTS (L)  9.5  0.2  9.0-9.9  *  *  *
 t½ke0 (min)  0.53  0.02  0.49-0.58  *  *  *
 G (L.min-1.Torr-1)  0.42  0.01  0.40-0.44  *  *  *
 C50 (ng.ml
-1)  1.6  0.03  1.5-1.67  0.14  0.10  0.05-0.34
 Q  (L.min-1)  5.5  0.35  4.9-6.2  *  *  *
 σA
2  0.044  0.0026  0.04-0.05
 σB
2  0.22  0.0069  0.21-0.23
 σv
2  5.55  0.11  5.4-5.8
 Propofol effect on G  0.46  0.015  0.43-0.49
 Propofol effect on C50  0.84  0.030  0.79-0.90
V0 is baseline ventilation (i.e., ventilation prior to remifentanil infusion); 
P0 is baseline end-tidal PCO2 (i.e., end-tidal PCO2 prior to remifentanil infusion); 
IOV is the interoccasion variability (each subject participated in three distinct runs) based on the variability in VCO2, 
which was incorporated for V0 and P0; 
VTS is tissue volume (see eqn. 2); 
t½ke0 is the blood-effect-site equilibration half-life for remifentanil; G is the central gain of the respiratory controller;
C50 is given the (effect-site) concentration remifentanil causing 50% depression of ventilation; Q is cardiac output; 
σA
2 and σB
2 are variances of the residual error of PCO2 (see eqn. (9)); σv
2 is the variance of ventilation; 
Propofol effect: A significant effect (at the P < 0.05 level) of propofol was observed on G and C50. The factor by which 
propofol was affected is the estimate given: Gc during the combined infusion of propofol and remifentanil was 
0.46*[Gc observed during just remifentanil] = 0.46*0.42 = 0.19 L.min-1.Torr-1. Similarly for C50, during the combinded 
remifentanil/propofol infusion C50 = 0.84*1.6 = 1.3 ng.ml
-1.
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Figure 4. Goodness of fit plots for the pharmacokinetic model. A and B are the measured concentrations (y-axis) 
versus the individual (A) and population (B) predicted values. C. The pharmacokinetic analysis performed according 
to the parameter estimates of Minto et al.17 (that is without a factor for V2).
Figure 5. Examples of data fits of the effect of remifentanil on ventilation in one subject in the awake state (panels 
A-C) and asleep with propofol (panels D-F). A and D: Measured remifentanil concentration (closed circles), 
pharmacokinetic data fits (thin line), and estimated effect-site (thick line) concentrations. B and E: Minute ventilation 
with each spontaneous breath an open circle. Artificial breaths are depicted by closed squares. The lines through the 
data are the data fits. During sleep (panel E) the subject is apneic and requires artificial breathing assistance. C and F: 
End-tidal carbon dioxide values (open circles) and data fits. In panel F the effect of the artificial ventilation is clearly 
visible in the data fits.
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of that of Minto et al. The factor in V2 causes population measured versus population 
predicted concentrations to lie more closely on the line of identity. Without the factor, 
concentrations at the high end are underestimated and vice versa (figure 4C).
3.3.2 PHARMACODYNAMIC ANALYSIS
The pharmacodynamic model adequately described the data. Examples of data fits 
are given in Fig. 5. The data are from one subject (id006) and are fits of ventilation and 
end-tidal carbon dioxide concentrations under awake (panels A-C) and sedated (panels 
D-F) conditions. The effect of artificial ventilation by mask is clearly visible on end-tidal 
carbon dioxide in panel F as these periods of artificial ventilation were incorporated in the 
pharmacodynamic model. Since no spontaneous ventilation was observable during the 
period of artificial ventilation the fit through the ventilation data still (correctly) predicts 
apnea (Fig. 5E). 
In table 2 the population pharmacodynamic model parameters are given. The concentration 
remifentanil causing 50% respiratory depression is 1.6 ± 0.03 ng.ml-1. A notable observation 
is the low value for G in the remifentanil runs (0.42 L.min-1.Torr-1). Low-dose propofol 
significantly decreased parameters G by more than 50% to 0.19 L.min-1.Torr-1, and 
parameter C50 by about 20% to 1.3 ng.ml-1. Propofol had no effect on baseline ventilation, 
baseline end-tidal carbon dioxide concentration, VTS, Q and remifentanil t½ke0. All of 
these latter values were within the expected ranges. 
3.3.3 SENSITIVITY ANALYSIS
The results of the likelihood profile method of the pharmacodynamic model are shown 
in figure 6. The Δ-2log likelihood (or the ‘cost’ function) indicates that the estimated 
model parameters (G, C50, t½ke0, VTS, Q) when applying relatively slow remifentanil 
input functions (that is, step durations of 1 and 5 min) were estimated with acceptable 
accuracy (± 10% of the actual value). Due to noise on the simulated data, deviations 
from optimal parameter values were sometimes observed (i.e., lower values of -2LL at 
‘optimal’ parameter values that were different from those used in the simulation). Much 
faster infusion (step duration is 0.1 min) yielded a significant estimation bias. Since we 
applied mostly slow input functions (step duration 1 min or larger in 9 out of 10 subjects) 
we may assume that all important model parameters were estimable without any bias. 
Furthermore, visual inspection of the sensitivity analysis indicates that combining fast and 
slow input functions (as performed in our study) yields a reliable estimation without bias 
for all estimated parameters (intersection of all three in lines is around the x-value of 1, the 
simulated parameter value). Interestingly, Q was estimable at acceptable accuracy (which 
is an argument for the two-compartment carbon dioxide model that we used). Of the fixed 
parameters, estimation of parameters τ and VALV was poor (τ) or impossible (VALV). We 
relate this to the specific design of the study. A different experiment design with periods 
of artificial ventilation will result in estimability of VALV, while steps in carbon dioxide 
would have resulted in the accurate estimation of τ.




Results of six simulations are given in Fig. 7. Linear remifentanil infusions with a rate of 
rise of 5 ng.ml-1.min-1 (panels A-C), 0.5 ng.ml-1.min-1 (panels D-F) and 0.2 ng.ml-1.min-
1 (panels G-I) are shown for the awake condition (thin line) and at the background of 
propofol (thick lines). The effects of the rate of rise on the nadir in ventilation (in the 
awake studies) and duration of apnea (in the propofol studies) are given in figure 8 for 
all 30 simulations. For both end-points the effect of slowing the rate-of-rise is biphasic. 
The nadir in ventilation decreased going from 5 to 1 ng.ml-1.min-1 (from 2.3 to 1.6 L.min-1, 
figure 5), after which it increased (5 ng.ml-1.min-1= linear infusion of 1 min; 1 ng.ml-1.min-1 
= linear infusion of 5 min). The duration of apnea increased going from 2.5 to 0.6 ng.ml-1.
min-1 (2 min and 9 min, respectively) after which it decreased rapidly. At infusion rates 
of 0.31 ng.ml-1.min-1 (16 min) and slower no apnea occurred. During the two most rapid, 
short-term infusions (5 and 2.5 ng.ml-1.min-1 or 1 and 2 min infusions) the remifentanil 
exposure was insufficient to cause apnea.
Figure 6. Sensitivity analysis for the model parameters. A-D and F: estimated parameters, E and G: fixed parameters. 
Δ–2LL is the difference in –2log likelihood between the simulated data and the best fit with one of the parameters 
held constant. The x-axis of each plot shows the parameter value as fraction of the value observed or fixed in the 
analysis of the experimental data set. The short-dashed line indicates the P = 0.01 level, the long-dashed line, the P = 
0.05 level. •-• input function: step increase in plasma concentration of 1 ng.ml-1, duration of step is 1 min (rate of rise 
= 1 ng.ml-1. min-1), number of steps is 5. °-° input function: step increase in remifentanil concentration is 1 ng.ml
-1, 
duration of step is 5 min (rate of rise = 0.2 ng.ml-1.min-1), number of steps is 5.  X-X input function: step increase in 
plasma concentration of 1 ng.ml-1, duration of step is 0.1 min (rate of rise = 10 ng.ml-1.min-1), number of steps is 5.
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Figure 7. Simulation study on the effect of changes in the rate of rise of the effect-site remifentanil concentration on 
breathing (panels A, D and G) and end-tidal carbon dioxide concentration (panels B, E and H) in awake state (no 
propofol present, thin lines) and during sleep (due to a low-dose propofol background infusion, thick line). The 
remifentanil rates of rise are linear and vary from 5 ng.ml-1.min-1 given for 1 min (panels A-C) to 0.5 ng.ml-1.min-1 
given for 10 min (panels D-F) and 0.2 ng.ml-1.min-1 given for 25 min (panels G-I), so that peak effect-site remifentanil 
concentration was 5 ng.ml-1 in all simulations. Panels C, F and I depict the counter clockwise end-tidal carbon 
dioxide  – ventilation loops (continuous lines) and metabolic hyperbola (dashed line). The gray triangles depict the 
linear remifentanil infusion schemes.
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The carbon dioxide concentration – ventilation (counter clockwise) loops shown in Fig. 7 
(panels C, F and I) are graphical representations of the link between the two parameters 
in areas below and above the metabolic hyperbola (dashed lines). In the simulation 
studies we assumed no effect of adding low dose propofol on metabolic rate (which was 
experimentally verified, as resting PCO2 and minute ventilation were similar between the 
awake and propofol sedates states). The graphs indicate that loops in the horizontal plane 
(such as observed in panel I) are desirable when aiming at and maintaining spontaneous 
breathing. The graphs show further that independent of the infusion rate hyperventilation 
in the recovery phase (upswing of the loop) is greater when ventilatory depression is more 
pronounced and carbon dioxide accumulates in the body.  
Finally, the simulations are in close agreement with the observed data; for example 
compare panels 7B with 5B, and 7E with 5E and 3C.
3.4 DISCUSSION
Using a ‘simple’ non-steady-state pharmacokinetic-pharmacodynamic model of opioid-
induced respiratory depression (eqn. 6), we described the ventilatory behavior of varying 
remifentanil infusion schemes in awake and propofol sedated volunteers. The model is 
based on the linear relationship between carbon dioxide and ventilation. Most important 
parts of the model parameters were identifiable and estimable (e.g., the drug concentration 
causing 50% respiratory depression, the gain factor of the respiratory controller, the 
remifentanil effect-site equilibration half-life), while others were fixed to values obtained 
from previous studies from our laboratory or obtained from the literature (the time 
constant for carbon dioxide of the ventilatory control system and alveolar volume). As 
we assumed that ventilation was dependent not only on the remifentanil concentration at 
its effect-site (the brainstem) but also on the metabolic product carbon dioxide, our model 
may be described as an indirect response model. The first (and only) previous indirect 
response model of opioid-induced respiratory depression was developed by Bouillon et 
al.11,12 While their model differs at important points from ours it even so shares important 
characteristics. We will discuss the similarities and differences between the two models in 
the section ‘Model Comparisons’ below. 
3.4.1 THE MODEL: HOW IT WORKS AND PARAMETER ESTIMATES
 A schematic description of the model is given in Fig. 2. The model has three parts. The 
remifentanil pharmacokinetic part (part I), consisting of the distribution of remifentanil 
throughout the body. Part of the remifentanil passes (with a delay described by rate 
constant ke0) to the effect site, the brainstem, where it affects the control of breathing 
(part II of the model via term 1 of eqn. 6: [1 – CREM/2C50]). Respiration is diminished 
(with time constant τ) due to activation of μ-opioid receptors expressed on key-parts of 
the ventilatory control system (for example, premotor neurons of the ventral respiratory 
group (especially within the pre-Bötzinger complex) and the pontine respiratory group).1,2 
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Part III of the model, the carbon dioxide kinetics, is affected by the diminished breathing 
as it reduces the efficacy of carbon dioxide output and as a consequence arterial PCO2 
increases. This again has an effect on the respiratory control system (part 2 of the model) 
as it stimulates breathing (via term 2 of eqn. 6: G  [PE – PE_0]). So, two opposing additive 
effects influence breathing after remifentanil infusion: the direct depressant effect via 
depression of respiratory neurons and a stimulatory effect of the increasing arterial PCO2. 
In figure 9A, the effect of just term 1 of eqn. 6 is plotted (lines 1 for awake and line 3 for 
asleep subjects). The effect of combining terms 1 and 2 is represented by lines 2 (awake) 
and 3 (asleep). It is apparent from the graphs that adding term 2 has a stimulatory effect 
on the remifentanil-ventilation data.
An important assumption on which our model is based is that opioids (in our case 
remifentanil) cause a linear increase in the position of the ventilatory carbon dioxide 
response curve (in our model parameter B) with little change in the value of the response 
slope (in our model parameter G). There is ample evidence that opioids indeed cause 
a parallel shift of the steady-state Ventilatie-PCO2 response slope.10,21,22 However, some 
studies indicate that there is some sex dependency with a reduction in slope in women 
(we exclusively performed studies in men), while others showed that the opioid effect 
is dependent on the technique used to measure the response slope.23 As discussed 
previously, we consider the parallel shift of the Ventilatie - PCO2 response slope a typical 
opioid effect and reduction of the slope is in our opinion due to a lowered arousal state 
(from sleep or sedatives/anesthetics).10 
The value of t½ke0 that we observed (0.5 min) is in the same range as values from Babenco et 
al. using the isohypercapnic method (2 min) and studies on electroenecephalographic end-
points (1.6 min).8 The low t½ke0 value is related to remifentanil’s rapid passage across the 
blood-brain barrier. This rapid movement of remifentanil into the brain compartment is a 
potential danger, as it may produce depression of respiratory neurons (via term 1 of eqn. 
6, fig 9A) before any stimulatory effect of the accumulation of carbon dioxide is generated 
(via term 2 of eqn. 6, Fig. 9A). Other opioids with a much slower passage across the blood-
brain barrier (such as morphine and its active metabolite morphine-6-glucuronide with 
a slow passage (t½ke0 in the range of hours), but also drugs as buprenorphine (1 hour), 
and fentanyl (5 min)), do allow for at least some accumulation of carbon dioxide while 
the respiratory neurons are being depressed, hence with a lesser chance of apnea.24-26 
However, this is only true when the drug is not overdosed. Otherwise, severe respiratory 
depression with apnea should always be in mind.27 Our data further indicate that the 
chances of apnea are increased when the subject is asleep (BIS values = 80) with propofol. 
When term 2 of equation 6 equals zero the remifentanil concentration causing 50% 
depression of ventilation is by definition C50 (now only term 1 of eqn. 6 is operative). 
This occurs in situation in which PCO2 remains constant at baseline levels (e.g., in 
isohypercapnic experiments or when carbon dioxide has not yet risen above baseline 
values due to the rapid action of the opioid). Our C50 (1.6 ng.ml-1) is therefore well 
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comparable to values observed in isohypercapnic studies (cf. Babenco et al.8 who estimated 
a value of 1.4 ng.ml-1). In a previous isohypercapnic study from our laboratory studying 
the remifentanil propofol interaction the C50 value 0.7 ng.ml-1 for ventilation measured 
at a fixed end-tidal PCO2 of 55 Torr.10 The observed C50 is a low value, probably related 
to a differences in parameterization (see eqn. (4) of ref. 10) and the fact that we analyzed 
the whole remifentanil-propofol surface rather than just the remifentanil-ventilation 
relationship.
The value of G (table 2) is smaller than observed in a previous study on the effect of 
combining remifentanil and propofol on the ventilatory carbon dioxide response curve 
(value of G at CREM > 0 = 1.6 L.min-1.Torr-1, see figure 1).10 The reason for the smaller 
estimated value of G may be the fact that we previously tested our subjects in normoxia 
versus hyperoxia in the current study. Hyperoxia significantly blunts the peripheral 
chemoreceptors at the carotid bodies causing a 30-40% reduction of G.15 Furthermore, 
we believe that the current study was performed on the dog-leg of the V - PCO2 response 
slope. There is ample proof that the linear response curve flattens around resting carbon 
dioxide values.14 The value observed by us is in agreement with the value presented by 
Babenco et al. following a remifentanil bolus infusion.8 Reassuring is the observation of 
a 50% reduction of G by low-dose propofol, which is in agreement with earlier findings.8 
The likelihood profile method is a tool to assess whether the parameters may be estimated 
from the data and also yield their 95% confidence intervals. We observed that the ability 
to obtain accurate parameter estimates is dependent on the specific input function chosen. 
Slower remifentanil infusion rates (duration 1 min or longer) resulted in more precise 
estimates than a rapid bolus infusion (see figure 6). This may be related to the fact that we 
applied a rapid infusion in just one subject while the nine others received the slower rates. 
However, the analysis also indicates that when applying fast and slow infusion rates in one 
study and analyzing the data set using a population approach, the estimation precision is 
acceptable and that the fast infusions do not affect the outcome of the estimates negatively.
3.4.2 SUMMARY
In summary, the estimated parameter values are in close agreement to previous reported 
values in the literature. This together with the results of the sensitivity analysis gives us 
confidence that our model adequately describes the effect of remifentanil on breathing. 
Furthermore, we were well able to describe and predict the occurrence of apnea.
Apnea. To the best of our knowledge there are no earlier studies that assessed remifentanil 
effect on apnea in healthy volunteers. The study of Egan et al.28 comes closest to ours. 
They assessed the effect of various bolus doses of remifentanil and used a respiratory 
intervention scale, based primarily on SpO2, as endpoint. Low SpO2 values (< 85%) did 
occur at the higher dose range (100 μg and greater), and predominantly in a population 
of older subjects (60 – 75 years). The low SpO2 values are most probably related to the 
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occurrence of apnea. We simulated the dosing schedule of Egan et al. and observed 
apnea at doses of 100 μg and greater (data not shown). The observation of hypoxemia 
is of interest. Similarly to Egan et al.28 we observed hypoxia although it was mild and 
occurred late in the experiment (3-5 min after the start of apnea). We relate this to the 
inspiration of 100% oxygen in our study causing an oxygen store sufficient for 4-5 min 
before serious desaturation (SpO2 < 90%) sets in. Low arterial oxygen has a stimulatory 
effect on breathing through activation of the peripheral chemoreceptors at the carotid 
bodies and increases the value of G.15,16 This may have occurred in our experiments and 
may have had an effect on the duration of apnea. We did not take this into account in our 
current model but a G dependent on SpO2 may be introduced in future models.  
Remifentanil-propofol interaction. We previously assessed the interactive effects 
of remifentanil (0 – 2 ng.ml-1) and propofol (0 – 2 μg.ml-1) on breathing using steady-
state isohypercapnic response surface modeling techniques.10 We observed a synergistic 
interaction of the two drugs on resting ventilation, resting end-tidal PCO2, ventilation at 
a fixed PCO2 of 55 Torr and the V - PCO2 response slope. Comparison with the current 
data analysis is difficult due to the differences in experimental set up and modeling 
approach. In contrast to our previous study, we currently studied just one low propofol 
plasma concentration (target on average 1 μg.ml-1). However, we believe (in retrospect) 
that the observation of large periods of apnea (1 – 7 min) during infusion of remifentanil 
against the background of low-dose propofol precludes testing of higher propofol doses 
in volunteers. The large difference in responses to remifentanil in awake and propofol-
sedated states on apnea occurrence is in agreement with a synergistic interaction between 
the two drugs. Whether the propofol effect is related to γ-amino-butyric acidergic 
depression of respiratory neurons or secondary to the change in arousal-state remains 
unknown.2 In agreement with the latter possibility is the finding that sleep induces a 
substantial enhancement of the depressant effect of morphine on ventilatory control.29 
Speed of remifentanil infusion. It has been suggested that by slowing the opioid 
infusion rate the degree of respiratory depression diminishes due to the stimulatory effect 
of the accumulation of carbon dioxide.3,12 We performed a simulation study to test this 
suggestion and observed a more complex interaction between remifentanil infusion rate 
and degree of depression of ventilation as measured by the nadir in ventilation (awake 
studies) and duration of apnea (propofol sedated studies; Fig. 7 and 8). Going from a 
rapid (linear) infusion (5 ng.ml-1.min-1) to a slow (linear) infusion (0.17 ng.ml-1.min-1) in 
target effect-site concentration (peak concentration = 5 ng.ml-1), both endpoints showed 
a worsening of ventilatory depression with a lower nadir in ventilation going from 5 to 1 
ng.ml-1.min-1 (infusion duration: from 1 to 5 min) and an increase in apnea duration going 
from 2.5 to 0.55 ng.ml-1.min-1 (infusion duration: from 2 to 9 min). Thereafter respiratory 
depression decreased with slowing of the infusion rate. Apnea disappeared at infusion 
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rates ≤ 0.31 ng.ml-1.min-1 (infusion duration = 16 min). Our analysis indicates that the 
degree of respiratory depression (as defined by the nadir in ventilation and duration of 
apnea) is related to the opioid’s pharmacokinetics, the speed of opioid infusion, the total 
amount opioid given (at infusion durations of 1 and 2 min the total amount of remifentanil 
given is insufficient to cause apnea, Fig. 8), and the target plasma concentration, all 
relative to the carbon dioxide kinetics and dynamics. In order to prevent overt respiratory 
depression and apnea one should be considering all of these variables. As the simulations 
performed by us are not to be extrapolated to other scenarios than those applied here, a 
simulation for each new circumstance should be performed.
Respiratory variability. We observed great variability in the respiratory data during 
exposure to low-dose remifentanil (see Fig. 3 and 5). Mitsis et al. modeled variability of 
spontaneous respiration during low-dose remifentanil administration and concluded that 
the increase in variability due to the opioid was related to a decrease in the strength of 
the controller part of the ventilatory loop.30 Our observation of a low value of G is in 
agreement with this statement and indeed may be the cause for the inability to strictly 
perform a breath-to-breath feedback control based upon the also quite varying carbon 
Figure 8. Simulation study on the effect of varying linear rates of rise of remifentanil effect-site concentration on the 
nadir in ventilation (simulations performed in the absence of propofol, closed circles) and on the duration of apnea 
(simulations performed in the presence of propofol, open squares). 
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Figure 9. A. The relationship between remifentanil concentration and ventilation is made up of two additive 
linear terms (eqn. 6). The term that describes the effect of remifentanil on ventilation when carbon dioxide has not 
accumulated (the first term of eqn. 6) is given by the linear line 1 for the awake state and line 3 for the propofol 
sedated state. A steady state in ventilation occurs when carbon dioxide accumulates: for the awake state this is 
reflected by the non-linear line 2, and for the sedated state by the non-linear line 4. Now both terms of eqn. 6 are 
active.  X are C50 values.
B. Comparison of the remifentanil – ventilation relationships derived from the model advanced by Bouillon et 
al.12 and our model. Lines 1 and 2 are the acute (line 1) and steady-state (line 2) relationships derived from eqn. 6. 
Equivalent lines for the Bouillon model are lines 3 (acute relationship) and 4 (steady-state relationship) as derived 
from equation 14 of ref. 12. The large difference between models is the inability to predict apnea in the latter model 
(line 3). The steady-state relationships are much alike (compare lines 3 and 4). 
dioxide input. 
Model Comparisons. Bouillon et al. were the first to study and model the respiratory 
effects of opioids (alfentanil and remifentanil) in the non-steady state.11,12 Their initial 
attempts are well appreciated and our modeling work should be considered an extension 
to the original ideas postulated by Bouillon et al. 
Bouillon et al.11-13 used an indirect response model consisting of two multiplicative terms, 
a sigmoidal Emax function and a power function of the form (eqn. 11 in ref.12): 
where F is the slope of the ventilatory carbon dioxide response curve (equivalent to our 
parameter G) and γ a shape parameter. We compared the model to our model in Fig. 9 
(panel B) by plotting the acute (term 1, the sigmoid-Emax function: line 3 in Fig. 9B), and 
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the combined (term 1 + term 2, line 4) steady-state relationships. The largest difference 
between the two models is the difference in the acute relationship as reflected by lines 1 and 
3. Due to the sigmoidal Emax nature of term 1 and the multiplicative nature of the model, 
no apnea may be described or predicted. At 2 times the C50 the Bouillon model predicts 
ventilation levels > 2 L.min-1,12 while in our approach 2C50 equals the concentration at 
which apnea occurs (CAPNEA = 3.2 ng.ml-1; Fig. 9). The overall steady-state relationships 
(lines 3 and 4) are comparable between models. In order to get an impression of the ability 
of the model of Bouillon et al.10 to describe our data, we analyzed our data with their 
model. In contrast to Bouillon et al. we added a delay between remifentanil concentration 
and effect-site (parameter ke0). Without this parameter no meaningful data fits were 
obtained. Two main observations were made: as expected, the occurrence of apnea could 
not be modeled but yielded systematic misfits; and the effect of manual ventilation on 
PCO2 yielded misfits as well. The latter is probably related to the single carbon dioxide 
compartment in the Bouillon et al. model versus two compartments in our model. In the 
study of Bouillon et al. no systematic misfits were reported. However, this may partly be 
related to the remifentanil function applied (one to four 15 min steps of varying magnitudes 
of CREM, which yielded changes towards the steady state in both PCO2 and ventilation) 
together with a relatively small number of arterial carbon dioxide samples. This may 
have yielded little contribution of the first term of the model to the overall effect but a 
predominant contribution of the power function, which depends on the accumulation of 
carbon dioxide. Possibly at different input functions (such as bolus infusions) or during 
sedation, the misspecifications of the model would become apparent. Bouillon  et  al.12 
suggest to address the issue of apnea by using a logistic probability model. Our current 
model indicates that this is not required as apnea is accurately predicted at realistic drug 
concentrations. Our model has two linear terms (eqn. 6). In order to assess whether non-
linear functions would improve the data fits we analyzed the data with a model consisting 
of power functions. No systematic improvements were observed (data not shown).
In conclusion, we developed a novel pharmacokinetic-pharmacodynamic model that is 
able to describe the non-steady-state effects of remifentanil on breathing under a variety 
of circumstances ranging from fast to slow drug infusions, under awake and sleeping 
conditions. Furthermore and possibly most important, the model allowed description and 
prediction of an important idiosyncrasy of the ventilatory control system, the development 
of opioid-induced apnea. 
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It is well known that opioids are able to produce life-threatening respiratory depression.1 
A recent editorial brought to attention the sharp rise, since the early 1990s, of unintentional 
drug overdose and consequently loss of life due to ingestion of prescription painkillers in 
the United States.2 As discussed, this is related to a 10-fold increase in the medical use 
of synthetic opioids, marketing tactics and the proactive identification of patients with 
chronic pain.2 Also in the perioperative setting opioid-induced respiratory depression is 
a common observation with regular reports of fatalities.3-5 Overall there is the ongoing 
need for vigilance when potent opioids are administered to spontaneously breathing 
and opioid-naïve patients.1,2 Opioid risk (in the acute setting: respiratory depression) 
is best viewed in context of its beneficial effect, ie. analgesia. Recently, Katz proposed 
the construction of a risk benefit composite for opioid use in chronic pain patients. This 
composite is based on days of chronic pain treatment causing pain relief ≥30% and no 
or mild adverse effects.1 One method to quantify opioid-induced respiratory depression 
relative to analgesia is the construction of a Utility (or safety) Function (UF). Cullberg first 
introduced the concept of UFs when characterizing the outcome of a thrombin inhibitor.6 
He defined the UF as the probability of drug-induced thrombus regression minus the 
probability of drug-induced bleeding related event. In the current study we constructed 
the UF for the opioid analgesic fentanyl. The fentanyl UF is constructed based on the 
results of a population pharmacokinetic-pharmacodynamic (PK-PD) study on the effect of 
fentanyl on respiration and antinociception. Next, a simulation study is performed, using 
the PK-PD parameter estimates and their variances, in which 9,999 simulated subjects 
received fentanyl. The resultant distributions are used to calculate the UF. In the current 
approach we calculated the probability of an increase in pain tolerance of 50% or more 
minus the probability of respiratory depression of 50% or more.
4.2 METHODS EN MATERIALS
4.2.1 SUBJECTS
After approval of the protocol by the local Human Ethics Committee (Commissie 
Medische Ethiek, LUMC, Leiden) and the Central Committee on Research involving 
Human Subjects (Commissie Mensgebonden Onderzoek, The Hague, The Netherlands) 
and informed consent was obtained according to the Declaration of Helsinki, 12 male 
volunteers, aged 18-45 years, were initially recruited to participate in the study. One 
subject dropped out and was replaced by a 13th subject. All recruits were subjected to a 
medical history, physical examination, 12-leads electrocardiogram and blood screening 
before inclusion. Only healthy subjects, without a history of alcohol or illicit drug abuse 
and a body mass index between 20 and 28, were included in the study. 
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4.2.2 STUDY DESIGN
All subjects were studied twice with at least two weeks between sessions (the sequence 
of sessions was random). On one occasion the effect of a single intravenous infusion of 
fentanyl (3.5 μg.kg-1 infusion over 90-s) on respiration was tested, on the other occasion the 
effects of fentanyl (3.5 μg.kg-1 infusion over 90-s) pain responses to a cutaneous noxious 
electrical stimulus were tested. 
Respiratory measurements. During the respiratory studies, subjects breathed through 
a facemask (fitted over nose and mouth). The airway gas flow was measured with a 
pneumotachograph (#4813, Hans Rudolph, Kansas City, MO) connected to a pressure 
transducer, which yielded a volume signal. The pneumotachograph was heated (37 oC) 
throughout the study period. This signal was calibrated with a 1 L calibration syringe (Hans 
Rudolph). The pneumotachograph was connected to a T-piece; one arm of the T-piece 
received a gas mixture with a flow of 45 L.min-1 from a gas mixing system, consisting 
of three mass-flow controllers (Bronkhorst High-Tec, Veenendaal, The Netherlands) via 
which the flow oxygen, nitrogen and carbon dioxide could be set individually at any 
desired level. A computer provided control signals to the mass-flow controllers allowing 
adjustment of the inspired gas mixture to force the end-tidal gas concentrations of oxygen 
and carbon dioxide to follow a specific pattern in time. Gas concentrations were measured 
with a gas analyzer (Datex Multicap, Helsinki, Finland); arterial hemoglobin oxygen 
saturation was measured via a finger probe with a Masimo pulse oximeter (Irvine, CA).
Respiration was measured at a clamped elevated end-tidal carbon dioxide tension (PCO2) 
using the ‘Dynamic End-Tidal Forcing’ (DEF) technique.7-10 In each subject, the end-tidal 
PCO2 was elevated in steps of 2-3 mmHg until ventilation reached a value 20 - 24 L.min-1. 
The end-tidal PCO2 was kept constant at this level throughout the study (baseline end-
tidal PCO2 level). This procedure was performed in a ‘training’ session 30 to 45 min prior 
to dosing. The end-tidal oxygen concentration (PO2) was kept constant at 110 mmHg 
throughout the study. After a steady state in ventilation was obtained, fentanyl was 
infused and continuous breath-to-breath ventilatory measurements were obtained for the 
next 90 min. Thereafter, 3-min measurements were obtained at 30-min intervals until t = 4 
h following administration and at 1-h intervals until t = 6 h. The following variables were 
collected on a breath-to-breath basis on a computer disc for further analysis: inspiratory 
minute ventilation, end-tidal PCO2, end-tidal PO2 and oxygen saturation. 
Pain responses. Acute pain was induced by an electrical current through two surface 
electrodes (Red Dot, 3M, London, Ontario, Canada) placed on the skin overlaying the left 
tibial bone (transcutaneous electrical stimulation).10-12 The electrodes were attached to a 
computer interfaced current stimulation (Leiden University Medical Center, Leiden, The 
Netherlands). The intensity of the noxious stimulation was increased from 0 mA in steps 
of 0.5 mA.2 s-1. The stimulus train consisted of a square-wave pulse of 0.2 ms duration 
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applied at 10 Hz and had a cutoff of 128 mA. The subjects were instructed to press a control 
button when they felt pain (pain threshold) and when no further increase in stimulus 
intensity was acceptable (pain tolerance; this ends the stimulus train). Pain responses were 
obtained at baseline and at t = 10, 25, 40, 55, 70, 90, 110, 130, 160, 190, 220, 250, 310 and 370 
min. after dosing. We analyzed the pain tolerance data for the current report.
Blood sampling and plasma drug concentrations measurements. Blood samples (3 mL) 
were obtained from an arterial line placed in the left or right radial artery (opposite of the 
arm through which the drug was infused) for determination of the plasma concentrations 
of fentanyl. Blood samples were obtained at t = 2, 5, 10, 15, 30, 60, 90, 150, 210, 270, 330, 
390 and 480 min after dosing. Plasma was separated within 30 min of blood collection and 
stored at -20oC until analysis. 
Samples were prepared by liquid/liquid extraction of the plasma samples with t-butyl 
methyl ether. Samples with fentanyl concentrations above the calibration range were 
diluted prior to the measurement using human blank plasma. Chromatographic separation 
was performed using an Agilent 1200 liquid chromatograph (Agilent Technologies Inc., 
Santa Clara, CA) and a PAL HTC-xt (Axel Semrau GmbH & Co., Sprockhövel, Germany) 
autosampler.  A Pursuit 3μ C18 30 x 2 (30 mm x 2 mm) column (Varian, Walnut Creek, 
CA) and MetaGuard Pursuit 3μ C18 10 x 2 mm guard column (Varian, Walnut Creek, CA) 
were used as stationary phases. The analytes were eluted using gradient elution with a 
mobile phase consisting of formic acid (0.1%) and acetornitril (containing 0.1% formic 
acid) at 30°C with a flow rate of 0.7 ml.min-1. Fentanyl was detected in the MRM mode 
using an electrospray ion source on a triple quadrupole mass spectrometer API-5500 
QTrap equipped with a Turbo-Ionspray™ Interface (Applied Biosystems, Framingham, 
MA) operating in positive ionization mode. The MS/MS transitions 337/188 for fentanyl 
and 342/188 for D5-fentanyl were monitored for quantitation of the compound. The 
calibration range of the bioanalytical assay was 0.005 – 5.00 ng.ml-1. Calibration samples 
were prepared at 0.005, 0.010, 0.050, 0.200, 1.00, 2.00, 3.75 and 5.00 ng fentanyl.mL-1 
plasma. Qualtity control samples were prepared at concentrations of 0.015, 2.00 and 5.00 
ng fentanyl.ml-1 plasma. The values for the overall accuracy and the overall precision for 
quality controls assayed during analysis of study samples were 97.2% – 106.2% and 1.7% 
– 9.5%, respectively. The samples were analyzed in six batches with interbatches accuracy 
of 95.9% – 104.9% and coefficient of variation of 1.9 – 6.9% over the calibration range of 
0.005 to 5.0 ng.ml-1.
4.2.3 PHARMACOKINETIC-PHARMACODYNAMIC ANALYSIS
Multiple compartment models were fitted to the fentanyl pharmacokinetic data. Model 
selection (the number of compartments) was based on the Goodness of Fit criterion. Only 
the ‘best’ models will be described here. 
To eliminate a possible hysteresis between plasma concentration and effect, an effect 
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compartment was postulated that equilibrates with the plasma compartment with a half-
life t½ke0 (i.e., the blood-effect-site equilibration half-life). 
The ventilation data were modeled as:7-10
Effect(t) = Emax + [Emin –  Emax] • [A/(1+A)] and A = [Ce(t)/C50]γ  eqn.(1)
where effect is the effect at time t (minute ventilation), Emax maximum or predrug effect 
(baseline ventilation), Emin minimum effect (an Emin of zero indicates that apnea may 
be reached), Ce(t) effect-site concentration at time t, and C50 the effect-site or steady-state 
concentration causing 50% depression of ventilation.
Transcutaneous electrical pain responses were modeled as:10-12
Pain Response(t) = Baseline • [1 + 0.25 • B] and B = [Ce(t)/C25]γ   eqn.(2)
where Pain Response(t) is the stimulus intensity at which a pain tolerance response 
occurs at time t, Baseline the predrug stimulus intensity at which a pain threshold or 
pain tolerance response occurs, Ce(t) the effect-site concentration at time t, and C25 the 
effect-site or steady-state concentration causing an increase of 25% stimulus intensity for a 
response. Estimation of C25 rather than C50 was performed as the 25% increase in stimulus 
intensity was midpoint of the observed responses.   
The pharmacokinetic-pharmacodynamic data were analyzed with the mixed-effects 
modeling software NONMEM VII (ICON Development Solutions, Ellicott City, MD)13 
The PK/PD analysis was performed in two stages. From the first stage (pharmacokinetic 
analysis), empirical Bayesian estimates of the pharmacokinetic parameters were obtained. 
In the second stage (pharmacodynamic analysis), the pharmacokinetic parameters were 
fixed to those obtained in the first stage. An integrated data analysis was performed in 
NONMEM, i.e. combining all pharmacodynamic data (respiratory and pain data) in one 
analysis. Model parameters were assumed to be log-normally distributed. Residual error 
was assumed to have both an additive and a relative error for concentrations and only an 
additive error for all effect parameters. Covariance between random effects (ηs) for the 
pharmacodynamic end-points were explored using $OMEGA BLOCKs.
The number of compartments in the pharmacokinetic analysis was determined by the 
magnitude of the decrease in the minimum objective function value (MOFV; X2-test; P < 
0.01 was considered significant). In the pharmacokinetic analysis weight and height were 
considered as covariates. P-values less than 0.01 were considered significant. 
4.2.4 VISUAL PREDICTIVE CHECK
Visual predictive checks were performed to assess the adequacy of the description of both 
fixed and random effects by simulating data using the models and calculating their 2.5th, 
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50th and 97.5th percentile at all sampling times. 
4.2.5 UTILITY FUNCTION
The utility of drug effect, U, was defined as the probability of obtaining the desired effect 
minus the probability of obtaining a side effect.6,14 If we define the desired effect as an 
increase in pain tolerance of 50% or more and the side effect as respiratory depression of 
50% or more, and the probability of obtaining these as P(A) ≥ 0.5 and P(R) ≥ 0.5, respectively, 
then U = P(A ≥ 0.5) – P(R ≥ 0.5). The utility of fentanyl’s effect was calculated as function of 
effect site concentration (U1) and of time (U2) after administration of 3.5 μg.kg-1:
U1(Ce) = P(A(Ce) ≥ 0.5) – P(R(Ce) ≥ 0.5)    eqn.(3)  
           
and
U2(t) = P(A(t) ≥ 0.5) – P(R(t) ≥ 0.5)     eqn.(4),
where P is probability, A analgesia and R respiratory depression.
          
The UF was calculated from the population pharmacokinetic and pharmacodynamic 
model with established values for the population and their inter-individual variability 
parameters (ω2). To this end 2 × 9,999 simulations were performed using NONMEM’s 
simulation step (with SUBPROBLEMS = 9999). The occurrence of desired and side effects 
were counted and divided by 9999 to estimate probabilities (note that these are uncorrelated 
because no correlations between the ω2 were identified in the pharmacodynamic analysis). 
U-values range from –1 to +1; U > 0 indicate that the chance for a desired effect exceeds the 
chance for an unwanted effect (here respiratory depression) while U < 0 indicates that the 
chance for the unwanted effect exceeds the chance for analgesia. U-values between –0.2 
and 0.2 are small effects, U-values between –0.2 and –0.4, and 0.2 and 0.4 are moderate 
effects and U-values < –0.4 and > 0.4 are large effects. Small effects indicate absence 
of selectivity of action (i.e., no clinically relevant greater chance for analgesia than for 
respiratory depression and vice versa).
Sensitivity analyses were performed to assess the effect of changes in context (numerical 
response thresholds in P(A) and P(R)) and effect of changes in pain parameter estimates 
t½ke0 and C50 on the form of the utility functions.
4.3 RESULTS
One subject dropped out and was replaced by another. The pharmacodynamic data of 
the dropout were incomplete and therefore discarded. His pharmacokinetic data were 
used in the population analysis. Consequently the number of subjects was 13 for the 
pharmacokinetic data and 12 for the pharmacodynamic data. In one subject just one set 
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of pharmacokinetic data was available due to failure of arterial line insertion on one 
occasion. No unexpected or major side effects occurred during the studies. All subjects 
(n = 13) were white males with a mean age of 22.1 years (range 19-27 years), height 186 
cm (176-200 cm), weight 80.5 kg (64-111 kg) and body mass index of 23.2 kg.m-2 (21-28 
kg.m-2). 
Mean fentanyl plasma concentrations, respiration and pain responses are shown in 
Figure 1. In Figure 2, the individual pain responses are plotted showing the variability 
in the data. The peak increase in pain tolerance averaged to 21.9 mA, which (apart from 
one outlier of 91 mA) was normally distributed (range 5.5 to 33.5 mA, n = 11). Similar 
response variabilities have been observed in other studies on opioid analgesic efficacy 
using this same pain model.10-12
4.3.1 PHARMACOKINETIC ANALSIS
The mean plasma fentanyl concentrations are given in Figure 1A. The variability in fentanyl 
concentrations obtained on the two distinct study occasions was small as observed in 
Figure 1A. The final pharmacokinetic model consisted of a three-compartment model 
with one central (V1) and two peripheral compartments (V2 and V3). The pharmacokinetic 
Figure 1. A. Mean plasma concentrations of fentanyl 
observed on occasions A and B. B.  Mean ventilation data 
following fentanyl infusion (for clarity reasons only 1 in 
every 3 error bars are shown). C. Mean pain threshold 
(closed squares) and pain tolerance data (open squares) 
following fentanyl infusion. The values plotted at t = 0 
are pre-drug baseline values. Fentanyl was administered 




Figure 2. Spaghetti-plot of the pain tolerance responses during and following fentanyl infusion. The lines are the 
individual responses, the oranges squares are the mean data.
Table 1. Pharmacokinetic model parameter estimates
Parameter Typical value SEE (%) ω2 SEE η-shrinkage&
 V1 (L) 8.867 0.652 (7) 0.065* 0.021 (32) 1%
 V2 (L) 42.056 3.243 (8) 0.042 0.016 (38) 4%
 V3 (L) 191.709 9.529 (5) 0.027 0.011 (41) 4%
 CL1 (L.h
-1) 0.751 0.0538 (7) 0.027 0.016 (59) 4%
 CL2 (L.h
-1) 4.291 0.322 (8) 0.065* 0.021 (32) 6%
 CL3 (L.h
-1) 1.932 0.157 (8) 0.065* 0.021 (32) 6%
 IOV on CL1 0.004 0.002 (50) 77%
 σ2 0.109 0.005 (5) 8%#
* one η was used for V1, CL2 and CL3.  
SEE is standard error of the estimate in the column to the left (in brackets the SEE as %).
V1, V2 and V3 are the volumes of compartments 1, 2 and 3; CL1 is elimination clearance; CL2 and CL3 are the clearances 
between compartment 1 and compartment 2 and 3, respectively.                  
IOV is inter-occasion variability.                                                                                                                       
ω2 is the inter-subject variability (in the log-domain).                                                                                         
η2 is the variance of the residual (relative) error.
&: η shrinkage of empirical Bayesian estimates to the population values. 
#: ε shrinkage of model output to the observations.
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parameter estimates are given in Table 1. Covariate weight (WT in kg) had a significant 
effect on parameters V1, V2, CL1 and CL2 with the volumes scaled by (WT/70) and the 
clearances scaled by (WT/70)0.75 (P < 0.01). No effect of WT was observed for V3 and 
CL3. Covariate height had no effect on any of the model parameters. Goodness of fit 
plots (measured versus individual predicted concentrations and individual weighted 
residuals versus time) are given in Fig. 3. Examples of data fits are given in Figures 4 and 
5. The goodness of fit plots and inspection of the individual data fits indicate that the 
pharmacokinetic model adequately describes the pharmacokinetic data.
Figure 3. Goodness of fit plots. 
A. Individual predicted 
concentrations versus measured 
concentration. 
B. Individual weighted residual 
(IWRES) of concentration versus 
time. 
C. Measured ventilation versus 
individual predicted ventilation. 
D. Individual weighted residuals 
(IWRES) of ventilation versus time. 
E. Measured versus individual 
predicted pain response. 
F. IWERS of pain tolerance responses 
versus time. In panels B, D and F 




Figure 4. Effect of fentanyl on ventilation. Best, median and worst fits (as determined by the coefficient of 
determination, R2) are given together with the corresponding pharmacokinetic data fits. Open symbols are the 
measured values; the continuous lines are the data fits. A and D. subject id 002, best pharmacodynamic fit; B and 
E. subject id 208, median pharmacodynamic fit; C and F. subject id 005, worst pharmacodynamic fit. Since fentanyl 
was given on two occasions both pharmacokinetic fits are given (panels A-C).
4.3.2 PHARMACODYNAMIC ANALYSIS
Mean ventilatory and pain responses are given in Figures 1 and 2. These figures show that 
fentanyl had an appreciable effect on both end-points. Best, median and worst PD data 
fits (and corresponding pharmacokinetic fits; the pharmacokinetic fits include the data 
from both occasions) for the three end-points are given in Fig. 4 and 5. The goodness of 
fit plots are given in Figure 3C to F. These plots and inspection of the individual data fits 
indicate that the pharmacodynamic models adequately describe the pharmacodynamic 
data. Model parameter values are given in Table 2. The ventilation Emin value was not 
significantly different from 0 L.min-1 (P > 0.05), which indicates that at a sufficiently 
high fentanyl dose apnea will occur. A critical ventilation level (arbitrarily defined as < 
4 L.min-1 or 20% of baseline) is attained at steady-state plasma fentanyl concentrations 
of 4 ng.ml-1 or greater. Potency estimates for respiratory depression and pain responses 
were 1.0 ng.ml-1 (C50) and 0.9 ng.ml-1 (C25), respectively (P < 0.01). The intra-individual 
variabilities (ηs) were not correlated indicating that the parameter values (t½ke0, C50 and 
γ) of the three end-points were uncorrelated. Peak respiratory depression ranged among 
subjects from 7 to 12 min following the start of the 90-s infusion.
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The results of the Visual Predictive Checks (VPC) for pharmacokinetic and 
pharmacodynamic data are plotted in Figure 6, showing the median predicted values 
(continuous lines) and 95% intervals (dashed lines). 
Figure 5. Effect of fentanyl on pain tolerance. Best, median and worst fits (as determined by the coefficient of 
determination, R2) are given, together with the corresponding pharmacokinetic data fits. A and D. subject id 004, 
best pharmacodynamic fit; B and E. subject id 012, median pharmacodynamic fit; C and F. subject id 011, worst 
pharmacodynamic fit. Since fentanyl was given on two occasions both pharmacokinetic fits are given if available 
(panels A-C; subject id004 has PK data from just one occasion).
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Table 2. Fentanyl pharmacodynamic model parameters
Typical value SEE (%) ω2 SEE η-shrinkage&
Ventilation
 t½ke0 (min) 17.10 3.44 (20) 0.49 0.12 (24) –2%
 Emax (L.min-1) 19.90 0.92 (5) 0.02 0.01 (50) 1%
 Emin (L.min-1) 0 (fixed) * 0 (fixed) * -
 C50 (ng.ml
-1) 1.02 0.18 (18) 0.31 0.07 (23) –2%
 γ 1 (fixed) * 0.41 0.26 (63) *
 Σ
2 3.71 0.59 (16) 1%#
 Pain Relief Response
 t½ke0 (min) 41.6 9.27 (22) 0.15 0.07 (47) 20%
 Baseline tolerance (mA) 26.0 2.87 (7) 0.14 0.04 (29) –5%
 C25 (ng.ml
-1) 0.91 0.29 (32) 0.85 0.35 (41) 16%
 γ 1.59 0.05 (3) 0 (fixed) * -
 σ2 10.9 3.84 (35) 8%#
*: not estimable. 
ω2 is the inter-subject variability (in the log-domain), σ2 is the variance of the residual error.                                                                    
t½ke0 is the blood-effect-site equilibration constant; C50 and C25 are potency parameters or steady-state concentrations 
at which 50% or 25% of the effect op occurred; Emax is baseline ventilation level; Emin is the minimum ventilation 
level; γ is a shape parameter.
– Not included in the statistical model. 
SEE is standard error of the estimate in the column to the left (in brackets the SEE as %). 
&: η shrinkage of empirical Bayesian estimates to the population values. 
#: ε shrinkage of model output to the observations
4.3.3 UTILITY FUNCTION
The calculated UFs are shown in Fig. 7A and B. In the concentration domain (U1, eqn. 
3), the utility is positive for low fentanyl effect-site or steady-state concentrations (< 0.7 
ng.ml-1, fig. 7B). At high concentrations the function is negative indicating that the chance 
for respiratory depression of 50% or greater exceeds the chance for analgesia (increase 
in pain tolerance by 50% or more). At a concentration of 1.74 ng.ml-1 the UF was most 
negative (U1 = –0.23) with a chance for analgesia and respiratory depression of 60% and 
83%, respectively.
In the time domain (U2, eqn. 4, Fig. 7A), the UF after a fentanyl dose of 3.5 μg.kg-1 is 
initially negative due to the high fentanyl concentrations from the bolus infusion (at t = 
6.6 min the value of U2 = –0.44 with changes for analgesia and respiratory depression of 
21% and 65%). With decreasing concentrations the function becomes positive at t > 100 
min. This corresponds with plasma fentanyl concentrations < 0.6 ng.ml-1. At t = 240 min 
the value of U = 0.06 with changes for analgesia and respiratory depression of 10% and 
4% respectively.
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Figure 6. Visual Predictive Checks of the fentanyl pharmacokinetic and pharmacodynamic model outcomes. 
Simulations performed with an input function similar to the current study. 
A. Fentanyl concentration. B. Ventilation. C. Pupil diameter. D. Pain tolerance. E. Pain threshold. Continuous lines: 
the median data fit; broken lines ± 95% confidence intervals.
Figure 7. Utility functions (P(A ≥ 50%) – P(R ≥ 50%)) for respiratory responses and pain relief in the time (A, 
following a 3.5 μg.kg-1 injection) and concentration domains (B), where P(A ≥ 50%) is the probability for an increase 
in pain tolerance of 50% or greater and P(R ≥ 50%) is the probability for respiratory depression of 50% or greater. 
P(A) > P(R) indicates that the probability for positive effects (analgesia) exceeds the probability for negative effects 
(respiratory depression); P(R) > (P(A) indicates that the probability for negative effects (respiratory depression) 




Effect of variations in P(A) and P(R) response thresholds. The results of the sensitivity 
analyses are given in Fig. 8A and B. Fig. 8A shows the results of the analyses in the 
concentration domain, while Fig. 8B gives the analyses in the time domain. Each set of 
lines with identical lines represents a set of fixed probabilities for respiratory depression, 
while within these sets the probability for analgesia increases from top to bottom. For 
analgesia, the probability for greater analgesic effects (for example P(A > 75%) or an 
increase in pain tolerance of at least 75%) occurs at the lower end of the set as the greater 
opioid concentrations that are required to reach such analgesic levels coincide with a 
greater probability for respiratory depression. For respiratory depression, going from P(R 
> 75%) to P(R > 25%) the probability for respiratory depression increases irrespective of 
the P(A) thresholds. For example, the probability of respiratory depression of at least 25%, 
P(R > 25%), exceeds that observed for the other effect threshold values, and consequently 
the function P(A) – P(R) is more negative than the other functions. 
Effect of variations in (pain model) parameter estimates t½ke0 and C50. The results are 
given in figure 9 and show that an increase in analgesic potency and, although to a lesser 
extent, a smaller value for t½ke0 causes an upward shift of the utility function. The reverse 
is true in case of a lesser analgesic potency and a slower analgesic onset/offset. 
Figure 8. Sensitivity analysis of the effect of different numerical response threholds in P(A) and P(R) on the shape 
of the utility functions. Each set of lines with identical lines represents a set of fixed probabilities for respiratory 
depression, while within these sets the probability for analgesia increases from top to bottom (See legend). A. UFs 
in the concentration domain. B. Utility functions in the time domain. 
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Figure 9. Influence of variations in blood-effect-site equilibration half-life, t½ke0 (A and B), and potency parameter, 
C50 (C and D), on the shape of the utility functions (UFs). Continuous lines are the data estimated from the current 
study (UF in time domain are constructed for a 3.5 μg/kg fentanyl injection). A and B. Dashed line is the UF with 
analgesia’s t½ke0 × 2, the dotted line is the UF with analgesia’s t½ke0 × 0.5 (Note that in the concentration domain 
changes in t½ke0 do not affect the shape of the UF). C and D. x-x- are the UFs with a lower potency for analgesia (C25 




The risk of opioid toxicity is best considered in the context of the opioid’s benefit (i.e. 
analgesia). Integrating opioid risk and benefit is important in acute and chronic pain 
treatment as it allows the comparison of net efficacy among opioids. For example, Katz 
showed in 946 patients with chronic lower back pain that the risk-benefit composite 
(defined as the proportion of days where the patient is an opioid responder (ie. 
experiencing ≥30% pain relief) with no or just moderate adverse events) is significantly 
greater for the opioid tapentadol than for oxycodone (30 vs. 25%).* This may help in the 
choice of opioid treatment for that specific patient population. In the current study, we 
assessed the risk-benefit composite of fentanyl in an acute administration paradigm by 
construction of a Utility Function as previously described by Cullberg,6 i.e. the difference 
between the probability of a wanted effect (antinociception, a positive effect) minus the 
probability of a side effect (respiratory depression, a negative effect). 
The UF is context sensitive. The context is the chosen probability for effect and side effect. 
We chose P(A ≥ 0.5) –  P(R ≥ 0.5) which is the probability for an increase in pain tolerance 
of at least 50% minus the probability for 50% respiratory depression or more. We choose 
50% as it compares to other 50% response values used in anesthesia such as minimum 
alveolar concentration (which gives the anesthetic concentration causing a response in 
50% of patient) and C50 (which is the drug concentration causing 50% effect). Evidently 
other probabilities will result in UFs that deviate in shape from the current functions. A 
sensitivity analysis using different numerical response threholds in P(A) and P(R) does 
indeed show that the UF is context sensitive (Fig. 8). The response threshold of P(A ≥ 0.5) 
–  P(R ≥ 0.5) is well positioned in the middle of the observed functions and reflects the 
“mid”-response comparable to the minimum alveolar concentration or C50. How these 
results may be interpreted in a clinical setting and which of the response thresholds is 
most appropriate requires further studies.  
The UFs were constructed from 2 × 9,999 simulations using the PK-PD parameter estimates. 
The sometimes-large variance of some parameters is therefore taken into account in the UF. 
We determined the utility as function of effect-site or steady-state concentration (U1, eqn. 
3) and time (U2, eqn. 4) following a 3.5 μg.kg-1 fentanyl injection. Following the injection, 
U2 values are negative for the first 90 min with large negative values (< –0.4) from t = 2 to t 
= 17 min (Fig. 6A). At t > 90 min, when plasma fentanyl concentrations were < 0.6 ng.mL-1, 
U2 becomes positive, but the positive values are small. The U1 (concentration) function 
shows a variation of 0.25, a rather modest variation ranging from +0.05 to –0.20, but still 
predominantly negative (Fig. 6B). Overall the UFs show what also clinically is apparent: 
(1) following a fentanyl bolus dose the probability of respiratory depression (relative 
to analgesia) is highest in the first hour following the injection, with a diminishing (but 
certainly not vanishing) probability of respiratory depression at later times; and (2) only 
at low doses of fentanyl (up to 50 μg) does the probability for analgesia exceed that of 
respiratory depression. 
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The UFs we constructed are based on specific pharmacodynamic end-points commonly 
used in our laboratory when studying opioid effect and therefore allow comparison 
among opioids. Ventilation was measured with the dynamic end-tidal forcing technique in 
which the end-tidal PCO2 is clamped at a fixed elevated level such that pre-drug baseline 
ventilation increased to 20 - 24 L.min-1.(7-10,15-17) This approach has various advantages 
including the assessment of respiratory effect at constant carbon dioxide stimulation. 
Under ‘non-clamped’ conditions (i) the arterial carbon dioxide level changes over time 
following the administration of an opioid resulting in confounding variations in the 
stimulation of peripheral and central chemoreceptors, and (ii) the speed of opioid injection 
influences the time profile of respiratory depression.18 The estimated model parameters of 
the respiratory effects of fentanyl (C50 = 1 ng.ml-1, t½ke0 = 17 min) are in close agreement 
with earlier observations in healthy volunteers.9,19 In the current study, C50 is the fentanyl 
concentration at the effect site (or the steady-state plasma concentration) causing 50% 
depression of ventilation under conditions of a clamped and elevated end-tidal carbon 
dioxide concentration. Under non-clamped conditions the estimated C50 value will result 
in an increase in arterial PCO2 by 30 to 40% combined with a reduction in ventilation by 
30-40%. 
The nociceptive model used by us is transcutaneous electrical stimulation. This model 
is used frequently in pain research as it allows repetitive testing without confounders 
such as sensitization or adaptation.10-12,19 The opioid response to electrical stimulation is 
slower than expected from other end-points including respiratory depression and changes 
in electroencephalographic parameters.11,19-22 The slower response has been observed for 
other opioids as well and is further discussed by Olofsen et al.,11 It is most probably related 
to slow neuronal dynamics and activation of short-term potentiation at central sites 
involved in the processing of electrical pain.11 Irrespective, the fentanyl potency value 
(C25 = 0.9 ng.mL-1; extrapolated C50 = 1.4 ng.mL-1) is well within the expected clinical 
concentration range and corresponds with the concentration causing a 40% reduction in 
isoflurane minimum alveolar concentration and potent analgesia in clinical settings.23 To 
get an indication of the importance of variations in t½ke0 and potency on the shape of the 
UFs we performed an additional set of simulations (Fig. 9) with variations in the analgesia 
model parameters. Variation in C25 was the more dominant factor with larger changes 
in the shape of the UF compared to changes in t½ke0. At a lower analgesic potency the 
UF becomes more negative, both in time and concentration domains. A smaller value for 
t½ke0 (ie. a more rapid onset/offset of effect) results in an upward shift of the UF (Fig. 9A). 
Variations in t½ke0 have no effect on the steady-state UF (Fig. 9B). 
The UF in drug research is still experimental and our study is exploratory. It may already 
be argued that the UF may be useful for comparing the safety profile of specific drugs 
and for choosing a specific opioid dose with an optimal UF. Traditionally the behavior 
of opioids is presented in terms of concentration-effect relationships (Fig. 10). However, 
in contrast to the UF, such static relationships do not take into account the dynamics of 
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the response (as represented in our model by parameter t½ke0) and most importantly 
do not address the large inter-individual variability in the measured responses. While 
the static relationships are important in understanding the steady-state behavior of the 
opioid (for example, such analyses enable the direct comparison of multiple effects, Fig. 
10C), the UF gives an insightful and dynamic presentation of possible drug effects in time 
and concentration domains in terms of probability of occurrence of multiple effects. For 
example, in Fig.11, UFs are created for two 3-h continuous infusions of fentanyl (one at 
relative high dose: 0.25 mg.h-1 for a 70 kg patient; and one at a dose commonly used 
Figure 10. Static fentanyl concentration-effect relationships (A and B) and static pharmacodynamic-
pharmacodynamic analysis (C). A. Fentanyl effect-site concentration versus respiratory depression. B. Fentanyl 
effect-site concentration versus pain response (pain toleranace). C. Ventilation versus pain response (values are 
aligned at identical effect-site concentration). 
Figure 11. Effect of a continuous fentanyl infusion (A and C) on the utility function (P(A ≥ 50%) – P(R ≥ 50%)) 
for respiratory responses and pain relief over time (B and D). A and B. Infusion duration is 3 h. Continuous line: 
fentanyl dose = 0.25 mg.h-1 in a 70 kg patient; dashed line: fentanyl dose = 0.07 mg.h-1 in a 70 kg patient. C and D. 
Infusion duration is 100 h (continuous line) and 3 h (dashed line). 
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for treatment of chronic pain in transdermal patch formulations: 0.07 mg.h-1) and one 
100 h infusion (dose 0.07 mg.h-1). As expected the UF is initially more negative for the 
high-dose infusion (minimum value –0.34; Fig. 11 A and B). Subsequently this UF slowly 
increases due the increase in the probability for analgesia. At the low-dose infusion (Fig. 
11C and D), the UF value slowly decreases in value (i.e. it becomes more negative over 
time) as the probability for respiratory depression increases more than the probability for 
analgesia. The UF reaches a steady state after 17-18 h (steady-state value –0.23, Fig. 11D). 
This suggests that patients on a fentanyl patch have a predominant (moderate) negative 
UF. Ending the 0.07 mg.h-1 infusion after 3 h causes an increase in UF to a positive value 
(maximum value +0.06, Fig. 11B). Such behaviors could not be predicted from static 
concentration-effect relationships.  Apart from respiratory depression other end-points 
may be used in the construction of UFs, including sedation, dizziness, nausea/vomiting, 
and psychomimetic side effects.
In conclusion, we performed an explorative study on the construction of utility functions 
in which the probability for respiratory depression is subtracted from the probability for 
analgesia as part of a risk-benefit analysis of opioid effect. The shape of the utility function 
is dependent on the context, that is the numerical response thresholds for P(A) and P(R) 
as well as the administration history (i.e. the change in effect-site concentration over time). 
In the current study probabilities for P(A) and P(R) of ≥ 50% were used that reflect an 
increase in pain tolerance of at least 50% and respiratory depression of at least 50%. These 
functions are useful in the comparison of the safety profile among drugs relative to their 
analgesic efficacy, and consequently may become an important tool in drug development. 
Further studies are required to compare our experimental data with clinical observations 
and assess whether the UF is valuable in clinical practice as well.
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Opioid analgesics form the cornerstone of contemporary treatment of moderate to severe 
(acute and chronic) pain. Opioids are associated with a series of side effects including 
opioid-induced respiratory depression (OIRD), which is potentially life threatening.1 In 
recent years the number of lethal opioid-related respiratory complications has increased 
significantly,2,3 mainly due to the misuse or abuse of legally prescribed opioids for 
moderate to severe chronic pain (most importantly lower back pain). Opioids produce 
respiratory depression via activation of μ-opioid receptors (MORs) expressed on pontine 
neurons involved in the respiratory control.4 Full MOR agonists produce a dose dependent 
respiratory depression with apnea at high doses.5 Few studies address the (positive or 
negative) contribution of the other opioid receptors on respiratory depression. We recently 
showed both in rodents and humans that buprenorphine (a partial agonist at the MOR, 
antagonist at the κ-opioid receptor (KOR), and with activity at the opioid-receptor-like 
(ORL1) receptor) produces a ceiling in respiratory depression; ceiling is defined as an 
apparent maximum effect regardless of drug dose tested.5,6 This is a major advantage 
over other opioids and implicates some protective effect at high doses. The molecular 
mechanism underlying the ceiling in respiratory effect has not yet been elucidated. In 
mice, Lutfy et al. showed that the ceiling in analgesia is related to the activation of the ORL1 
receptor.7 Extrapolation of these findings to the respiratory system would suggest that 
some of the opioid receptors may counteract, at least in part, the respiratory depression 
induced by the activation of the MOR.5,6  
In the current phase 1 study, we assessed the respiratory and analgesic effects of the 
experimental drug MR30365/07, an opioid with high affinity for the MOR, δ-opioid 
receptor (DOR), KOR and lower affinity for the ORL1 receptor (confidential data, 
Mundipharma Research Ltd.). We compared MR30365/07 to fentanyl, a selective and 
high affinity MOR agonist that produces dose-dependent respiratory depression and 
apnea at high doses (2-3 μg.kg-1 and greater).5,6,8 Experiments were performed in healthy 
male volunteers. The study consisted of two parts. Part 1 was a single blinded, placebo 
controlled pilot study on the respiratory effects of a range of MR30365/07 doses, designed 
to select the MR30365/07 dose most suitable for use in the main phase of the study (Part 
2). Part 2 was a double-blind, randomized, placebo-controlled study, which compared the 
respiratory and analgesic effects of MR30365/07 and fentanyl. 
5.2 METHODS
This phase 1 study had two parts. Initially a MR30365/07 dose-ascending, cohort group, 
single-blinded pilot study (part 1) was performed for dose-finding. After the pilot study 
was completed, the MR30365/07 doses were selected for the main study (part 2), a 
randomized, double-blind, placebo- and active comparator (fentanyl)-controlled parallel 
group study was performed.
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5.2.1 SUBJECTS
One hundred and two healthy male volunteers (10 in the pilot study and 92 in the main 
study) participated in the study after approval of the protocol was obtained from the 
Leiden University Medical Center (LUMC) Human Ethics Committee and the Central 
Committee on Research Involving Human Subjects (CCMO, The Hague). Written and oral 
informed consent was obtained prior to enrolment into the study. All volunteers provided 
a medical history, and a physical examination, 12-lead ECG and blood screening was 
conducted before enrollment. The eligible volunteers were between the ages of 18 and 45 
years, weighed between 60 and 100 kg, had a body mass index between 18 and 30 kg.m-2, 
and a forced expired lung volume in 1 s of > 85% of predicted. Study subjects were healthy 
with no history of major medical disease, alcohol abuse, illicit drug use or heavy smoking. 
Volunteers could not have used medication (including vitamins, herbal and/or mineral 
supplements) in the seven days preceding dosing, or during the course of the study, or 
opioids or opioid antagonists in the 90 days prior to dosing. Finally, participants had to 
fast for 6 hours prior to the administration of study medication.
5.2.2 STUDY DESIGN
Pilot study. The respiratory effects of 3 escalating doses of MR30365/07 and 1 infusion 
of placebo were tested on 4 separate days with at least 1 week for wash-out between 
test sessions. Three subjects received 0.025, 0.05 and 0.1 μg.kg-1 MR30365/07 and placebo 
(cohort 1), three others 0.0125, 0.075 and 0.1 μg.kg-1 MR30365/07 and placebo (cohort 2) 
and the last three subjects 0.05, 0.125 and 0.15 μg.kg-1 MR30365/07 and placebo (cohort 3). 
From the results of this study the doses of the main study were determined. After infusion 
of the drug was completed, ventilation was continuously measured breath-to-breath for 1 
h under iso-hypercapnic conditions (see below).
Main study. In this double-blind randomized study 92 volunteers participated. None of 
them had been part of the pilot study and all were dosed only once. 46 subjects participated 
in the respiratory part of the study, 46 others in the analgesia part. In both parts, placebo (n 
= 6), 0.0125 μg.kg-1 MR30365/07 (n = 4), 0.075 μg.kg-1 MR30365/07 (n = 6), 0.125 μg.kg-1 
MR30365/07 (n = 6), 0.15 μg.kg-1 MR30365/07 (n = 4), 0.5 μg.kg-1 fentanyl (n = 4), 1 μg.kg-1 
fentanyl (n = 6), 2 μg.kg-1 fentanyl (n = 6) and 3 μg.kg-1 fentanyl (n = 4) were administered 
by intravenous infusion over 10 min. The randomization list was prepared by the sponsor 
of the study and sent to the local pharmacy where blinded syringes were prepared based 
on the weight of the subject. Each syringe was identical in size, drug volume and color and 
was unmarked. The randomization list was available to the sponsor, the pharmacy and an 
independent data safety monitoring committee. 
Study medications. Citrate buffer, fentanyl and MR30365/07 were obtained from 
Mundipharma Research Limited (Cambridge, UK). All drugs were infused intravenously 
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(in the arm or hand) using a syringe pump (Beckton Dickinson, St. Etienne, France). 
5.2.3 MEASUREMENTS
Respiratory measurements. Following infusion, ventilation was continuously measured 
on a breath-to-breath basis for 1 hour under iso-hypercapnic conditions. End-tidal gas 
forcing and data acquisition were performed using the dynamic end-tidal forcing 
technique (see Dahan et al.9,10 for an explanation of the technique). In brief: Subjects 
breathed through a facemask connected to a pneumotachograph and differential pressure 
transducer (#4813, Hans Rudolph, Myandotta, MI). The pneumotachograph was connected 
to a custom-made gas mixing system attached to three mass-flow controllers (Bronkhorst, 
Veenendaal, The Netherlands). A computer delivered signal to the mass flow controllers 
so that the composition of the inspired gas could be adapted to steer the end-tidal oxygen 
and carbon dioxide concentrations according to a pre-set pattern over time. The inspired 
and expired oxygen and carbon dioxide concentrations and the arterial hemoglobin–
oxygen saturation were measured with a Datex Multicap gas monitor (near the mouth) 
and Datex Satellite Plus pulse oximeter, respectively (Datex-Engstrom, Helsinki, Finland). 
End-tidal concentrations of oxygen and carbon dioxide, inspired minute ventilation (Vi), 
and oxygen saturation were collected for further analysis. Ventilation levels and end-
tidal concentrations were observed in real time on a breath-to-breath basis on a computer 
screen. 
In the current study the end-tidal oxygen level was clamped to a value of 110 mmHg, while 
the end-tidal carbon dioxide concentration was slowly increased to a value that caused 
ventilation levels of 20 ± 2 L.min-1. This end-tidal carbon dioxide value was maintained 
throughout the study. Respiratory measurements started when the inspired minute 
ventilation had reached a steady state; 4-5 min later drug infusion started. Respiratory 
measurements ended 60 min after the end of drug infusion (t = 70 min). 
Pain measurements. Pain was induced using a transcutaneous electrical stimulus to the 
skin over the left tibial bone (10 cm above the ankle).11 A 20 Hz (pulse duration 0.1 ms) 
stimulus train was delivered to the subject causing activation of cutaneous nociceptors. 
The stimulus train starts at 0 mA and was increased at a rate of 0.5 mA per 2 s (with 
a cutoff value of 128 mA). The delivery of the current is controlled by a computer via 
a current stimulator, which is connected to a control box with two buttons. The subject 
was instructed to press the first button when pain was felt (i.e. pain threshold) and the 
second button when the subject wanted the stimulus train to stop (i.e. pain tolerance). 
These respective currents were collected on disc for further analysis. The subject was 
familiarized with the system prior to the study to obtain reliable baseline values. In this 
study, the pain threshold values were used in the analysis. Four pain threshold values 
were obtained in the 30 minutes prior to drug infusion. These values were averaged and 
served as a baseline estimate. Following drug infusion, pain measurements were obtained 
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at the following time points (t = 0 is the start of drug infusion): 10 (end of infusion), 15, 30, 
45, 60, 75, 90, 105, 120, 150, 180, 210, 240, 300, 360, 420 and 480 min. 
5.2.4 SAMPLE SIZE AND STATISTICAL ANALYSIS
The pilot study was designed to determine which doses of MR30365/07 were to be tested 
in the main study. Four doses were chosen for the main study: 0.0125, 0.125, 0.075 and 0.15 
μg.kg-1.  
For the main study, sample size selection was achieved by performing a power analysis in 
NONMEM,12 using estimated data on the effect of opioids on respiratory depression.8 We 
assumed inter-subject variability in effect of 50% (ω2 = 0.25) and a 10% residual error for 
effect (σ2 = 0.01) and aimed to detect a value of ρ < 0.5 or > 2.0 (where C50A, MR30365/07/
C50R,MR30365/07) = ρ × C50A,FENTANYL/C50R,FENTANYL and C50A and C50R are the 
concentrations causing 50% analgesia and respiratory depression for drugs  MR30365/07 
and fentanyl, respectively), with α < 0.05 and β = 0.8. In the analysis we assumed that 
C50A,MR30365/07 = C50A,FENTANYL (i.e. concentrations are equianalgesic). Values of ρ < 0.5 
indicate that fentanyl produces respiratory depression at concentrations at least twice as 
low as MR30365/07 and vice versa for ρ > 2. It was assumed that the logarithm of the 
C50 ratio has a normal distribution with variance = 1. The sample size selection was next 
verified by simulations in NONMEM with 1,000 simulated data sets. The analysis resulted 
in a sample size of 34, which was rounded upwards to 40 (20 subjects per opioid treatment). 
Six additional subjects were added to receive placebo. The subject number chosen for the 
analgesia part of the study was identical to that calculated for the respiratory part of the 
study, as we, somewhat arbitrarily, assumed similar drug effects and variability. 
Average respiratory drug effect. The breath-to-breath data were averaged over 1-min 
episodes. In order to get an impression of the average drug effect on respiration, we 
calculated the area below the respiration curve (AUC) from t = 0 to t = 70.5,13 The AUC 
was subtracted from the area obtained by taking baseline ventilation forward (BASELINE 
AREA, from t = 0 to t = 70 min, see Fig. 1). Next the data were normalized by the baseline 
area giving an average % of respiratory depression (average drug effect = [baseline area 
AUC – AUC]/baseline area AUC). An average drug effect of 40 indicates an average of 
40% respiratory depression over the measured time period (0-70 min). The average drug 
effect and time to peak effect were analyzed using a one-way analysis of variance (factor 
dose). The MR30365/07 and fentanyl data were analyzed separately in Sigmaplot v12.3 
(Systat Software GmbH, Ekrath, Germany).  P-values < 0.05 were considered significant. 
Values given are mean ± SD.
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Peak respiratory depression. For each subject peak respiratory depression was calculated 
as the nadir in ventilation and presented as ratio relative to baseline (e.g. a value of 0.5 
indicates a nadir in ventilation in magnitude 50% of baseline ventilation). Using the 
statistical package R (version 8.2; www.r-project.org), a sigmoid EMAX function was 
fitted through the MR30365/07 and fentanyl dose-effect data (effect = peak respiratory 
depression) using a model of the form:
Peak effect(dose) = 100 + [EMIN – 100] × [doseγ + ED50γ]   eqn. (1)
where ED50 is the dose causing a 50% effect (ventilation in the middle of baseline ventilation 
and EMIN), EMIN the asymptotic minimum in ventilation, and γ a shape parameter. 
P-values < 0.01 were considered significant. The data analysis was performed on the 
complete data set (fentanyl data and MR30365/07 data from pilot and main studies). The 
data are presented as mean ± SD.
Analgesic effect. Two measures of analgesic effect were calculated in each experiment: 
peak analgesia (defined as the highest value of pain threshold in mA) and average analgesic 
effect (as defined as the area under the pain threshold curve from t = 0 to t = 8 h normalized 
by the baseline area, see above). Peak and average analgesic effects were analyzed using 
a one-way analysis of variance (factor ‘dose’). The MR30365/07 and fentanyl data were 
analyzed separately using SigmaPlot v. 12.3. P-values < 0.05 were considered significant. 
Values given are mean ± SD.
5.3 RESULTS
Pilot study. Nine volunteers completed the study without unexpected side effects. One 
subject developed ECG changes that, although not clinically relevant, precluded proper 
assessment of the effect of the study medication on the ECG. As a precautionary measure, 
Figure 1. Calculation of the average respiratory 
drug effect. First the area-under-the curve 
(AUC) is calculated for the respiration curve 
(line from A to A’). This AUC (grey field) was 
subtracted from the area obtained by taking 
baseline ventilation (A) forward (the arrow from 
point A to B; the baseline area AUC is the box 
depicted by the red broken lines ABCD). Next 
the data were normalized by the baseline area 
giving an average % of respiratory depression 
(average drug effect = [baseline area AUC – 
AUC]/baseline area AUC).
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another subject replaced this subject after having completed a placebo and 0.05 μg.kg-1 
MR30365/07 experiment. The clamped end-tidal PCO2 was 6.6 ± 0.5 kPa (49.5 ± 4.5 
mmHg) and baseline (pre-drug) ventilation was 21.5 ± 1.7 L.min-1. The mean respiratory 
responses to MR30365/07 are given in Fig. 2A. At all dosages, the drug displayed a nadir 
in ventilation, which occurred at t = 17.1 ± 3.8 min following the start of drug infusion. 
The respiratory responses to MR30365/07 dosages of 0.075, 0.10, 0.125 and 0.15 μg.kg-1 
overlap. The dose-response curves (peak respiratory depression and average drug effect) 
are given in Figs. 2B and C showing that the dose-response levels off at dosages of 0.075 
μg.kg-1 and greater (MR30365/07 at 0.075, 0.125 and 0.15 μg.kg-1: P > 0.05).
Figure 2. Results of the pilot study. A. Mean respiratory responses to placebo and MR30365/07. B. Dose-response 




A small positive trend was observed in the ventilation data as was best observed in the 
placebo responses (Figs. 2-4). The magnitude of the trend ranged from 30-60 ml.min-2 
(about 1.5-3% of total ventilation) and corresponds with the presence of a slow component 
(time constant about 1 h) in the ventilatory response to CO2.9,14
Main study: Respiration. All 46 subjects completed the study without unexpected side 
effects. In the MR30365/07 experiments, the end-tidal PCO2 was clamped at 6.8 ± 0.2 
kPa (51.0 ± 1.5 mmHg) and baseline (pre-drug) ventilation was 19.3 ± 1.4 L.min-1. The 
Figure 3. Results of the main study: Effect of MR30365/07 on respiration. A. Mean respiratory responses to placebo 
and MR30365/07. B. Dose-response data: Peak respiratory depression. C. Dose-response data: Average drug effect. 
The data in panels B and C are mean ± SD. 
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mean respiratory responses to MR30365/07 are given in Fig. 3A. No nadir in ventilation 
was observed in the placebo data and the lowest MR30365/07 dose tested. The time to 
peak effect was dose-independent and occurred at 17.3 ± 5.5 min. The dose-response 
curves for peak respiratory depression and average drug effect are given in Figs. 3B 
and C, respectively, showing that the dose-response levels off at a ventilation level of 
approximately 50% of baseline. None of the subjects that received MR30365/07 developed 
irregular breathing or apnea.
Figure 4. Results of the main study: Effect of fentanyl on respiration. A. Mean respiratory responses to placebo and 
the four fentanyl dosages. B. Dose-response data: Peak respiratory depression. C. Dose-response data: Average drug 
effect. The data in panels B and C are mean ± SD. 
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In the fentanyl experiments, the end-tidal PCO2 was clamped at 6.6 ± 0.1 kPa (49.5 ± 0.8 
mmHg) and baseline (pre-drug) ventilation was 20.2 ± 0.9 L.min-1. A nadir in respiratory 
response was observed for all doses tested (Fig. 4A). The time to peak effect was dose-
independent and occurred on average at 12.8 ± 2.1 min. The dose-response curves for peak 
respiratory depression and average drug effect are given in Figs. 4B and C, respectively. 
Dose-dependent respiratory depression was apparent in peak ventilation (P < 0.001) 
and average drug effect (P < 0.001). The maximum observed respiratory depression was 
observed at the highest fentanyl dose tested (3 μg.kg-1; peak effect = 19% of baseline). Two 
subjects developed irregular breathing after the highest dose of fentanyl, one of which 
developed apnea (defined by the absence of breathing activity > 20 s), just after ending the 
10-min fentanyl infusion.
The parameter estimates of the model analysis of peak respiratory depression are given 
in Table 1. The model fits are given in Figs. 5A (MR30365/07) and B (fentanyl). Two 
parameters were significantly different between treatments (P < 0.01): ED50 and EMIN. An 
apparent 30-fold difference in potency was observed with ED50 values of 0.04 μg.kg-1 for 
MR30365/07 and 1.27 μg.kg-1 for fentanyl. For fentanyl the value of EMIN or the asymptotic 
minimum ventilation was not different from zero, but greater than zero for MR30365/07: 
32.8% of baseline ventilation or 6.6 L.min-1 (P < 0.01). The shape parameter γ and residual 
error variance (σ2) did not differ between treatments. 
Main study: Analgesia. All 46 subjects completed the study without unexpected side 
effects. Baseline pain thresholds were 11.8 ± 0.9 mA (MR30365/07), 12.7 ± 0.4 mA (fentanyl) 
and 11.0 ± 0.6 mA (placebo). The effect of placebo was limited with an effect no greater 
than 10% of baseline. Both MR30365/07 and fentanyl produced dose-dependent effects 
in terms of peak analgesic effect and average drug effect (Figs. 6 A and B; drug-effect: P < 
0.01) with no indication of reaching a ceiling. 
5.4 DISCUSSION
Development of novel opioid analgesics with limited respiratory depression at high 
doses is highly relevant as OIRD is a major cause of opioid morbidity and mortality.1-3 
In this experimental phase 1 study we showed that in contrast to fentanyl, MR30365/07 
displayed a ceiling in respiratory depression in the tested dose range starting at 0.075 
μg.kg-1. The respiratory effects of MR30365/07 0.075, 0.10, 0.125 and 0.15 μg.kg-1 overlap 
with peak respiratory depression at about 40% of baseline ventilation. Fentanyl showed 
dose-dependent respiratory depression with, at high dose, irregular breathing and apnea. 
Neither fentanyl, nor MR30365/07, produced a ceiling in analgesia over the dose range 
tested. 
We used the computer-steered ‘dynamic end-tidal forcing’ or DEF technique to clamp end-
tidal PCO2 to a fixed ventilation level of 20 ± 2 L.min-1.9,10 On average this was achieved by 
increasing end-tidal PCO2 to 6.65 kPa (50 mmHg). The advantages of the DEF technique 
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Table 1. Parameter estimates of the model analysis of peak respiratory depression
Parameter Mean SD 2.5% percentile 97.5% percentile
 ED50 MR30365/07 (μg.kg
-1 ) 0.04 0.009 0.026 0.06
 ED50 Fentanyl (μg.kg
-1) 1.27 0.116 1.04 1.50
 γ 1.80 0.32 1.23 2.51
 EMIN MR30365/07 (% of baseline)* 32.8 0.06 16.7 42.6
 EMIN Fentanyl (% of baseline)* 0 - - -
 σ2 0.014 0.002 0.010 0.019
ED50 is the dose causing a 50% reduction in ventilation, EMIN the asymptotic minimum in ventilation, γ a 
shape parameter, and σ2 the variance of the residual error. 
* baseline ventilation = 100%.
Figure 5. Model fits of peak respiratory depression versus dose for MR30365/07 (A) and fentanyl (B). On the y-axis, 
ventilation relative to pre-drug baseline ventilation. The continuous thick lines are the model fits and the thin lines 
are the 2.5% and 97.5% percentiles. The curves are extrapolated to 0.3 μg.kg-1 MR30365/07 and 6 μg.kg-1 fentanyl. In 
panel A, the closed circles are data from the main study, the open circles are data from the pilot study. In panels A 
and B, the respective ED50 and EMIN values are depicted by the symbol × and broken grey lines. For both drugs the 
ED50 is the dose half-way between baseline ventilation and EMIN; for fentanyl this is at 50% respiratory depression, 
for MR30365 at 33.6%.
CHAPTER 5
100
over more conventional techniques are that respiratory response of the test drug is (i) 
independent of the confounding effects of changes in arterial CO2 and (ii) independent 
of the speed of administration of the drug.5,6,15 These two items are interconnected. For 
example, we showed previously that administration of remifentanil aimed at a target plasma 
concentration of 5 ng.ml-1 will cause severe respiratory depression when the drug target 
is reached after 5 min.14 This is due to the rapid transport of the drug to the brain causing 
immediate depression of brainstem respiratory neurons (no CO2 having accumulated at 
this time). Respiratory depression is less likely when the remifentanil target is reached after 
30 min. Part of the respiratory depression is offset by the accumulation of CO2 in the brain 
compartment. Performing studies under poikilocapnic conditions would therefore lead 
to an underestimation of respiratory potency of a drug as is exemplified by the study of 
Mildh et al. for fentanyl.16  They estimated the fentanyl plasma concentration that caused 
a 50% depression in respiration at 6.1 ng.ml-1. Considering the changes in arterial CO2 (for 
example, by modeling the stimulatory effects of CO2 on the respiratory control system) 
Figure 6. Results of the main study: Effect of MR30365/07 and fentanyl on pain threshold. A. Peak analgesia, 
defined as the highest value of pain threshold in mA). B. Average analgesic effect, defined as the area under the pain 
threshold curve (AUC) from t = 0 to t = 8 h normalized by the baseline area. Note that the logarithmic x-axis scales.
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or by using the DEF technique, a value of 1.1 ng.ml-1 is estimated;8 6-fold lower than 
estimated from poikilocapnic studies and in agreement with clinical observations. The 
DEF technique allows reliable comparison of drug effect on the respiratory control system. 
In our studies, the differences observed for MR30365/07 and fentanyl in dose-response 
relationship (ceiling in respiratory depression for MR30365/07 but not fentanyl), the more 
rapid onset of effect for fentanyl (peak effect occurred at 2.8 min after the end of the 10 min 
infusion versus 7.3 min for MR30365/07) and the longer-lasting respiratory depression are 
due to CO2-independent differences in pharmacokinetics and pharmacodynamics. 
From a clinical perspective, the existence of ceiling in respiratory depression is 
advantageous only when no ceiling in analgesic efficacy exists or when ceiling occurs at 
much higher (supra clinical) drug concentrations. Indeed, in our study we observed that 
over the dose range tested, both fentanyl and MR30365/07 displayed a dose-dependent 
increase in peak pain response and average analgesic effect (Figs. 6A and B). These data 
give reasonable evidence that for MR30365/07, in contrast to respiration, pain relief does 
not display ceiling over the dose range tested. At the highest dose tested both drugs 
produced an increase in pain threshold of about 100% (MR30365/07 0.15 μg.kg-1 response 
= 1.95 × pre-drug response; fentanyl 3.0 μg.kg-1 response = 2.1 × pre-drug response). 
This indicates a MR30365/07-fentanyl difference in potency of 18.5. This difference is 
smaller than the apparent potency difference observed for respiratory depression (factor 
= 30). However, since the ED50 is an estimation of ventilation in the middle of baseline 
ventilation and EMIN, a better comparison than ED50 would be the dose causing 50% 
depression of ventilation (in absolute values). For fentanyl this is identical to ED50 (1.27 
μg.kg-1), and for MR30365/07 this is 0.075 μg.kg-1. This then suggests a potency difference 
of 17 very similar to the value observed for antinociception. Taking all data together, our 
data suggests that MR30365/07 has a better therapeutic window than fentanyl. 
Three issues remain unresolved by our studies. The first is the cause of the ceiling 
in MR30365/07 respiratory effect. To the best of our knowledge, ceiling in respiratory 
depression has been demonstrated in humans for only one other opioid, buprenorphine.5,6 
The partial agonism (i.e. partial effect despite full receptor occupancy) of buprenorphine 
at the MOR is considered responsible for its ceiling effect. This mechanism is not relevant 
for our studies as MR30365/07 is a full agonist at the MOR. Lutfy et al.,7 however, propose 
a different mechanism for development of ceiling. They showed lack of buprenorphine-
induced antinociception in MOR knockout mice but enhancement of antinociception 
in ORL1 receptor knockout mice with loss of ceiling in analgesia. In that study, it was 
concluded that the concurrent activation of ORL1-receptors severely compromised the 
MOR-mediated antinociceptive effect of buprenorphine in mice.7 In contrast to these data, 
a recent study in primates shows that ORL1 receptor agonists enhance buprenorphine-
induced antinociception, however, without causing additional respiratory depression.17 
These data suggest that ORL1 activation may be implicated in the mechanism of ceiling in 
respiratory effect as observed in our studies. However, although MR30365/07 has affinity 
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for the ORL1 receptor, its Ki is several orders of magnitude higher than for the MOR 
(confidential data, Mundipharma Research Limited). Whether such low affinity for the 
ORL1 receptor is sufficient to cause the profound ceiling we observed is questionable. 
Another possible mechanism may be related to MR30365/07’s high affinity for the KOR, 
which is approximately 1 order of magnitude lower than for the MOR (confidential data, 
Mundipharma Research Limited). There is evidence that KOR agonists may selectively 
antagonize MOR agonist effects, including respiratory depression.18,19 For example, the 
KOR agonist U50,488H antagonized MOR agonist-induced respiratory depression in the 
rat, a KOR mediated effect.18 It may well be that at high doses the MR30365/07-induced 
and MOR-mediated respiratory depression is antagonized by the effect of MR30365/07 at 
the KOR. KOR agonists have been associated with dysphoria.20 Interestingly, in our study, 
over a 24-h observation period no significant differences in dysphoria were observed 
between MR30365/07 and fentanyl. 
A final proposed mechanism involves the intra neuronal regulatory protein β-arrestin.6 
Opioid receptors belong to the 7-transmembrane G-protein-coupled receptors that, 
upon activation, bind to intracellular G-proteins and β-arrestin 1 and/or β-arrestin 2 
proteins. Recent studies show that absence of β-arrestin 2 protein causes the attenuation 
of morphine-induced respiratory depression with maintained antinociception.21,22 It was 
hypothesized that (G-protein independent) activation of β-arrestin 2 is involved in MOR 
signal transduction of respiratory neurons but not in neurons involved in modulation 
of pain pathways.21 It may well be that extent of G protein and of β-arrestin 2 activation 
is ligand specific. Such ligand-specific, i.e. biased differences in G protein and β-arrestin 
activation, has been first described for the angiotensin1A receptor.23 Extrapolating these 
findings to our study would suggest that our results are then well explained by a lesser 
ability of MR30365/07 to activate β-arrestin 2. Further work is required to elucidate the 
mechanism by which ceiling of respiratory effect is observed at the high MR30365/07 
doses as observed in our study.
A second issue is the mechanism of the differential MR30365/07 effect on respiration and 
analgesia. We previously proposed and discussed that this may be due to a difference 
in receptor density at brain sites involved in analgesia versus brain sites involved in 
respiratory depression.6 This has for example been demonstrated experimentally by 
performing a progressive MOR knockdown by administration of the MOR antagonist 
β-funaltrexamine.24 Reduction of opioid bindings sites transformed the MOR agonist 
alfentanil into a partial agonist. Another mechanism involved may be the lesser ability 
of MR30365/07 to engage the transduction protein β-arrestin 2, as discussed above. This 
latter mechanism explains both the observed ceiling effect in MR30365/07-mediated 
respiratory depression and the selectivity of the ceiling effect. 
A third issue is whether the experimental observation of ceiling in the respiratory effects of 
MR30365/07 may be extrapolated to the clinical setting, and whether such a phenomenon 
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indeed leads to less respiratory events in patients. This is a highly relevant topic as there 
has been a recent increase in the number of fatalities from misuse or abuse of legally 
prescribed opioids.1-3,25 An apparent ceiling in respiratory depression at higher doses of 
MR30365/07 is certainly an advantage over other opioids that lack such a profile. However, 
whether this behavior persists in patients with their own complexities (co-medication, 
underlying disease, genetics, overdosing, etc.), needs to be further investigated. 
In conclusion, we showed in this phase 1 study that in contrast to fentanyl, MR30365/07 
shows ceiling in respiratory depression, but not analgesia over the dose range tested 
(0.0125-0.15 μg.kg-1 MR30365/07).
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Chronopharmacology studies the effect of the timing of drug administration (in terms of 
the hour in a 24 h period, the day in a 1 month or 1 year period, or the year in a life-time) 
on the drug’s pharmacokinetics and/or pharmacodynamics.1,2 When applied to the 24 h 
circadian rhythm, it is now known that numerous drugs exhibit a differential response 
depending on the time of administration. This also applies to drugs used in anesthesia such 
as local anesthetics, barbiturates, muscle relaxants and opioids.1-2 For opioids, circadian 
effects have been observed for drug disposition (e.g., meperidine and morphine) and 
therapeutic sensitivity (e.g., tramadol and codeine).2,4 However, the number of studies on 
opioid pharmacology is restricted and hence knowledge on the influence of the circadian 
rhythm on opioid analgesic efficacy remains poor.2 Evidently further understanding and 
application of a chronotherapeutic approach to opioid treatment of acute and chronic pain 
would increase opioid efficacy and possibly improve the efficacy-safety balance. 
To scrutinize the hypothesis that opioids display a diurnal antinociceptive effect, we 
performed a study on the influence of four distinct timing moments on fentanyl-induced 
analgesia in healthy volunteers. The analgesic effect of intravenous fentanyl, administered 




Following approval of the protocol by the Leiden University Human Ethics Committee 
sixteen healthy volunteers (age 18-30, BMI < 28 kg.m-2, 12 women, 4 men) were enrolled 
in the study. The study was registered at trialregister.nl (#NTR1254). Written and oral 
informed consent were obtained prior to the inclusion in the study. Exclusion criteria 
were: age < 18 years, body mass index > 30 kg.m-2, presence of underlying disease, history 
of drug allergy, history of psychiatric disease, history of illicit substance abuse. All female 
subjects were taking oral contraceptives. The subjects were instructed not to eat or drink 
for at least 6 h before the study. 
6.2.2 DESIGN
The subjects were randomly divided into two experimental groups. The first group received 
fentanyl at 2 PM and 2 AM; the second group at 8 AM and 8 PM. The experimental days 
were separated by a two week washout period. We studied two distinct groups in order to 
reduce the number of occasions at which the healthy volunteers received a potent opioid. 
At the appropriate time 2.1 μg.kg-1 intravenous fentanyl was administrated intravenously 
over 90 s. Subsequently, heat pain measurements were taken every 10 minutes for 3 hours 
(first pain test at10 min after the start of the fentanyl infusion). Additionally, at each testing 
interval a Verbal Rating Score of sedation using a scale ranging from 0 to10 (0 = fully alert 
– 10 = severely sedated and sleepy) and end-tidal carbon dioxide measurements were 
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obtained via a face mask connected to a gas monitor (Multicap, Datex, Helsinki). Arterial 
hemoglobin oxygen saturation was measured via a finger probe (SpO2) with a Masimo 
pulse oximeter (Irvine, CA). The study was powered to observe a 1 cm difference in visual 
analogue score (VAS) of a 10 cm scale ranging from 0 (= no pain) to 10 (= most intense pain 
imaginable) between two study groups (power = 90%, alpha = 0.05).
6.2.3 MESUREMENTS
Heat pain was induced using the TSA-II Neurosensory Analyzer (Medoc Ltd., Ramat 
Yishai, Israel). Using a 3 cm2 probe, the skin on the volar side of the left or right forearm 
was stimulated with a gradually increasing stimulus (0.5 oC.s-1 ; baseline temperature 
32 oC). Following heat stimulation, the subjects scored their VAS pain intensity on a 10 
cm long scorecard. The thermode peak temperature depended on an initial trial phase in 
which the subject rated the pain to three peak temperatures: 46, 48 and 49 oC. The lowest 
stimulus causing a VAS > 5 cm was used in the remainder of the study. The test data were 
discarded. Next, baseline values (i.e., pre drug VAS) were obtained. The volar side of the 
arm was divided into six zones and marked as previously described.5 The thermode was 
moved from zone to zone between stimuli to avoid sensitization to heat stimulus. 
6.2.4 PHARMACOKINETIC-PHARMACODYNAMIC ANALYSIS
A linear mixed model was used to compare the baseline parameter values (thermode 
temperature to reach a VAS > 5, sedation score and end-tidal CO2) using SPSS 16.0. 
(Chicago, IL). P-values < 0.05 were considered significant. In order to quantify the effect 
of fentanyl on pain relief we initially assessed the effect relative to baseline (i.e. ΔVAS, 
by subtraction of baseline VAS at each time point), and subsequently we calculated the 
area between the VAS data points and the zero-line (area between the effect-time curves, 
AEC). Consequently, a more negative the AEC means a higher analgesic the response. We 
present the AEC data as mean change in VAS over time (i.e., AEC/180 min, unit = cm). 
Next, to get an indication of the presence of a circadian effect on fentanyl analgesia, the 
data were modeled using a sinusoid function:
AEC(t) = offset + A.sin(2πft + ϕ)     (eqn. 1)
where the A = amplitude, f = frequency (occurrence of the sinus per 24 h) and ϕ = a phase 
shift. To obtain the 95% confidence interval of the sinusoid a bootstrap analysis was 
performed using 1000 reiterations with replacement. Data analysis was performed using 
the statistical package NONMEM version VI (ICON Development Solutions, Ellicott City, 




No differences in baseline parameters were observed with-in group or between groups 
(see table 1). In each group there were 6 women and 2 men. All subjects completed the 
study without major side effects. Incidental occurrences of low SpO2 (< 95%) were treated 
by prompting the subject to take a deep breath. 
All injections were performed at the planned time of day ± 4.3 min (maximal range; not 
significant different between groups). After injection, all volunteers reached maximal 
analgesia within 20 min and returned to within 10% of their baseline pain sensitivity levels 
by the end of the experiment. The influence of the time of infusion on ΔVAS is shown in 
Fig. 1 and 2. Time-related variations are observed for peak analgesic effect (with the least 
effect at 2 AM), duration of effect (with the shortest duration at 8 AM) and the occurrence 
of a small hyperalgesic response (most pronounced at 2 AM). Individual AEC values (all 
divided over 180 min giving the mean change in VAS over 180 min) versus study time are 
given in Fig. 3 together with the data fit (± 95% confidence interval). A significant sinus 
wave was present in the data (the wave was significantly different from a linear response 
line, P < 0.01). Parameter values are: offset = –0.63 ± 0.25 cm, A = 0.65 ± 0.20 cm, ϕ = 27 ± 
21 degrees (all parameters P < 0.01, values are typical value ± SE). 
Figure 1. Effect of fentanyl on heat pain scores in two groups of subjects. One group received intravenous 2.1 μg.kg-1 
fentanyl at 8 AM and 8PM (A and C), the other group at 2 PM and 2 AM (B and C). Values are mean ± SD.
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Figure 2. Mean pain scores after injection of 2.1 μg.kg-1 fentanyl observed at 2 AM, 8AM, 2 PM and 8 PM. 
Figure 3. Data fit of analgesic effect from 2.1 μg.kg-1 iv fentanyl versus time of day at which the drug was injected. 
Analgesic effect is defined as the mean change in VAS over the 180 min study period. Each circle represents the 
analgesic effect of one subject. The fit is a sinusoidal curve (thick continuous line) ± 95% confidence interval (thin 
continuous lines). The broken line denotes a separation between mean analgesic responses (data below the broken 
line) and hyperalgesic responses (above the broken line).
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The negative value of the offset indicates that on average at all times an analgesic response 
occurred. An amplitude of 0.65 means that the average VAS varied by 1.3 cm over time 
(recalculation for just the first 90 min of the experiment would yield a variation in VAS 
of 2 cm; Note that these variations are model predictions). The value of ϕ of 27 degrees 
indicates that at midnight (0 h in figure 3) the sinus was shifted by 27 degrees. The 
frequency value f was fixed to 1 as we assumed that the sinus occurred once every 24 h. 
Fentanyl was most analgesic in the late afternoon and early evening hours (between 2 PM 
and 8 PM, minimum of the sinus occurred at 5 AM), while it was least analgesic in the 
early morning hours (from 2 AM to 8 AM, maximum of the sinus occurred at 3 PM).  
Side effects showed much less of a variation over time than analgesia with no differences 
among observations within and between groups (anova: P > 0.05; table 1). A significant 
sinus could not be demonstrated for end-tidal PCO2 or sedation.
Table 1. Baseline parameter values and 3-hour area-under-the-time-effect curve for end-tidal CO2 and sedation
8 AM – 8 PM 2 AM – 2 PM
Baseline values
 Temperature of thermode (oC) 48.5 ± 0.8 – 48.6 ± 0.8 48.2 ± 1.5 – 48.7 ± 1.4
 Baseline pain VAS (cm) 7.8 ± 0.4 – 7.7 ± 0.4 6.6 ± 0.9 – 6.8 ± 0.7
 Baseline CO2 (vol. %) 4.7 ± 0.6 – 5.1 ± 0.5 4.7 ± 0.8 – 4.6 ± 0.5
 Baseline sedation NRS (cm) 3.1 ± 0.7 – 1.9 ± 0.8 2.0 ± 0.4 – 1.0 ± 0.3
 3 h AUEC’s
 CO2 (time.vol. %) 47 ± 22 – 41 ± 21 33 ± 40 – 48 ± 14
 Sedation (time*cm) 125 ± 131 – 198 ± 153 188 ± 110 – 272 ± 190
No significant differences in parameter values were obtained among the study times (analysis of variance: P > 0.05) 
6.4 DISCUSSION
We observed a circadian sinusoidal rhythm in the analgesic effect of fentanyl. Variations 
were observed for peak analgesic effect, duration of effect and the occurrence of 
hyperalgesia. When using AEC as end-point, we observed a peak in pain relief late in the 
afternoon (5:30 PM) and a trough in the early morning hours (5:30 AM). The difference 
between the peak and trough in pain relief corresponds to a difference in VAS of 1.3 to 
2 cm. This indicates that the magnitude of the diurnal variation of fentanyl analgesia is 
significant albeit relatively small with increased sensitivity to fentanyl in the late afternoon 
and evening hours (1 to11 PM). 
6.4.1. OPIOID EFFECT ON THE CIRCADIAN RHYTHM
In mammals the suprachiasmatic nucleus (SCN) in the hypothalamus is the site 
that controls circadian behavioral rhythmicity (i.e., the master clock).7,8 The SCN is 
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synchronized by external stimuli of which the light/dark cycle is the most important (the 
retina is directly linked to the SCN via the retinohypothalamic tract). Other synchronizers 
include locomotor activity, drugs (e.g., benzodiazepines, opioids, serotonin agonists) 
and social interaction. The SCN controls many cyclic events in the mammalian body 
including the synthesis and release of hormones such as melatonin and cortisol and 
body temperature. Generation of rhythmicity in the SCN is genetically determined and 
based on feedback loop that involves several genes, including Per1, Per2 and Clock.7,8 The 
SCN and its afferent and efferent pathways contain various neurotransmitters including 
neuropeptide Y, γ-amino butyric acid (GABA) and enkephalins. The role of enkephalins in 
the circadian system has received increasing attention as δ-opioid receptors were identified 
in the hamster SCN and the μ-opioid receptor agonist fentanyl induces a phase shift in 
the circadian rhythm of hamsters independent of any behavioral effects of the opioid.9,10 
We showed previously that fentanyl modifies the circadian pacemaker possibly via direct 
effects on SCN electrical activity and regulation of Per genes.9 This suggests that pathways 
regulating the circadian clock intersect directly or indirectly with pathways that express 
opioid receptors. Our current study, in which a diurnal variation in fentanyl’s analgesic 
behavior is observed (i.e., an effect opposite to fentanyl’s influence on the clock), similarly 
suggests involvement of the opioid system in the circadian rhythm.
We refrained from measuring plasma fentanyl concentrations in our observational study. 
We argued that frequent blood sampling could interfere with the subjects rating of 
heat pain possibly causing stress-induced analgesia that encompasses strong circadian 
variations.11 Consequently, the variation in fentanyl’s effect may be due to a true increase 
in the opioid’s antinociceptive efficacy (a pharmacodynamic effect), as suggested above, 
but we cannot exclude a diurnal variation in fentanyl’s pharmacokinetics.  An increase 
in plasma fentanyl concentrations in the late afternoon and early evening may well 
explain our findings. Variations in plasma morphine concentrations following oral 
administration in patients with cancer pain have been observed due to variations in 
absorption and/or changes in the volume of distribution over a 24 h period.12 Similarly, 
intramuscular meperidine injections in patients with sickle cell anemia were associated 
with circadian changes in drug disposition and elimination over the day.2 In contrast, 
oral codeine and tramadol given to healthy volunteers in the morning or evening did not 
show any differences in pharmacokinetics.4 Similarly, and of importance to our study, in 
two separate studies in volunteers receiving intravenous fentanyl, the plasma fentanyl 
concentration-time profiles were independent of the time of infusion.13 This then suggests 
that our findings are related to a circadian effect on fentanyl’s pharmacodynamics and not 
to its pharmacokinetics.  
6.4.2 CIRCADIAN VARIATIONS IN PAIN RESPONSE
Several animal studies showed that the response to noxious stimuli is not constant over 
a 24 h period.1,2,11,14 The results of human experimental and clinical studies are less clear 
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with some studies finding no difference in pain over time, while other found more pain in 
the morning or evening.1-3,15,16 Experimental pain studies indicate that variations in pain 
sensitivity depend on the tissue tested and the nociceptive assay employed.1-3,15,16 Using a 
similar thermode as we did, Strian et al.15 did observe a variation in pain threshold values 
to warm and cold stimuli but these variations were small and had no consistent pattern 
among subjects. Our study was not designed or powered to study variations in pain 
sensitivity and, as expected, we did not observe significant differences in temperature to 
induce VAS > 5 cm. However, at this point we cannot exclude some effect of variations in 
pain sensitivity on the antinociceptive responses that we observed with less pain reporting 
between 1 and 11 PM (and hence a greater analgesic response at these times). Indeed, skin 
sensitivity to heat is minimal at 6 PM and maximal at 6 AM and also painful stimulation 
of the nasal mucosa with carbon dioxide is increased during evening test sessions.3,17 
Further studies are needed to investigate the complex interaction between variations in 
pain sensitivity and opioid treatment. An important question in this respect is, for example, 
whether the pain and analgesic rhythms display antagonistic or synergistic interactions.
6.4.3 MECHANISMS OF OPIOID CIRCADIAN RHYTHM
The mechanism though which the circadian rhythm affects opioid analgesic efficacy 
remains unknown. Variations in hormones (e.g., cortisol, melatonin) and endogenous 
opioid peptides (meta-enkephalin and β-endorphins) could play an important role 
interacting with the nociceptive pathways and opioid system.18-20 For example, the 
analgesic effect of melatonin is more pronounced at night.21 An interesting observation 
in mice is that μ-opioid receptor expression displays a 24-h rhythm.22 Down regulation 
of the brain μ-opioid receptor was associated with a decrease in morphine analgesia. 
Extrapolation of these animal data to ours in humans then suggests that during the late 
evening, morning and early afternoon, human μ-opioid receptors are down regulated 
via a direct or indirect (e.g. hormonal) influence of the SCN. Our finding of enhanced 
analgesic fentanyl efficacy from 1 to 11 PM is in agreement with other human studies 
showing similar patterns of opioid effect. Non-lethal opioid overdose (i.e., increased opioid 
sensitivity causing respiratory depression) shows a significant peak in the afternoon and 
early evening, an effect that was independent of the opioid plasma concentrations.23 Oral 
codeine and tramadol display greater analgesic sensitivity when administered in the early 
evening.4 
6.4.4 HYPERALGESIA
A somewhat surprising observation in our study was the occurrence of a moderate 
hyperalgesic response (pain sensitivity greater than baseline) following analgesia in 
subjects receiving fentanyl at 2 AM (figure 1). This phenomenon was outspoken in 
5 subjects tested at 2 AM and occurred on 11 occasions in the whole study (figure 3). 
Hyperalgesia in response to opioids has been observed in various species, including 
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humans. Recent data indicate that opioid-induced hyperalgesia is not related to activation 
of opioid receptors but possibly due to activation of N-methyl-D-aspartic acid receptors 
within pain pathways.24,25 Animal studies showed that hyperalgesia induced by opioid-
receptor blockade by naloxone (i.e., a non opioid receptor phenomenon) follows a diurnal 
rhythm.26 This then suggests that our results may have been influence by three separate 
rhythms: an inherent pain rhythm, a fentanyl analgesic and anti-analgesic rhythm. 
6.4.5 CRITIQUE OF METHODS
It is possible that the observed rhythm is entirely due to the use of two distinct subject 
groups, one of which was studied at 8 AM and 8 PM, the other at 2 PM and 2 AM. This 
could, for example, occur when the two groups would differ in their AEC’s without a 
within-group difference between measurement points (for example: [AEC(group 1) at 2 
PM = 2 AM] > [AEC(group2) at 8 AM = 8 PM]). However, this was not the case (figures 1 
and 2). In both groups the data collected in the morning hours (2 AM or 8 AM) displayed 
a peak effect and AEC of lesser magnitude than the data collected in the afternoon or early 
evening hours (2 PM or 8 PM). This suggests that the observed rhythm was inherently 
present in the two study groups and not related to the design of the study. 
We modeled the data with a symmetrical sinusoid function. This function was significantly 
better than a linear function. We did assess also non-symmetrical sinusoid functions by 
allowing the four parts of the sinusoid to vary independently in amplitude (with factor 
FAC). However, no significant improvements in minimum objective function were 
observed in comparison to FAC values of 1. Furthermore, assessing the residuals of the 
symmetrical sinusoid functions showed the absence of any bias (means residuals per 
test period not different from zero). This indicates that the sinusoid chosen adequately 
described the data. 
We subtracted the baseline pain score from the VAS-time data to allow objective assessment 
of the change in VAS over time (AEC). This was possible in our data set as we observed 
little variation in the baseline VAS (i.e., predrug) score. We cannot exclude, however, that 
some error in baseline values may erroneously propagate to the estimates of the model 
parameters. However, in our analysis, the error only propagates to the inter-individual 
variability of the model parameter offset. We tested the variance in offset and observed 
that it was not different from zero, suggesting that subtraction of baseline pain scores did 
not affect our study outcome. In some studies the analysis of circadian effects is sensitive 
to ‘edge effects’ or the moment in time defined as the start of day or start of analysis (this 
is often related to the use of a smoothing function).27 We chose midnight as starting point 
of our analysis. Our NONMEM analysis of the data with a non-smoothed sinusoid does 
not have any edge effects. 
Recent studies on chronopharmacology of labor analgesia with intrathecal bupivacaine 
indicate that one has to be careful with the interpretation of rhythmic patterns in the 
duration of analgesia.27 This concerns patient studies in which daily routines (external 
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rhythms such nursing and anesthesia provider shifts) produce artifacts (suggesting a 
biological rhythm in intrathecal analgesia duration) that have little to do with biological 
rhythms.27,28 We were aware of these pitfalls and designed our study to prevent influences 
from external rhythms. However, despite our efforts we cannot exclude some albeit small 
effect from external sources on our study outcome. 
6.5 CONCLUSIONS
We observed a circadian rhythm in the analgesic effect of fentanyl in human volunteers 
using an experimental heat pain model. Our data indicate an increase in analgesic efficacy 
in the late afternoon and early evening hours. We argue that the most probable cause 
for our findings is chrono-pharmacodynamic effect regulated by the circadian clock in 
the hypothalamus. This may be a direct effect through shared pathways of the circadian 
system and the opioid system or an indirect effect via diurnal variations in hormones or 
endogenous opioid peptides that rhythmically change the pain response and/or analgesic 
response to fentanyl. 
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Despite many side effects opioids remain the first choice in the treatment of severe acute 
and chronic pain in contemporary medicine. In this thesis, the influence of strong opioids, 
used in the treatment of severe acute and chronic pain, on the control of breathing are 
studied and discussed relative to their wanted effect, analgesia. The issue of opioid-
induced respiratory depression is highly relevant as accidental casualties due to OIRD 
do regularly occur. In some areas, such as the US and Canada, the number of accidental 
deaths from legally prescribed drugs (predominantly opioids prescribed for chronic non-
cancer pain and sedatives voor anxiety and sleeping disorders) is high with a frightening 
70 deaths per day.1,2
In Chapter 2 the detrimental respiratory effects of opioids and their relevant 
pharmacokinetics and dynamics are discussed in the first part of the chapter. Opioids 
induce respiratory depression via activation of μ-opioid receptors (MORs) at specific 
sites in the central nervous system including the pre-Bötzinger complex, a respiratory 
rhythm generating area in the pons. A distinction is made between full and partial MOR 
agonists. Full opioid agonists like morphine and fentanyl affect breathing with onset and 
offset profiles that are primarily determined by opioid transfer to the receptor site, while 
the effects of partial MOR agonists such as buprenorphine are governed by transfer to 
the receptor site together with receptor kinetics, in particular dissociation kinetics. In the 
second part of the chapter respiratory depression reversal options are discussed. Opioid-
induced respiratory depression (OIRD) may be reversed by the opioid receptor antagonist 
naloxone, an agent with a short elimination half-life (30 min). The rate-limiting factor in 
naloxone-reversal of opioid effect is the receptor kinetics of the opioid agonists that requires 
reversal. Agents with slow dissociation kinetics (buprenorphine) require a continuous 
naloxone infusion while agents with rapid kinetics (fentanyl) will show complete reversal 
upon a single naloxone dose. Since naloxone is non-selective and reverses analgesia 
as well, efforts are made by several pharmaceutical companies on the development of 
compounds that reverse OIRD without affecting analgesic efficacy. Such agents include 
ampakines and 5HT-receptor agonists which are aimed at selectively enhancing central 
respiratory drive. A novel approach is aimed at the reduction of respiratory depression 
from opioid-activation of (micro-)glia cells in the pons and brainstem using microglia cell 
stabilizers. Since this approach simultaneously enhances opioid analgesic efficacy it seems 
an attractive alternative to the classical reversal strategies with naloxone.
In Chapter 3 the dynamic effects of the potent opioid remifentanil on respiration are 
described and a mathematical model of respiratory depression is developed. Studies as 
described here are rarely performed possibly due to the complexity of the respiratory 
control system. We show here that a model with intact feedback control of carbon 
dioxide on ventilation (non-steady-state models) that correctly incorporates the complex 
interaction between drug concentration, PCO2 and ventilation yields reliable descriptions 
and predictions of the opioid’s behavior. We measured the respiratory effect of remifentanil 
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with and without a background infusion of propofol.
Ten male healthy volunteers received remifentanil infusions with different infusion speeds 
(target concentrations of 4 to 9 ng.ml-1 at infusion rates of 0.17 to 9 ng.ml-1.min-1) while 
awake and at the background of low-dose propofol. The data were analyzed with a non-
linear model consisting of two additive linear parts, one describing the depressant effect 
of remifentanil and one the stimulatory effect of carbon dioxide on ventilation.
The model adequately described the data including the occurrence of apnea. Most 
important model parameters were: C50 for respiratory depression with an estimated 
value of 1.6 ± 0.03 ng.ml-1 (median ± SE), the gain of the respiratory controller (G) 
with an estimated value of 0.42 ± 0.1 L.min-1.Torr-1 and the remifentanil blood effect-
site equilibration half-life (t½ke0) with a value 0.5 3± 0.2 min. Propofol caused a 20-50% 
reduction of C50 and G but had no effect on t½ke0. Apnea occurred during propofol infusion 
only. A simulation study revealed an increase in apnea duration at infusion rates of 2.5 to 
0.5 ng.ml-1.min-1 followed by a reduction in duration. At speeds ≤ 0.31 ng.ml-1.min-1 no 
apnea was present. This is related to the slow accumulation of CO2. This study shows that 
the mathematical description of the respiratory depressant effects of remifentanil together 
with the respiratory stimulating effects of carbon dioxide is possible. Furthermore it 
allows for the prediction of the opioid’s respiratory behavior and as such may be used in 
the development of infusion regimens aimed at the sustainment of spontaneous breathing 
activity even at high remifentanil infusion dosages. With the presented model we were 
able to remove some of the limitations of models derived from earlier studies. Further 
studies are required to incorporate a fourth and fifth factor, next to drug concentration, 
PCO2 and ventilation, in the model, namely pain and upper airway obstruction. These 
factors have excitatory (pain) and disturbing (upper airway obstruction) influences on 
the control of breathing. Both factors are present in our (often obese) patient population 
treated with potent opioids for a variety of reasons (such as postoperative pain relief, 
chronic pain relief, sedation for diagnostic procedures, dyspnea, palliation), although 
their presence is often episodic rather than continuous, a fact that makes incorporation in 
a predictive model difficult but hopefully not impossible. 
Integrating opioid risk and benefit is important as it allows for the comparison of net 
efficacy among opioids. In Chapter 4 an explorative study on the effects of fentanyl on 
analgesia and respiratory depression was performed to construct fentanyl risk-benefit or 
utility functions, a new concept in opioid pharmacology. Twelve volunteers received a 
3.5 μg.kg-1 fentanyl intravenous injection on two separate study days. On one occasion 
ventilation at a clamped elevated carbon dioxide was measured, on another the pain 
tolerance to electrical stimulation. In both sessions arterial plasma samples were obtained. 
The data were analyzed with a population pharmacokinetic-pharmacodynamic (PKPD) 
model. Two-times 9,999 simulations were performed, using the PK-PD parameter 
estimates and their variabilities, in which simulated subjects received 3.5 μg.kg-1 fentanyl. 
The resultant distributions were used to calculate the utility functions, defined as the 
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probability of at least 50% analgesia (an increase in pain tolerance by at least 50%) minus 
the probability of at least 50% respiratory depression. Utility functions were constructed 
in concentration (UFc) and time domains (UFt). The PKPD analysis showed that fentanyl 
had an approximate two-fold faster onset/offset and two-fold greater potency with respect 
to respiratory depression compared to analgesia. The constructed utility functions were 
successful with negative UFc values at effect-site concentrations > 0.5 ng.mL-1 and negative 
UFt values in the first 90 min following the 3.5 μg.kg-1 bolus infusion. From these results 
it may be concluded that successful construction of clinically relevant utility functions 
is possible. UF of other opiods may be constructed from previous studies performed in 
our laboratory. One such opioid, morphine, displays UFc and UFt values more positive 
than fentanyl. While this suggest that morphine has a lower probability than fentanyl in 
producing respiratory depression for a given amount of analgesia it is important to be 
vigilant as severe respiratory depression in an individual patient remains possible, even 
at low dose morphine. Further studies should address the issue of applicability of the UF 
under clinical circumstances and assess the influence of pain of the function. For now it 
can be concluded that the UF is useful in drug selection in drug development programs 
and dose selection for experimental Phase III studies. 
In Chapter 5 a phase 1 study is presented, in which the effect of an experimental opioid 
from Mundipharma Research Ltd (Cambridge, UK), MR30365/07, with high affinity for 
the three classical opioid receptors (MOR, delta-opioid receptor, (DOR), kappa-opioid 
receptor, (KOR)) and low affinity for the recently discovered opioid-receptor-like (ORL1) 
receptor, on respiration and analgesia was compared to fentanyl, a selective, high affinity 
MOR agonist that, at high doses, produces dose dependent respiratory depression and 
apnea. In this double-blind, randomized controlled study 46 healthy male volunteers 
participated in respiratory studies, 46 others in analgesia studies. In each group, six 
subjects received placebo, twenty received MR30365/07 (four received 0.0125, six 0.075, 
six 0.125 and four 0.15 μg.kg-1) and twenty received fentanyl (four received 0.5, six 1.0, 
six 2.0 and four 3.0 μg.kg-1). Active and placebo treatment was given intravenously over 
10 min. Breathing was measured on a breath-to-breath basis at a fixed elevated end-tidal 
PCO2. Analgesic responses to pain detection (pain threshold) were measured using 
transcutaneous electrical stimulation. 
Fentanyl displayed typical dose-dependent effects in respiratory depression and analgesia. 
MR30365/07 showed dose-dependent respiratory depression with ceiling starting at a 
dose of 0.075 μg.kg-1, with a minimum ventilation of 32.8% of baseline. No ceiling was 
observed in the analgesic effects of MR30365/07 over the dose range tested. MR30365/07 
was about 18 times more potent than fentanyl in producing analgesia. 
These data are promising in that this is an opioid with limited respiratory effect (at least 
as observed over the dose range tested) retaining full analgesia efficacy. In contrast to 
buprenorphine which shows similar behavior, this drug is a full agonist for the MOR. 
Possibly the favorable behavior of MR30365/07 is due to its agonist effect at the KOR 
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although other mechanisms are not excluded (including a differential effect at recruitment 
of second messengers and intracellular peptides). Further studies are required to assess 
the behavior of this opioid at higher doses, in clinical settings and in the combination with 
other drugs (such as sedatives) to assess whether the ceiling in respiratory depression is 
sustained. 
Chronopharmacology studies the effect of the timing of drug administration on drug effect 
and may have important effects in clinical practice and is possibly an important cause of 
opioid variability. In Chapter 6, the influence of four timing moments on fentanyl-induced 
analgesia was evaluated. Eight healthy volunteers received 2.1 μg.kg-1 intravenous 
fentanyl at 2 PM and 2 AM, with at least 2 weeks between occasions, eight others at 8 
AM and 8 PM. Heat pain measurements using a thermode placed on the skin were taken 
at regular intervals for 3 h and Verbal Analogue Scores (VAS) were then obtained. The 
data were modeled with a sinusoid function using the statistical package NONMEM. 
A significant circadian sinusoidal rhythm in the antinociceptive effect of fentanyl was 
observed. Variations were observed for peak analgesic effect, duration of effect and the 
occurrence of hyperalgesia. A peak in pain relief occurred late in the afternoon (5:30 PM) 
and a trough in the early morning hours (5:30 AM). The difference between the peak and 
trough in pain relief corresponds to a difference in VAS of 1.3 to 2 cm. Only when given at 2 
AM did fentanyl cause a small but significant period of hyperalgesia following analgesia. 
No significant changes were observed for baseline pain, sedation or the increase in end-
tidal CO2. The observed possible influence of the circadian rhythm may be a direct effect 
through shared pathways of the circadian and opioid systems or an indirect effect via 
diurnal variations in hormones or endogenous opioid peptides that rhythmically change 
the pain response and/or the analgesic response to fentanyl.
These data show significant but small effects of the circadian clock on fentanyl-induced 
analgesia. It remains questionable whether such effects may be unearthed from the 
noise (related to a multitude of other factors, including sex, age, underlying disease, 
comedication, anxiety, and genetics) in a clinical setting. 
7.2 CONCLUSIONS
The following conclusions may be drawn from the data presented in this thesis:
1. The results from this thesis indicate that currently-used opioids may produce life-
threating respiratory depression. Despite our efforts to understand OIRD, individual 
prediction of development of OIRD is limited and therefore titration to effect is the best 
option when treating patients with potent opioid analgesics. This is true for all patients 
receiving opioids, irrespective of the indication.
2. The ideal drug for antagonism of respiratory depression has not yet been found. At 
present naloxone seems the most appropriate drug although reversal of OIRD coincides 
with loss of analgesia. New reversal agents acting via non-opioidergic pathways are under 
investigation and are aimed at reversal of OIRD without compromising analgesia.
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3. Mathematical modeling of the non-steady state effects of respiratory depression by 
opioids is not only possible, but also yields comprehensible results. Still despite adequate 
prediction of a drug’s respiratory behavior on a population level, the model does not 
allow individual prediction. 
4. Utility functions may serve as a composite function to describe the effect-side effect 
profile of a drug. For example, the utility function of fentanyl is predominantly negative 
except at low dose, indicating that for the dose tested the probability of respiratory 
depression exceeds the probability for analgesia. While this function seems applicable in 
experimental and phase I/II/III settings, its clinical use requires further validation. 
5. The Anesthesia & Pain research Unit is especially appropriate for studying the effect 
of experimental drugs on respiration and analgesia. An example of such a drug is 
MR30365/07, an opioid acting at all three classical opioid receptors. In contrast to fentanyl 
this agents produces ceiling in respiratory depression but not analgesia over the dose 
range tested. 
6. Fentanyl-induced pain relief is influenced by the circadian clock with increased efficacy 
during the later hours of the afternoon. Whether such effects are sustained in a clinical 
setting remains unknown. 
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Ondanks veel bijwerkingen blijven opioiden de eerste keus in de behandeling van ernstige 
acute pijn in de huidige tijd.
In dit proefschrift wordt de invloed van sterke opioïden, gebruikt in de behandeling van 
ernstige acute en chronische pijn, op de controle van de ademhaling bediscussieerd. Dit 
effect op de ademhaling, een bijwerking, wordt ook gerelateerd aan het gewenste effect, 
analgesie.
Het onderwerp van de opioïd-geinduceerde ademhalingsdepressie is zeer relevant, 
aangezien er regelmatig slachtoffers vallen als gevolg van deze ademhalingsdepressie.
In sommige gebieden, zoals de US en Canada, is het aantal slachtoffers als gevolg van 
legaal voorgeschreven geneesmiddelen (voornamelijk opioïden voorgeschreven voor 
chronische niet-kanker pijn en slaapmiddelen voor anst en slaapstoornissen) met een 
beangstigend aantal van 70 doden per dag.1,2
In hoofdstuk 2 worden de ernstige ademhalingsbijwerkingen van opioïden en hun 
relevante farmacokinetiek en -dynamiek bediscussieerd in het eerste gedeelte van het 
hoofdstuk. Opioïden induceren ademhalingsdepressie via activatie van de μ-opioïd 
recptoren (MORs) op specifieke lokaties in het centrale zenuwstelsel, waaronder het pre-
Bötzinger complex, een gebied in de pons wat het ademhalingsritme genereert.
Een onderscheid wordt gemaakt tussen volledige en partiële MOR-agonisten. Volledige 
opioïd-agonisten, zoals morfine en fentanyl, hebben invloed op de ademhaling met 
in- en uitwerkingsprofielen (‘onset and offset profiles’) die in eerste instantie vooral 
bepaald worden door de overgang van het opioïd naar de lokatie van de receptor, tewijl 
de effecten van partiële MOR-agonisten, zoals buprenorphine, veroorzaakt worden 
door overgang naar de lokatie van de receptor , in combinatie met receptor-kinetiek, in 
het bijzonder de dissociatiekinetiek. In het tweede gedeelte van het hoofdstuk worden 
mogelijkheden voor antagoneren van ademhalingsdepressie besproken. Opioïd-
geinduceerde ademhalingsdepressie (OIRD) kan geantagoneerd worden door de opioïd 
receptor antagonist naloxon, een middel met een korte eliminatie-halfwaardetijd (30 
min). De snelheidsbeperkende factor bij antagonisme van een opioïd-effect door naloxon 
is de receptorkinetiek van de opioïd-agonist die antagonering behoeft. Middelen met 
een langzame dissociatiekinetiek (buprenorphine) hebben een continue naloxon-infusie 
nodig, terwijl middelen met een snelle kinetiek (fentanyl) volledige omkering van het 
effect zullen laten zien na een enkele dosering naloxon. Aangezien naloxon niet-selectief 
is en analgesie ook teniet doet, wordt er door diverse farmaceutische industrieën 
gewerkt aan het ontwikkelen van middelen die ademhalingsdepressie opheffen, maar 
het analgetisch effect niet. Zulke middelen zijn onder andere ampakines en 5HT receptor 
agonisten, welke gericht zijn op het selectief doen toenemen van de ademhalingsprikkel. 
Een nieuw aangrijpingspunt is gericht op het verminderen van ademhalingsdepressie 
door opioïd activatie van (micro-)glia cellen in de pons en de hersenstam, gebruik makend 
SAMENVATTING EN CONCLUSIES
127
van microglia-cel stabiliserende middelen. Aangezien deze benadering tegelijkertijd een 
positieve invloed heeft op het analgetisch effect van opioiden, lijkt dit een aantrekkelijke 
mogelijkheid ten opzicht van de klassieke antagoneringsmethoden.
In hoofdstuk drie worden de dynamische effecten van het potente opioïd remifentanil op 
de ademhaling beschreven en wordt er een wiskundig model van ademhalingsdepressie 
ontwikkeld. Studies zoals hier beschreven worden zelden verricht vanwege de 
complexiteit van het ademhalingssysteem. We laten hier zien dat een model met een intact 
feedback systeem van koolstofdioxide op ademhaling (zogenaamde non-steady-state 
modellen), wat op juiste wijze de complexe interactie tussen geneesmiddelenconcentratie, 
PCO2 en ademhaling incorporeert, een bruikbare beschrijving en voorspelling van 
geneesmiddeleneffect geeft. We onderzochten het effect van remifentanil op ademhaling 
zowel met als zonder een achtergrondinfusie van propofol.
Tien gezonde mannelijke vrijwilligers ontvingen remifentanil infusies met verschillende 
toedieningssnelheden (doelconcentraties in plasma 4 tot 9 ng.ml-1 bij infusiesnelheden van 
0.17 to 9 ng.ml-1.min-1), zowel ‘wakker’ als met een achtergrondinfusie van laaggedoseerd 
propofol. De data werden geanalyseerd met een non-lineair model, bestaande uit twee 
additieve lineaire gedeelten, waarvan één het deprimerende effect van remifentanil op 
ademhaling beschrijft, en één het stimulerende effect van koolstofdioxide op diezelfde 
ademhaling.
Het model beschreef de gevonden waarden adequaat, inclusief het optreden van apneu. 
De belangrijkste modelparameters waren: C50 voor ademhalingsdepressie met een 
geschatte waarde van 1.6 +/- 0.03 ng.ml-1 (median ± SE), de responsecurve (ie. de ‘gain’) 
van het ademhalingscentrum (G) met een geschatte waarde van 0.42 +/- 0.1 L.min-1.Torr-1 
en de remifentanil bloed effect-site equilibrilatie halfwaarde tijd (t½ke0) met een waarde 
van 0.53 ± 0.2 min. Propofol veroorzaakte een 20 tot 50% afname van de C50 en G maar 
had geen effect op de T½ke0. Apneu trad alleen op tijdens propofol-infusie. Een simulatie-
studie liet een toename in apneu-duur zien bij infusie snelheden van 2.5 tot 0.5 ng.ml-1.
min-1 gevolgd door een afname van deze duur. Bij snelheden < 0.31 ng.ml-1.min-1 werd 
er geen apneu gezien. Dit is gerelateerd aan de langzamere toename van CO2  bij een 
langzamere infusieduur. Deze studie laat zien dat de wiskundige beschrijving van het 
ademhalingsdeprimerende effect van remifentanil  in combinatie met het stimulerende 
effect van koolstofdioxide mogelijk is. Verder staat het de voorspelling van het gedrag 
van het opioïd toe, en kan het gebruikt worden om infusie-regimes te ontwikkelen gericht 
op het behoud van spontane ademhaling, zelfs bij hoge doseringen remifentanil. Met het 
gepresenteerde model zijn we in staat geweest enige beperkingen van de modellen van 
eerdere studies op te heffen. 
Verder onderzoek is noodzakelijk om nog een vierde en vijfde factor aan het model te 
kunnen toevoegen, naast geneesmiddelenconcentratie, ademhaling en CO2, namelijk pijn 
en bovensteluchtwegobstructie. Deze factoren hebben respectievelijk een stimulerend (pijn) 
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en verstorend (bovenste luchtwegopstructie) effect op de regulatie van de ademhaling. 
Beide factoren zijn aanwezig in onze (vaak obese) patiëntenpopulatie die behandeld 
wordt met opioïden om uiteenlopende redenen (zoals postoperatieve pijnstilling, 
chronische pijnstilling, sedatie voor diagnostische procedures, dyspnoe, palliatie). Vaak 
is hun aanwezigheid echter meer intermitterend dan continue, wat implementatie in een 
voorspellend model zeer moeilijk, maar hopelijk niet onmogelijk maakt.
Het integreren van zowel werking als bijwerking van opioiden is belangrijk, aangezien 
het vergelijking van netto-effectiviteit van opioiden mogelijk maakt. In hoofdstuk 
4 wordt een verkennende studie van het effect van fentanyl op analgetisch effect en 
ademhalingsdepressie gepresenteerd. Deze is verricht teneinde voor fentanyl ‘risk-
benefit’ (ie. de verhouding werking-bijwerking) of ‘Utility Functions’ te construeren, een 
nieuw concept binnen het beschrijven van effecten van opioïden. Twaalf vrijwilligers 
ontvingen een 3.5 mcg.kg-1 fentanyl-injectie op twee verschillende studiedagen. Bij de ene 
gelegenheid werd de ademhaling gemeten bij een gecontroleerde verhoogde uitademings-
koolstofdioxide-concentratie, op de andere dag werd pijnstilling gemeten middels 
electrische stimulatie. Tijdens beide sessies werd arterieel plasma afgenomen. De data 
werden geanalyseerd middels een farmacokinetisch-farmacodynamisch (PK-PD) model 
op populatieniveau. Tweemaal 9.999 simulaties werden verricht, gebruikmakend van de 
PK-PD-parameter schattingen en hun variabiliteit, waarbij gesimuleerde proefpersonen 
3.5 mcg.kg-1 fentanyl toegediend kregen. De uiteindelijke uitkomsten werden gebruikt om 
‘Utility Functions’, gedefinieerd als de waarschijnlijkheid om 50% pijnstilling te verkrijgen 
(gemeten als een toename van 50% tolerantie ten aanzien van de electrische pijntest) minus 
de waarschijnlijkheid om 50% ademhalingsdepressie te verkrijgen. ‘Utility functions’ 
werden zowel voor het concentratiedomein (UFc) als het tijddomein (UFt) geconstrueerd. 
De PK-PD analyse liet zien dat fentanyl een ongeveer tweemaal grotere ‘onset/offset’ en 
een tweemaal grotere potentie met betrekking tot ademhalingsdepressie - in vergelijking 
met de analgesie - liet zien. De geconstrueerde Utility Functions  lieten negatieve UFc 
waarden bij effect-site-concentraties > 0.5 ng.ml-1 en negatieve UFt waarden in de eerste 
90 min volgend op de 3.5 mcg.kg-1 bolus-infusie. Uit deze resultaten kan geconcludeerd 
worden dat een succesvolle constructie van klinisch relevante utility functions mogelijk 
is. UF van andere opioiden kunnen geconstrueerd worden vanuit eerder onderzoek uit 
ons laboratorium. Eén van deze opioïden, morfine, laat UFc -en UFt-waarden zien die 
positiever zijn dan die van fentanyl. Terwijl dit suggereert dat morfine een lagere kans heeft 
dan fentanyl op het produceren van ademhalingsdepressie voor een gegeven hoeveelheid 
analgesie, is het belangrijk alert te blijven, aangezien ernstige ademhalingsdepressie in 
een individuele patient mogelijk blijft, zelfs bij een lage dosering morfine. Verdere studies 
zouden het vraagstuk van de toepasbaarheid van UF onder klinische omstandigheden 
moeten beoordelen, evenals de invloed van pijn op de uitkomsten. Vooralsnog kan 
geconcludeerd worden dat de Utility Function zinvol is in geneesmiddelenselectie in 
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geneesmiddelenontwikkelingsprogramma’s en doseringenselectie voor experimentele 
fase III studies.
In hoofdstuk 5 wordt een fase I studie gepresenteerd, waarin het effect van een 
experimenteel opioïd van Mundipharma Research Ltd (Cambridge, UK), te weten 
MR30365/07, met een hoge affiniteit voor de drie klassieke opioïdreceptoren (MOR, 
de δ-opioidreceptor, DOR, en de κ-opioidreceptor, KOR) en een lage affiniteit voor de 
recent ontdekte opioïd-receptor-like (ORL1) receptor, op ademhaling en analgesie werd 
vergeleken met fentanyl, een selectieve MOR-agonist met een hoge affiniteit die bij hoge 
doseringen, dosisafhankelijke ademhalingsdepressie en apneu laat zien. Binnen deze 
dubbelblinde gerandomiseerde en gecontroleerde studie namen 46 gezonde mannelijke 
proefpersonen deel aan een ademhalings-studie, en 46 anderen aan een analgesie-
studie. In elke groep ontvingen zes personen placebo, twintig ontvingen MR30365/07 
(vier ontvingen 0.0125, zes 0.075, zes 0.125 en vier 0.15 mcg.kg-1) en twintig ontvingen 
fentanyl (vier ontvingen 0.5, zes 1.0, zes 2.0 en vier 3.0 mcg.kg-1). Zowel de actieve als 
de placebobehandeling werd toegediend in 10 minuten. Ademhaling werd gemeten op 
een breath-to-breath basis (i.e. iedere ademhalingsteug werd gemeten) bij een op een vast 
niveau gefixeerde verhoogde uitademingskoolstofdioxide. Pijnstilling werd gemeten 
door bepaling van de pijnwaarnemingsdrempel op een electrische pijntest. 
Fentanyl liet een typisch dosis-afhankelijk effect zien in ademhalingsdepressie en 
analgesie. MR30365/07 liet een dosis-afhankelijke ademhalingsdepressie zien met een 
plafond effect beginnend bij dosering 0.075 mcg.kg-1, met een minimum-ademhaling van 
32.8% van de baseline. Er werd geen plafondeffect werd gezien bij de analgetische effecten 
van MR30365/07 over het geteste doseringsinterval. MR30365/07 was ongeveer 18 maal 
potenter dan fentanyl in het produceren van analgesie. Deze data zijn veelbelovend in 
de zin dat dit een opioïd lijkt met een beperkt effect op ademhaling (tenminste over het 
gemeten doseringsinterval) met behoud van analgetische effectiviteit. In tegenstelling 
tot buprenorphine, wat een soortgelijk gedrag laat zien, is dit middel een volledige 
agonist van MOR. Mogelijk is het gunstige gedrag van MR30365/07 te danken aan een 
agonistisch effect op de KOR, alhoewel andere mechanismen niet uitgesloten kunnen 
worden (inclusief een wisselend effect op de activering van ‘second messengers’ en 
intracellulaire signaaleiwitten). Verdere studies zijn nodig om het effect van dit opioid bij 
hogere doseringen te beoordelen, zowel in klinische omstandigheden als in combinatie 
met andere middelen (zoals sederende middelen) om te zien of het plafond-effect in 
ademhalingsdepressie aanhoudt.
Chonopharmacologie bestudeert het effect van het tijdstip van toediening van een 
geneesmiddel op het gemeten effect. Dit kan grote invloeden hebben op de klinische 
praktijk en is mogelijk een belangrijke oorzaak van variabiliteit in effect van opioiden. 
In hoofdstuk 6 wordt de invloed van moment van toediening op fentanyl-geinduceerde 
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analgesie geëvalueerd. Acht gezonde vrijwilligers ontvingen 2.1 mcg.kg-1 fentanyl 
intraveneus om 2 PM en 2 AM, met tenminste twee weken tussen de verschillende 
gelegenheden, acht anderen ontvingen deze infusie om 8 AM en 8 PM. Hittepijn-metingen, 
gebruikmakend van een thermode geplaatst op de huid, werden op gezete tijden verricht 
gedurende 3 uur, en Visual Analogue Scores (VAS) werden afgenomen om de pijnstilling 
te evalueren. De data werden gemodelleerd met een sinusoïdvormige functie – met behulp 
van het statistiekprogramma NONMEM. Er werd een significant  circadiaan ritme in het 
analgetisch effect van fentanyl gevonden. Variaties werden gezien in piek-analgetisch 
effect, duur van het effect en het optreden van hyperalgesie. Een piek in pijnstilling trad 
laat in de middag op (5:30 PM) en een dal vroeg in de ochtend (5:30 AM). Het verschil 
tussen de piek en het dal in pijnstillingseffect was een VAS-score van 1.3 tot 2 cm. Slechts 
om 2 AM gaf fentanyl een kleine maar significante periode van hyperalgesie volgend op 
analgesie. Er werden geen significante verschillen gevonden voor uitgangsscore in pijn, 
sedatie of toename van uitademings-CO2 concentratie. De mogelijke invloed van het 
circadiane ritme kan een direct effect zijn van gedeelde signaalpaden van het circadiane 
systeem en het opioïd-respons systeem of een indirect effect via 24-uurs variaties in 
hormonen of endogene opioïd-eiwitten die de pijnrespons en/of het analgetisch effect 
van fentanyl beïnvloeden.
Deze data laten een klein maar significant effect zien van het circadiane ritme op fentanyl 
geïnduceerde analgesie. Het blijft de vraag of zulke effecten van belangrijke invloed zullen 
zijn temidden van alle andere effecten (zoals bijvoorbeeld geslacht, leeftijd, onderliggende 
aandoening, comedicatie, angst en genetische effecten) die een rol spelen in klinische 
omstandigheden.
8.2 CONCLUSIES
De volgende conclusies kunnen getrokken worden uit de data gepresenteerd in dit 
proefschrift:
1. De resultaten van dit proefschrift laten zien dat de huidige gebruikte opioiden 
levensbedreigende effecten kunnen hebben op de ademhaling. Ondanks onze inspanningen 
om OIRD te begrijpen, is een individuele voorspelling van het ontwikkelen van OIRD 
slechts beperkt mogelijk, en is titreren naar effect de veiligste optie indien patienten met 
potente opioïden behandeld worden. Dit geldt voor alle patienten die opioïden krijgen, 
onafhankelijk voor welke indicatie.
2. Het ideale middel voor het antagoneren van ademhalingsdepressie is nog niet gevonden. 
Op dit moment lijkt naloxon het juiste middel, alhoewel omkering van OIRD samengaat 
met verlies van analgetisch effect. Nieuwe antagonisten, werkend via niet-opioïdreceptor 
gemedieerde wegen, worden op dit moment onderzocht en zijn gericht op omkering van 
OIRD zonder remming van het analgetisch effect.
3. Wiskundig modelleren van non-steady state effecten van ademhalingsdepressie 
door opioiden is niet alleen mogelijk, maar levert ook klinisch bruikbare resultaten op. 
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Ondanks adequate voorspellingen van een middel op populatie-niveau, levert het model 
geen goede resultaten bij voorspellingen voor het individu.
4. ‘Utility functions’ kunnen dienen als wiskundige beschrijving van de ratio werking-
bijwerking van een geneesmiddel. De ‘utility function’van fentanyl is voornamelijk negatief, 
behoudens bij lage doseringen, implicerend dat voor de geteste doseringsintervallen de 
kans op een bepaalde mate van ademhalingsdepressie de kans op eenzelfde mate van 
analgesie overtreft. Alhoewel deze beschrijving toepasbaar lijkt in experimentele en fase 
I/II/III settings, heeft de toepassing in de kliniek nader onderzoek nodig.
5. De Anesthesia & Pain Research Unit is speciaal geschikt voor het bestuderen van het 
effect van experimentele geneesmiddelen op ademhaling en analgesie. Een voorbeeld van 
een dergelijk middel is MR30365/07, een opioïd werkend op alle drie klassieke opioid-
receptoren. In tegenstelling tot fentanyl produceert dit middel een plafond-effect in 
ademhalingsdepressie maar niet in analgesie over het gemeten doseringsinterval.
6. Fentanyl-geinduceerde pijnstilling wordt beinvloed door het circadiane ritme met een 
toegenomen effectiviteit tijdens de late uren van de middag. Of zulke effecten van belang 
zijn in klinische omstandigheden blijft vooralsnog onduidelijk. 
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A   Amplitude
ADHD   Attention Deficit Hyperactivity Disorder
AEC   Area between the Effect-time Curve
Akt   Protein Kinase B
AMPA   α-amino-3-hydroxy-5-methyl-D-aspatate
ATP   Adenosinetriphosphaat
AUC   Area Under the Curve
B   Apneic treshold
BIS   Bispectral Index Monitoring
BMI    Body Mass Index
cAMP   Cyclic Adenosine Monophosphate
C   Content/Concentration
°C   Degrees of Celsius
CAPNEA   Concentration at which apnea occurs
Cdrug   Concentration of certain drug
CCMO   Committee on Research Involving Human Subjects
Ce(t)   Effect-site concentration at time t
CL   Clearance
CNS   Central Nervous System
CO2    Carbon dioxide
C50    Concentration causing 50% of drug effect
DAMGO  D-Ala2, N-MePhe4, Gly-ol]-enkephalin
DEF   Dynamic End-tidal Forcing
DOR   δ-opioid receptor
ED50   Dose causing 50% of effect
Emin/Emax  Minimum effect/Maximum effect
f   Frequency
G   Gain
GPCR   G-protein coupled receptor
GTP   Gai-guanosine tri-phosphate
h   Hour
HEK293   Human Embryonic Kidney (293) cells
5-HT    5-hydroxytrptamine
k   Constante
keo    Blood effect site rate constant
Ki   Concentration of drug necessary to occupy 50% of the receptors
KOR    κ-opioid receptor
LD50   Lethal dose for 50 % of subjects
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SYMBOLS AND ABBREVIATIONS
LUMC    Leiden University Medical Centre
mA   Milli Ampere
MAP   Microtubule-associated protein kinase
ERK     Signal-regulated kinase
min   Minute
MOR   μ-opioid receptor
M3G   Morphine-3-glucuronide
M6G   Morphine-6-glucuronide
O2    Oxygen
ODT   O-desmethyltramadol
OIRD    Opioid Induced Respiratory Depression
P    Partial pressure
P   Probability
PCO2    Carbon dioxide concentration
PO2   Concentration of oxygen
PET   Positron Emission Tomography
PD   Pharmacodynamics
PDE   Phosphodiesterase
PK   Pharmacokinetics
Q    Cardiac Output
R2    Coefficient of determination
s   Second
SCN   Suprachiasmatic nucleus
SEE   Standard Error of the Estimate
SpO2   Saturation
t½ke0   Blood-effect-site equilibration half-life
Tcp    Target Plasma Concentration 
TLR   Toll-like receptor
t   Time
t½   Half life
U   Utility of drug effect
V     Ventilation
V   Volume
Valv   Alveolair volume
Vts    Tissue volume
VCO2   Carbon dioxide production
VAS   Visual Analogue Scale
VPC   Visual Predictive Check 





γ   Shape parameter
λ   Solubility coefficient
ϕ   Phase shift
ρ   Measure of potency
σ2   Variance of the residual error
τ   Delay/time constant
ω2   Inter-subject variability 
&:η  Shrinkage of empirical Bayesian estimates to the population values
#:ε  Shrinkage of model output to the observations
(+) or (-)   Stereo-isomers
∈   Residual error
